

APPROVED DRUG PRODUCTS


With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by [DrugPatentWatch.com](https://www.drugpatentwatch.com)

**CUMULATIVE
SUPPLEMENT 6
JUNE 2013**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

33rd EDITION

Department of Health and Human Services

**Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs**

2013

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

33rd EDITION

Cumulative Supplement 6

June 2013

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Cumulative Supplement Content.....	iv
1.3 Applicant Name Changes.....	v
1.4 Levothyroxine Sodium.....	v
1.5 Availability of the Edition	vi
1.6 Report of Counts for the Prescription Drug Product List	vii
1.7 Cumulative Supplement Legend	viii
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

33rd EDITION

**CUMULATIVE SUPPLEMENT 6
June 2013**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 30th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 32nd Edition List will then be added to the "Discontinued Drug Product List" appearing in the 33rd Edition. The current Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

BIONICHE PHARMA USA LLC
(BIONICHE PHARMA USA)

MYLAN INSTITUTIONAL LLC
(MYLAN LLC)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck

KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB2	76752	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB3	76752	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper

versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2012) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2012</u>	<u>MAR 2013</u>	<u>JUN 2013</u>	<u>SEPT 2013</u>	<u>DEC 2013</u>
DRUG PRODUCTS LISTED	15343	15445	15408		
SINGLE SOURCE	2400 (15.9%)	2467 (16.0%)	2440 (15.8%)		
MULTISOURCE	12825 (83.6%)	12900 (83.5%)	12890 (83.7%)		
THERAPEUTICALLY EQUIVALENT	12683 (82.7%)	12758 (82.6%)	12750 (82.7%)		
NOT THERAPEUTICALLY EQUIVALENT	142 (0.9%)	142 (0.9%)	140 (0.9%)		
EXCEPTIONS ¹	78 (0.5%)	78 (0.5%)	78 (0.5%)		
NEW MOLECULAR ENTITIES APPROVED	17	9	5		
NUMBER OF APPLICANTS	835	844	841		

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.

CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

PRESCRIPTION DRUG PRODUCT LIST - 33RD EDITION

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2013

1-1

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

@ MIRROR PHARMS LLC 500MG;50MG;40MG A040883 001 Dec 23, 2008 Feb DISC

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

@ MIKART 356.4MG;30MG;16MG A040109 001 Aug 26, 1997 Feb DISC

>D> AA WRASER PHARMS LLC 356.4MG;30MG;16MG A040688 001 Apr 03, 2007 Jun DISC

>A> @ 356.4MG;30MG;16MG A040688 001 Apr 03, 2007 Jun DISC

TABLET; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

>D> AA BOCA PHARMA 712.8MG;60MG;32MG A040701 001 Apr 03, 2007 Jun DISC

>A> @ 712.8MG;60MG;32MG A040701 001 Apr 03, 2007 Jun DISC

@ MIKART 712.8MG;60MG;32MG A040316 001 Apr 28, 1999 Feb DISC

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA AUROLIFE PHARMA LLC 300MG;15MG A202800 001 Apr 15, 2013 Apr NEWA

AA 300MG;30MG A202800 002 Apr 15, 2013 Apr NEWA

AA 300MG;60MG A202800 003 Apr 15, 2013 Apr NEWA

>D> AA MIKART 300MG;30MG A089238 001 Feb 25, 1986 Jun DISC

>A> @ 300MG;30MG A089238 001 Feb 25, 1986 Jun DISC

@ 650MG;30MG A089231 001 Mar 03, 1986 Feb DISC

@ 650MG;60MG A089363 001 Sep 09, 1991 Feb DISC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

>D> AA MIKART 500MG;5MG A089008 001 Feb 21, 1986 Jun DISC

>A> @ 500MG;5MG A089008 001 Feb 21, 1986 Jun DISC

@ 500MG;5MG A081067 001 Nov 30, 1989 Feb DISC

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA PAI 325MG/15ML;7.5MG/15ML A040838 001 May 10, 2013 Apr NEWA

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA CARACO 325MG;5MG A090118 001 Dec 23, 2008 May CAHN

AA 325MG;7.5MG A090118 002 Dec 23, 2008 May CAHN

AA 325MG;10MG A090118 003 Dec 23, 2008 May CAHN

AA 500MG;5MG A090265 001 Dec 23, 2008 May CAHN

AA 500MG;7.5MG A090265 002 Dec 23, 2008 May CAHN

AA 500MG;10MG A090265 003 Dec 23, 2008 May CAHN

>A> AA 650MG;7.5MG A090380 001 Dec 23, 2008 Jun CAHN

>A> AA 650MG;10MG A090380 002 Dec 23, 2008 Jun CAHN

>A> AA 660MG;10MG A090380 003 Dec 23, 2008 Jun CAHN

>A> AA 750MG;7.5MG A090380 004 Dec 23, 2008 Jun CAHN

@ MIKART 500MG;2.5MG A089698 001 Aug 25, 1989 Feb DISC

@ 650MG;5MG A040849 001 Jun 09, 2010 Feb DISC

>D> AA SUN PHARM INDS INC 650MG;7.5MG A090380 001 Dec 23, 2008 Jun CAHN

>D> AA 650MG;10MG A090380 002 Dec 23, 2008 Jun CAHN

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

>D>	AA	SUN PHARM INDS INC	660MG;10MG	A090380	003	Dec 23, 2008	Jun	CAHN
>D>	AA		750MG;7.5MG	A090380	004	Dec 23, 2008	Jun	CAHN
	AA	TRIS PHARMA INC	325MG;5MG	A202214	001	Mar 27, 2013	Mar	NEWA
	AA		325MG;7.5MG	A202214	002	Mar 27, 2013	Mar	NEWA
	AA		325MG;10MG	A202214	003	Mar 27, 2013	Mar	NEWA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

	AA	ACTAVIS ELIZABETH	325MG;2.5MG	A201447	001	Apr 12, 2013	Apr	NEWA
	AA		325MG;5MG	A201447	002	Apr 12, 2013	Apr	NEWA
	AA		325MG;7.5MG	A201447	003	Apr 12, 2013	Apr	NEWA
	AA		325MG;10MG	A201447	004	Apr 12, 2013	Apr	NEWA

ACETAZOLAMIDE

TABLET; ORAL

ACETAZOLAMIDE

		@ WATSON LABS	250MG	A088882	001	Oct 22, 1985	Jan	DISC
--	--	---------------	-------	---------	-----	--------------	-----	------

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

AP		SAGENT AGILA	EQ 500MG BASE/VIAL	A200880	001	May 09, 2012	Jan	CAHN
----	--	--------------	--------------------	---------	-----	--------------	-----	------

ACITRETIN

CAPSULE; ORAL

ACITRETIN

	AB	BARR LABS INC	10MG	A091455	001	Apr 04, 2013	Mar	NEWA
	AB		25MG	A091455	002	Apr 04, 2013	Mar	NEWA
	AB	TEVA PHARMS USA	17.5MG	A202897	001	Apr 04, 2013	Mar	NEWA
	AB		22.5MG	A202897	002	Apr 04, 2013	Mar	NEWA
		SORIATANE						
	AB	STIEFEL LABS INC	10MG	N019821	001	Oct 28, 1996	Mar	CFTG
	AB		17.5MG	N019821	003	Aug 06, 2009	Mar	CFTG
	AB		22.5MG	N019821	004	Aug 06, 2009	Mar	CFTG
	AB	+	25MG	N019821	002	Oct 28, 1996	Mar	CFTG

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL

SEMPREX-D

	+	ACTIENT PHARMS	8MG;60MG	N019806	001	Mar 25, 1994	May	CAHN
--	---	----------------	----------	---------	-----	--------------	-----	------

ACYCLOVIR

OINTMENT; TOPICAL

ACYCLOVIR

AB		MYLAN PHARMS INC	5%		A202459	001	Apr 03, 2013	Mar	NEWA
		ZOVIRAX							
AB	+	VALEANT BERMUDA	5%		N018604	001	Mar 29, 1982	May	CAHN
AB	+	VALEANT INTL	5%		N018604	001	Mar 29, 1982	Mar	CFTG

SUSPENSION; ORAL

ZOVIRAX

>A>	AB	+	DELCOR ASSET	200MG/5ML	N019909	001	Dec 22, 1989	Jun	CAHN
>D>	AB	+	GLAXOSMITHKLINE	200MG/5ML	N019909	001	Dec 22, 1989	Jun	CAHN

TABLET; BUCCAL									
SITAVIG									
	+ BIOALLIANCE PHARMA	50MG				N203791	001	Apr 12, 2013	Apr NEWA
<u>ACYCLOVIR; HYDROCORTISONE</u>									
CREAM; TOPICAL									
XERESE									
	+ VALEANT BERMUDA	5%;1%				N022436	001	Jul 31, 2009	Apr CAHN
<u>ADENOSINE</u>									
INJECTABLE; INJECTION									
ADENOSINE									
	@ TEVA PHARMS USA	3MG/ML				A076564	001	Jun 16, 2004	Apr CAHN
	@	3MG/ML				A078676	001	Jul 31, 2008	Apr CAHN
<u>ALBENDAZOLE</u>									
TABLET; ORAL									
ALBENZA									
	+ AMEDRA PHARMS	200MG				N020666	001	Jun 11, 1996	Feb CAHN
<u>ALBUTEROL SULFATE</u>									
AEROSOL, METERED; INHALATION									
PROAIR HFA									
BX	+ TEVA BRANDED PHARM	EQ 0.09MG BASE/INH				N021457	001	Oct 29, 2004	Apr CAHN
VENTOLIN HFA									
BX	+ GLAXO GRP LTD	EQ 0.09MG BASE/INH				N020983	001	Apr 19, 2001	May CAHN
SOLUTION; INHALATION									
ALBUTEROL SULFATE									
	@ APOTEX INC	EQ 0.021% BASE				A078623	001	Apr 05, 2010	Apr DISC
	@	EQ 0.042% BASE				A078623	002	Apr 05, 2010	Apr DISC
	@	EQ 0.083% BASE				A075717	001	Feb 02, 2007	Apr DISC
	@	EQ 0.5% BASE				A076391	001	Apr 01, 2003	Apr DISC
AN	+ MYLAN SPECLT	EQ 0.083% BASE				A072652	001	Feb 21, 1992	Jan CAHN
	@ WOCKHARDT EU OPERATN	EQ 0.083% BASE				A075394	001	Nov 22, 1999	Mar DISC
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE</u>									
SOLUTION; INHALATION									
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE									
	@ APOTEX INC	EQ 0.083% BASE;0.017%				A077117	001	Dec 31, 2007	Apr DISC
<u>ALENDRONATE SODIUM</u>									
SOLUTION; ORAL									
ALENDRONATE SODIUM									
AA	ROXANE	EQ 70MG BASE/75ML				A090520	001	Feb 25, 2013	Feb NEWA
FOSAMAX									
AA	+ MERCK	EQ 70MG BASE/75ML				N021575	001	Sep 17, 2003	Feb CFTG
<u>ALFUZOSIN HYDROCHLORIDE</u>									
TABLET, EXTENDED RELEASE; ORAL									
UROXATRAL									
AB	+ COVIS PHARMA SARL	10MG				N021287	001	Jun 12, 2003	Apr CAHN

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

AB	ACCORD HLTHCARE	100MG	A203154 001	May 06, 2013	Apr	NEWA
AB		300MG	A203154 002	May 06, 2013	Apr	NEWA

ALOGLIPTIN BENZOATE

TABLET; ORAL

NESINA

TAKEDA PHARMS USA

EQ 6.25MG BASE

N022271 001 Jan 25, 2013 Jan NEWA

EQ 12.5MG BASE

N022271 002 Jan 25, 2013 Jan NEWA

+

EQ 25MG BASE

N022271 003 Jan 25, 2013 Jan NEWA

ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

KAZANO

TAKEDA PHARMS USA

EQ 12.5MG BASE;500MG

N203414 001 Jan 25, 2013 Jan NEWA

+

EQ 12.5MG BASE;1GM

N203414 002 Jan 25, 2013 Jan NEWA

ALOGLIPTIN BENZOATE; PIOGLITAZONE

TABLET; ORAL

OSEN

TAKEDA PHARMS USA

EQ 12.5MG BASE;EQ 15MG BASE

N022426 004 Jan 25, 2013 Jan NEWA

EQ 12.5MG BASE;EQ 30MG BASE

N022426 005 Jan 25, 2013 Jan NEWA

EQ 12.5MG BASE;EQ 45MG BASE

N022426 006 Jan 25, 2013 Jan NEWA

EQ 25MG BASE;EQ 15MG BASE

N022426 001 Jan 25, 2013 Jan NEWA

EQ 25MG BASE;EQ 30MG BASE

N022426 002 Jan 25, 2013 Jan NEWA

+

EQ 25MG BASE;EQ 45MG BASE

N022426 003 Jan 25, 2013 Jan NEWA

ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

OSEN

TAKEDA PHARMS USA

EQ 12.5MG BASE;EQ 15MG BASE

N022426 004 Jan 25, 2013 Feb CAIN

EQ 12.5MG BASE;EQ 30MG BASE

N022426 005 Jan 25, 2013 Feb CAIN

EQ 12.5MG BASE;EQ 45MG BASE

N022426 006 Jan 25, 2013 Feb CAIN

EQ 25MG BASE;EQ 15MG BASE

N022426 001 Jan 25, 2013 Feb CAIN

EQ 25MG BASE;EQ 30MG BASE

N022426 002 Jan 25, 2013 Feb CAIN

+

EQ 25MG BASE;EQ 45MG BASE

N022426 003 Jan 25, 2013 Feb CAIN

ALPRAZOLAM

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

>D>	AB	TEVA PHARMS	0.5MG	A077979 001	Feb 28, 2007	Jun	DISC
>D>	AB		1MG	A077979 002	Feb 28, 2007	Jun	DISC
>D>	AB		2MG	A077979 003	Feb 28, 2007	Jun	DISC
>D>	AB		3MG	A077979 004	Feb 28, 2007	Jun	DISC
>A>		@ TEVA PHARMS USA	0.5MG	A077979 001	Feb 28, 2007	Jun	DISC
>A>		@	1MG	A077979 002	Feb 28, 2007	Jun	DISC
>A>		@	2MG	A077979 003	Feb 28, 2007	Jun	DISC
>A>		@	3MG	A077979 004	Feb 28, 2007	Jun	DISC

ALPROSTADIL

INJECTABLE; INJECTION

ALPROSTADIL

AP	TEVA PHARMS USA	0.5MG/ML	A075196 001	Apr 30, 1999	Apr	CAHN
----	-----------------	----------	-------------	--------------	-----	------

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

	@ HOSPIRA	EQ 250MG BASE/ML	A063264 001	Nov 30, 1994	Mar	DISC
>D>	@ TEVA PARENTERAL	EQ 50MG BASE/ML	A064045 001	Sep 28, 1993	Jun	CAHN
>D>	AP	EQ 250MG BASE/ML	A064045 002	Sep 28, 1993	Jun	CAHN
>A>	@ TEVA PHARMS USA	EQ 50MG BASE/ML	A064045 001	Sep 28, 1993	Jun	CAHN
>A>	AP	EQ 250MG BASE/ML	A064045 002	Sep 28, 1993	Jun	CAHN

AMINOPHYLLINE

INJECTABLE; INJECTION

AMINOPHYLLINE

>D>	AP	INTL MEDICATION	25MG/ML	A087209 001	Feb 01, 1982	Jun	DISC
>A>	@	25MG/ML	A087209 001	Feb 01, 1982	Jun	DISC	
>D>	AP	PHARMA SERVE NY	25MG/ML	A087392 001	Dec 15, 1983	Jun	DISC
>A>	@	25MG/ML	A087392 001	Dec 15, 1983	Jun	DISC	

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDE

	@ APOTEX INC	50MG/ML	A076394 001	Apr 25, 2003	Apr	DISC
AP	+ MYLAN INSTITUTIONAL	50MG/ML	A076217 001	Oct 15, 2002	Apr	CAHN
	@ TEVA PHARMS USA	50MG/ML	A076163 001	Sep 05, 2003	Apr	CAHN

>D> AMLEXANOX

>D> PASTE; DENTAL

>D> APHTHASOL

>D>	+ ULURU	5%	N020511 001	Dec 17, 1996	Jun	DISC
-----	---------	----	-------------	--------------	-----	------

>A>	@	5%	N020511 001	Dec 17, 1996	Jun	DISC
-----	---	----	-------------	--------------	-----	------

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

AB	ACCORD HLTHCARE	EQ 2.5MG BASE	A202553 001	Apr 29, 2013	Apr	NEWA
AB		EQ 5MG BASE	A202553 002	Apr 29, 2013	Apr	NEWA
AB		EQ 10MG BASE	A202553 003	Apr 29, 2013	Apr	NEWA

AMLODIPINE BESYLATE; VALSARTAN

TABLET; ORAL

AMLODIPINE BESYLATE AND VALSARTAN

AB	PAR PHARM INC	EQ 5MG BASE;160MG	A090011 001	Mar 28, 2013	Mar	NEWA
AB		EQ 5MG BASE;320MG	A090144 001	Mar 28, 2013	Mar	NEWA
AB		EQ 10MG BASE;160MG	A090011 002	Mar 28, 2013	Mar	NEWA
AB		EQ 10MG BASE;320MG	A090011 004	Mar 28, 2013	Mar	NEWA

EXFORGE

AB	NOVARTIS	EQ 5MG BASE;160MG	N021990 002	Jun 20, 2007	Mar	CFTG
AB		EQ 5MG BASE;320MG	N021990 004	Jun 20, 2007	Mar	CFTG
AB	+	EQ 10MG BASE;160MG	N021990 003	Jun 20, 2007	Mar	CFTG
AB	+	EQ 10MG BASE;320MG	N021990 005	Jun 20, 2007	Mar	CFTG

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

AP		CARDINAL HEALTH 414	30MCI-300MCI/8ML (3.75-37.5MCI/ML)	A203700 001	Feb 25, 2013	Feb	NEWA
AP	+	FEINSTEIN	30MCI-300MCI/8ML (3.75-37.5MCI/ML)	N022119 001	Aug 23, 2007	Feb	CFTG
AP		MCPRF	30MCI-300MCI/8ML (3.75-37.5MCI/ML)	A203321 001	Feb 25, 2013	Feb	NEWA
>A>	AP	UCLA BIOMEDICAL	30MCI-300MCI/8ML (3.75-37.5MCI/ML)	A203812 001	Jun 27, 2013	Jun	NEWA

AMOXICILLIN

FOR SUSPENSION; ORAL

AMOXICILLIN

@ RANBAXY

200MG/5ML

A065113 001 Nov 29, 2002 Feb DISC

@

400MG/5ML

A065113 002 Nov 29, 2002 Feb DISC

TABLET; ORAL

AMOXICILLIN

>D>	AB	DAVA PHARMS INC	875MG	A065344 001	Jan 15, 2009	Jun	DISC
>A>		@	875MG	A065344 001	Jan 15, 2009	Jun	DISC

TABLET, CHEWABLE; ORAL

AMOXICILLIN

@ DAVA PHARMS INC

125MG

A064139 001 Jan 29, 1996 Mar DISC

@

250MG

A064139 002 Jan 29, 1996 Mar DISC

@ RANBAXY

200MG

A065060 001 Nov 29, 2000 Feb DISC

@

400MG

A065060 002 Nov 29, 2000 Feb DISC

AMOXIL

@ DR REDDYS LABS INC

200MG

N050761 001 Apr 15, 1999 Feb DISC

@

400MG

N050761 002 Apr 15, 1999 Feb DISC

TABLET, FOR SUSPENSION; ORAL

AMOXICILLIN

@ AUROBINDO PHARMA LTD

200MG

A065324 001 Jan 17, 2007 Jan DISC

@

400MG

A065324 002 Jan 17, 2007 Jan DISC

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

@ APOTEX INC

250MG;EQ 125MG BASE

A065333 001 Feb 24, 2009 Apr DISC

@

500MG;EQ 125MG BASE

A065333 002 Feb 24, 2009 Apr DISC

@

875MG;EQ 125MG BASE

A065317 003 Oct 20, 2008 Apr DISC

@ RANBAXY LABS

500MG;EQ 125MG BASE

A065109 001 Nov 04, 2002 Apr DISC

AB TEVA PHARMS USA

875MG;EQ 125MG BASE

A065096 001 Oct 29, 2002 Apr CRLD

AUGMENTIN '250'

AB + DR REDDYS LABS INC

250MG;EQ 125MG BASE

N050564 001 Aug 06, 1984 Apr CRLD

AUGMENTIN '500'

AB + DR REDDYS LABS INC

500MG;EQ 125MG BASE

N050564 002 Aug 06, 1984 Apr CRLD

AUGMENTIN '875'

AB + DR REDDYS LABS INC

875MG;EQ 125MG BASE

N050720 001 Feb 13, 1996 Apr CRLD

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

AMPHETAMINE ASP AMPHETAMINE SULF DEXTROAMPHET SACCHARATE & DEXTR SULF

AB	TEVA	1.25MG;1.25MG;1.25MG;1.25MG	A077488 001	Apr 29, 2013	Apr	NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A077488 002	Apr 29, 2013	Apr	NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A077488 003	Apr 29, 2013	Apr	NEWA

CAPSULE, EXTENDED RELEASE; ORAL

AMPHETAMINE ASP AMPHETAMINE SULF DEXTROAMPHET SACCHARATE & DEXTR SULF

AB	TEVA	5MG;5MG;5MG;5MG	A077488 004	Apr 29, 2013	Apr	NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A077488 005	Apr 29, 2013	Apr	NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A077488 006	Apr 29, 2013	Apr	NEWA

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	BARR LABS INC	1.25MG;1.25MG;1.25MG;1.25MG	A076536 001	Feb 12, 2013	Jan	NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A076536 002	Feb 12, 2013	Jan	NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A076536 003	Feb 12, 2013	Jan	NEWA
AB		5MG;5MG;5MG;5MG	A076536 004	Feb 12, 2013	Jan	NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A076536 005	Feb 12, 2013	Jan	NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A076536 006	Feb 12, 2013	Jan	NEWA

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

@	TEVA PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A040472 001	Sep 30, 2003	Jan	DISC
@		2.5MG;2.5MG;2.5MG;2.5MG	A040472 002	Sep 30, 2003	Jan	DISC
@		5MG;5MG;5MG;5MG	A040472 003	Sep 30, 2003	Jan	DISC
@		7.5MG;7.5MG;7.5MG;7.5MG	A040472 004	Sep 30, 2003	Jan	DISC

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

	AP	ACS DOBFAR SPA	EQ 500MG BASE/VIAL	A090884 001	Apr 03, 2013	Mar	NEWA
	AP		EQ 1GM BASE/VIAL	A090884 002	Apr 03, 2013	Mar	NEWA
	AP		EQ 2GM BASE/VIAL	A090884 003	Apr 03, 2013	Mar	NEWA
	AP		EQ 10GM BASE/VIAL	A090889 001	Apr 03, 2013	Mar	NEWA
>D>	AP	ANTIBIOTICE	EQ 250MG BASE/VIAL	A090354 001	Dec 28, 2009	Jun	DISC
>A>		@	EQ 250MG BASE/VIAL	A090354 001	Dec 28, 2009	Jun	DISC
>D>	AP		EQ 500MG BASE/VIAL	A090354 002	Dec 28, 2009	Jun	DISC
>A>		@	EQ 500MG BASE/VIAL	A090354 002	Dec 28, 2009	Jun	DISC
>D>	AP		EQ 1GM BASE/VIAL	A090354 003	Dec 28, 2009	Jun	DISC
>A>		@	EQ 1GM BASE/VIAL	A090354 003	Dec 28, 2009	Jun	DISC
>D>	AP		EQ 2GM BASE/VIAL	A090354 004	Dec 28, 2009	Jun	DISC
>A>		@	EQ 2GM BASE/VIAL	A090354 004	Dec 28, 2009	Jun	DISC

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

AB	ACCORD HLTHCARE	1MG	A090568 001	Jun 28, 2010	Apr	CAHN
	@ KUDCO IRELAND	1MG	A091331 001	Jan 05, 2011	Feb	DISC

ARIPIRAZOLE

FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

ABILIFY MAINTENA KIT

	OTSUKA PHARM CO LTD	300MG/VIAL	N202971 001	Feb 28, 2013	Feb	NEWA
+		400MG/VIAL	N202971 002	Feb 28, 2013	Feb	NEWA

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

ORPHENGESIC

@	PRINSTON INC	385MG;30MG;25MG	A075141 001	May 29, 1998	Apr	CAHN
---	--------------	-----------------	-------------	--------------	-----	------

ORPHENGESIC FORTE

@	PRINSTON INC	770MG;60MG;50MG	A075141 002	May 29, 1998	Apr	CAHN
---	--------------	-----------------	-------------	--------------	-----	------

ATENOLOL

TABLET; ORAL

ATENOLOL

@ WATSON LABS

50MG

A073352 001 Dec 27, 1991 Mar DISC

@

100MG

A073353 001 Dec 27, 1991 Mar DISC

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

AB KUDCO IRELAND

EQ 10MG BASE

A091624 001 Apr 05, 2013 Mar NEWA

AB

EQ 20MG BASE

A091624 002 Apr 05, 2013 Mar NEWA

AB

EQ 40MG BASE

A091624 003 Apr 05, 2013 Mar NEWA

AB

EQ 80MG BASE

A091624 004 Apr 05, 2013 Mar NEWA

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET; ORAL

LIPTRUZET

MERCK SHARP DOHME

EQ 10MG BASE;10MG

N200153 001 May 03, 2013 May NEWA

EQ 20MG BASE;10MG

N200153 002 May 03, 2013 May NEWA

EQ 40MG BASE;10MG

N200153 003 May 03, 2013 May NEWA

+

EQ 80MG BASE;10MG

N200153 004 May 03, 2013 May NEWA

AZELAIC ACID

GEL; TOPICAL

FINACEA

>A> + BAYER HLTHCARE

15%

N021470 001 Dec 24, 2002 Jun CAHN

>D> + BHP DERMATOLOGY

15%

N021470 001 Dec 24, 2002 Jun CAHN

AZITHROMYCIN

INJECTABLE; INJECTION

AZITHROMYCIN

AP SUN PHARM INDS LTD

EQ 500MG BASE/VIAL

A090923 001 Apr 02, 2013 Mar NEWA

BACITRACIN

OINTMENT; OPHTHALMIC

BACITRACIN

>D> + FERA PHARMS 500 UNITS/GM

A061212 001 Jun CAHN

>A> + PERRIGO CO TENNESSEE 500 UNITS/GM

A061212 001 Jun CAHN

POWDER; FOR RX COMPOUNDING

BACI-RX

@ X GEN PHARMS

5,000,000 UNITS/BOT

A061580 001 Mar DISC

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

>D> AT FERA PHARMS 400 UNITS/GM;EQ 3.5MG

A060764 002 Jun CAHN

BASE/GM;10,000 UNITS/GM

>A> AT PERRIGO CO TENNESSEE 400 UNITS/GM;EQ 3.5MG

A060764 002 Jun CAHN

BASE/GM;10,000 UNITS/GM

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN ZINC AND POLYMYXIN B SULFATE

>D> AT FERA PHARMS 500 UNITS/GM;10,000 UNITS/GM

A065022 001 Feb 27, 2002 Jun CAHN

>A> AT PERRIGO CO TENNESSEE 500 UNITS/GM;10,000 UNITS/GM

A065022 001 Feb 27, 2002 Jun CAHN

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

>D>	+	FERA PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062166 002		Jun	CAHN
>A>	+	PERRIGO CO TENNESSEE	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062166 002		Jun	CAHN

BACLOFEN

INJECTABLE; INTRATHECAL

GABLOFEN

AP		MALLINCKRODT INC	0.05MG/ML	N022462 001	Nov 19, 2010	May	CAHN
AP			0.5MG/ML	N022462 002	Nov 19, 2010	May	CAHN
			1MG/ML	N022462 004	Jun 22, 2012	May	CAHN
AP			2MG/ML	N022462 003	Nov 19, 2010	May	CAHN

BENZONATATE

CAPSULE; ORAL

BENZONATATE

AA		CARACO	100MG	A040587 001	Mar 19, 2008	May	CAHN
AA			200MG	A040587 002	Mar 19, 2008	May	CAHN

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

ACANYA

	+	DOW PHARM	2.5%;1.2%	N050819 001	Oct 23, 2008	Apr	CAHN
AB		VALEANT BERMUDA	5%;EQ 1% BASE	N050756 001	Dec 21, 2000	Apr	CAHN
BT	+		5%;EQ 1% BASE	N050756 002	Apr 20, 2007	Apr	CAHN

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL

BENZAMYCIN PAK

>D>	+	VALEANT INTL	5%;3%	N050769 001	Nov 27, 2000	Jun	CAHN
>A>	+	VALEANT LUXEMBOURG	5%;3%	N050769 001	Nov 27, 2000	Jun	CAHN

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

@ COREPHARMA

50MG

A040714 001 Oct 29, 2007 Feb DISC

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

BENZTROPINE MESYLATE

AP		NAVINTA LLC	1MG/ML	A091525 001	Feb 05, 2013	Jan	NEWA
----	--	-------------	--------	-------------	--------------	-----	------

TABLET; ORAL

BENZTROPINE MESYLATE

@ PROSAM LABS

0.5MG

A040699 001 Feb 14, 2008 Mar DISC

@

1MG

A040705 001 Feb 14, 2008 Mar DISC

@

2MG

A040706 001 Feb 14, 2008 Mar DISC

BETAMETHASONE

SYRUP; ORAL

CELESTONE

@ MERCK SHARP DOHME

0.6MG/5ML

N014215 002

Apr CAHN

BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

CELESTONE SOLUSPAN

AB	+	MERCK SHARP DOHME	3MG/ML;EQ 3MG BASE/ML	N014602 001		Apr	CAHN
----	---	-------------------	-----------------------	-------------	--	-----	------

BETAMETHASONE VALERATE

AEROSOL, FOAM; TOPICAL

BETAMETHASONE VALERATE

AB		PERRIGO	0.12%	A078337 001	Nov 26, 2012	Apr	CPOT
----	--	---------	-------	-------------	--------------	-----	------

LUXIQ

AB	+	STIEFEL	0.12%	N020934 001	Feb 28, 1999	Apr	CPOT
----	---	---------	-------	-------------	--------------	-----	------

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

@ APOTEX INC

EQ 0.5% BASE

A075446 001	Sep 28, 2000	Apr	DISC
-------------	--------------	-----	------

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

>A>	AA	CARACO	5MG	A040897 001	Apr 22, 2009	Jun	CAHN
>A>	AA		10MG	A040897 002	Apr 22, 2009	Jun	CAHN
>A>	AA		25MG	A040897 003	Apr 22, 2009	Jun	CAHN
>A>	AA		50MG	A040897 004	Apr 22, 2009	Jun	CAHN
>D>	AA	LANNETT	5MG	A040703 001	Mar 27, 2008	Jun	DISC
>D>	AA		50MG	A040677 001	Mar 27, 2008	Jun	DISC
>A>		@ LANNETT HOLDINGS INC	5MG	A040703 001	Mar 27, 2008	Jun	DISC
>A>		@	50MG	A040677 001	Mar 27, 2008	Jun	DISC
>D>	AA	SUN PHARM INDS INC	5MG	A040897 001	Apr 22, 2009	Jun	CAHN
>D>	AA		10MG	A040897 002	Apr 22, 2009	Jun	CAHN
>D>	AA		25MG	A040897 003	Apr 22, 2009	Jun	CAHN
>D>	AA		50MG	A040897 004	Apr 22, 2009	Jun	CAHN

BEXAROTENE

CAPSULE; ORAL

TARGRETIN

>D>	+	EISAI INC	75MG	N021055 001	Dec 29, 1999	Jun	CAHN
-----	---	-----------	------	-------------	--------------	-----	------

>A>	+	VALEANT LUXEMBOURG	75MG	N021055 001	Dec 29, 1999	Jun	CAHN
-----	---	--------------------	------	-------------	--------------	-----	------

GEL; TOPICAL

TARGRETIN

>A>	+	VALEANT LUXEMBOURG	1%	N021056 001	Jun 28, 2000	Jun	CAHN
-----	---	--------------------	----	-------------	--------------	-----	------

>D>	+	VALEANT PHARMS INC	1%	N021056 001	Jun 28, 2000	Jun	CAHN
-----	---	--------------------	----	-------------	--------------	-----	------

	+		1%	N021056 001	Jun 28, 2000	Feb	CAHN
--	---	--	----	-------------	--------------	-----	------

BICALUTAMIDE

TABLET; ORAL

BICALUTAMIDE

AB		ACCORD HLTHCARE	50MG	A078917 001	Jul 06, 2009	Apr	CAHN
----	--	-----------------	------	-------------	--------------	-----	------

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

BLEOMYCIN SULFATE

@ PHARMACHEMIE BV

EQ 15 UNITS BASE/VIAL

A065201 001	Dec 13, 2007	Feb	DISC
-------------	--------------	-----	------

BRIMONIDINE TARTRATE; BRINZOLAMIDE

SUSPENSION/DROPS; OPHTHALMIC

SIMBRINZA

+	ALCON RES LTD	0.2%;1%	N204251	001	Apr 19, 2013	Apr	NEWA
---	---------------	---------	---------	-----	--------------	-----	------

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

BROMDAY

+	ISTA PHARMS INC	EQ 0.09% ACID	N021664	002	Oct 16, 2010	Apr	CPOT
---	-----------------	---------------	---------	-----	--------------	-----	------

BROMFENAC SODIUM

AT	COASTAL PHARMS	EQ 0.09% ACID	A201211	001	May 11, 2011	Apr	CPOT
----	----------------	---------------	---------	-----	--------------	-----	------

AT	LUITPOLD	EQ 0.09% ACID	A202030	001	Jan 09, 2013	Apr	CPOT
----	----------	---------------	---------	-----	--------------	-----	------

AT		0.09%	A202030	001	Jan 09, 2013	Feb	CAHN
----	--	-------	---------	-----	--------------	-----	------

PROLENSA

+	BAUSCH AND LOMB	EQ 0.07% ACID	N203168	001	Apr 05, 2013	Apr	NEWA
---	-----------------	---------------	---------	-----	--------------	-----	------

XIBROM

@	ISTA PHARMS INC	EQ 0.09% ACID	N021664	001	Mar 24, 2005	Apr	CPOT
---	-----------------	---------------	---------	-----	--------------	-----	------

BUDESONIDE

SUSPENSION; INHALATION

BUDESONIDE

@	APOTEX INC	0.25MG/2ML	A078202	001	Mar 30, 2009	Apr	DISC
---	------------	------------	---------	-----	--------------	-----	------

@		0.5MG/2ML	A078202	002	Mar 30, 2009	Apr	DISC
---	--	-----------	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

UCERIS

+	SANTARUS	9MG	N203634	001	Jan 14, 2013	Jan	NEWA
---	----------	-----	---------	-----	--------------	-----	------

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE

>D>	AP	INTL MEDICATED	0.25%	A076012	001	Jan 09, 2002	Jun	DISC
-----	----	----------------	-------	---------	-----	--------------	-----	------

>A>		@	0.25%	A076012	001	Jan 09, 2002	Jun	DISC
-----	--	---	-------	---------	-----	--------------	-----	------

>D>	AP		0.5%	A076012	002	Jan 09, 2002	Jun	DISC
-----	----	--	------	---------	-----	--------------	-----	------

>A>		@	0.5%	A076012	002	Jan 09, 2002	Jun	DISC
-----	--	---	------	---------	-----	--------------	-----	------

>D>	AP		0.75%	A076012	003	Jan 09, 2002	Jun	DISC
-----	----	--	-------	---------	-----	--------------	-----	------

>A>		@	0.75%	A076012	003	Jan 09, 2002	Jun	DISC
-----	--	---	-------	---------	-----	--------------	-----	------

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE

AB	ACTAVIS ELIZABETH	EQ 2MG BASE;EQ 0.5MG BASE	A091422	001	Feb 22, 2013	Feb	NEWA
----	-------------------	---------------------------	---------	-----	--------------	-----	------

AB	+		EQ 8MG BASE;EQ 2MG BASE	A091422	002	Feb 22, 2013	Apr	CRLD
----	---	--	-------------------------	---------	-----	--------------	-----	------

AB		EQ 8MG BASE;EQ 2MG BASE	A091422	002	Feb 22, 2013	Feb	NEWA
----	--	-------------------------	---------	-----	--------------	-----	------

AB	AMNEAL PHARMS	EQ 2MG BASE;EQ 0.5MG BASE	A203136	001	Feb 22, 2013	Feb	NEWA
----	---------------	---------------------------	---------	-----	--------------	-----	------

AB		EQ 8MG BASE;EQ 2MG BASE	A203136	002	Feb 22, 2013	Feb	NEWA
----	--	-------------------------	---------	-----	--------------	-----	------

SUBOXONE

@	RECKITT BENCKISER	EQ 2MG BASE;EQ 0.5MG BASE	N020733	001	Oct 08, 2002	Mar	DISC
---	-------------------	---------------------------	---------	-----	--------------	-----	------

AB		EQ 2MG BASE;EQ 0.5MG BASE	N020733	001	Oct 08, 2002	Feb	CFTG
----	--	---------------------------	---------	-----	--------------	-----	------

@		EQ 8MG BASE;EQ 2MG BASE	N020733	002	Oct 08, 2002	Mar	DISC
---	--	-------------------------	---------	-----	--------------	-----	------

AB	+		EQ 8MG BASE;EQ 2MG BASE	N020733	002	Oct 08, 2002	Feb	CFTG
----	---	--	-------------------------	---------	-----	--------------	-----	------

BUPROPION HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL
APLENZIN

VALEANT BERMUDA 174MG
+ 348MG
522MG

N022108 001 Apr 23, 2008 Apr CAHN
N022108 002 Apr 23, 2008 Apr CAHN
N022108 003 Apr 23, 2008 Apr CAHN

BUPROPION HYDROCHLORIDE

TABLET; ORAL

BUPROPION HYDROCHLORIDE

@ TEVA 75MG
@ 100MG

A075310 001 Nov 29, 1999 Feb CDFR
A075310 002 Nov 29, 1999 Feb DISC

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

@ IMPAX LABS 300MG
AB1 WATSON LABS INC 100MG
AB1 150MG
AB3 150MG
AB1 200MG
AB3 300MG

A077415 002 Dec 15, 2006 Apr DISC
A077455 001 Jul 19, 2010 Apr CAHN
A077455 002 Mar 12, 2008 Apr CAHN
A077285 001 Nov 26, 2008 Apr CAHN
A077455 003 Jul 19, 2010 Apr CAHN
A077285 002 Aug 15, 2008 Apr CAHN

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

BUTOCONAZOLE NITRATE

+ PERRIGO ISRAEL 2%
GYNAZOLE-1
@ KV PHARM 2%

A200923 001 May 18, 2012 Mar CRLD
N019881 001 Feb 07, 1997 Mar DISC

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

BUTORPHANOL TARTRATE

@ APOTEX INC 2MG/ML

A075697 001 Oct 23, 2001 Apr DISC

BUTORPHANOL TARTRATE PRESERVATIVE FREE

@ APOTEX INC 1MG/ML
@ 2MG/ML

A075695 001 Oct 23, 2001 Apr DISC
A075695 002 Oct 23, 2001 Apr DISC

>D> STADOL

>D> AP + APOTHECON 2MG/ML

N017857 004 Jun DISC

>A> @ 2MG/ML

N017857 004 Jun DISC

>D> STADOL PRESERVATIVE FREE

>D> AP + APOTHECON 1MG/ML

N017857 001 Jun DISC

>A> @ 1MG/ML

N017857 001 Jun DISC

>D> AP + 2MG/ML

N017857 002 Jun DISC

>A> @ 2MG/ML

N017857 002 Jun DISC

CABERGOLINE

TABLET; ORAL

CABERGOLINE

AB APOTEX CORP 0.5MG

A201503 001 Mar 08, 2013 Feb NEWA

CAFFEINE; ERGOTAMINE TARTRATE

TABLET; ORAL

ERGOTAMINE TARTRATE AND CAFFEINE

AA MIKART 100MG;1MG
@ 100MG;1MG

A040590 001 Sep 16, 2005 Mar CMFD
A040590 001 Sep 16, 2005 Jan DISC

CALCITRIOL

CAPSULE; ORAL

CALCITRIOL

AB	BANNER PHARMACAPS	0.25MCG	A091174 001	May 24, 2013	May	NEWA
AB		0.5MCG	A091174 002	May 24, 2013	May	NEWA

CALCIUM ACETATE

CAPSULE; ORAL

CALCIUM ACETATE

AB	INVAGEN PHARMS	EQ 169MG CALCIUM	A203135 001	Feb 07, 2013	Jan	NEWA
----	----------------	------------------	-------------	--------------	-----	------

TABLET; ORAL

CALCIUM ACETATE

AB	INVAGEN PHARMS	EQ 169MG CALCIUM	A202420 001	Feb 05, 2013	Jan	NEWA
----	----------------	------------------	-------------	--------------	-----	------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION

ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER

@ B BRAUN	35MG/100ML; 5GM/100ML; 30MG/100ML; 7 4MG/100ML; 640MG/100ML; 500MG/100ML ; 74MG/100ML	N019867 001	Dec 20, 1993	Mar	DISC
-----------	---	-------------	--------------	-----	------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

@ FRESENIUS	18.4MG/100ML; 1.5GM/100ML; 5.08MG/1 00ML; 538MG/100ML; 448MG/100ML	N020374 001	Jun 13, 1994	Feb	DISC
-------------	---	-------------	--------------	-----	------

INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

@ FRESENIUS	18.4MG/100ML; 2.5GM/100ML; 5.08MG/1 00ML; 538MG/100ML; 448MG/100ML	N020374 002	Jun 13, 1994	Feb	DISC
-------------	---	-------------	--------------	-----	------

INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

@ FRESENIUS	18.4MG/100ML; 3.5GM/100ML; 5.08MG/1 00ML; 538MG/100ML; 448MG/100ML	N020374 003	Jun 13, 1994	Feb	DISC
-------------	---	-------------	--------------	-----	------

INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

@ FRESENIUS	18.4MG/100ML; 4.25GM/100ML; 5.08MG/ 100ML; 538MG/100ML; 448MG/100ML	N020374 004	Jun 13, 1994	Feb	DISC
-------------	--	-------------	--------------	-----	------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INTRATHECAL

ELLIOTTS B SOLUTION

>A>	+	LUKARE MEDICAL LLC	0.2MG/ML; 0.8MG/ML; 0.3MG/ML; 0.3MG/ ML; 1.9MG/ML; 7.3MG/ML; 0.2MG/ML	N020577 001	Sep 27, 1996	Jun	CAHN
>D>	+	QOL MEDCL	0.2MG/ML; 0.8MG/ML; 0.3MG/ML; 0.3MG/ ML; 1.9MG/ML; 7.3MG/ML; 0.2MG/ML	N020577 001	Sep 27, 1996	Jun	CAHN

CANAGLIFLOZIN

TABLET; ORAL

INVOKANA

		JANSSEN PHARMS	100MG	N204042 001	Mar 29, 2013	Apr	CAHN
	+		300MG	N204042 002	Mar 29, 2013	Apr	CAHN
		JANSSEN RES AND DEV	100MG	N204042 001	Mar 29, 2013	Mar	NEWA
	+		300MG	N204042 002	Mar 29, 2013	Mar	NEWA

CANDESARTAN CILEXETIL

TABLET; ORAL

ATACAND

AB	ASTRAZENECA	4MG	N020838 001	Jun 04, 1998	Apr	CFTG
AB		8MG	N020838 002	Jun 04, 1998	Apr	CFTG

TABLET; ORAL

ATACAND

AB	ASTRAZENECA	16MG	N020838 003	Jun 04, 1998	Apr	CFTG
AB	+	32MG	N020838 004	Jun 04, 1998	Apr	CFTG
CANDESARTAN CILEXETIL						
AB	SANDOZ	4MG	A078702 001	May 03, 2013	Apr	NEWA
AB		8MG	A078702 002	May 03, 2013	Apr	NEWA
AB		16MG	A078702 003	May 03, 2013	Apr	NEWA
AB		32MG	A078702 004	May 03, 2013	Apr	NEWA

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

AB	APOTEX INC	32MG;25MG	A202884 003	Jun 03, 2013	May	NEWA
AB	DR REDDYS LABS LTD	16MG;12.5MG	A202965 001	Jun 03, 2013	May	NEWA
AB		32MG;12.5MG	A202965 002	Jun 03, 2013	May	NEWA
AB		32MG;25MG	A202965 003	Jun 03, 2013	May	NEWA

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

>D>	AB	PRINSTON INC	12.5MG	A074477 001	Feb 13, 1996	Jun	DISC
>A>		@	12.5MG	A074477 001	Feb 13, 1996	Jun	DISC
>D>	AB		25MG	A074477 002	Feb 13, 1996	Jun	DISC
>A>		@	25MG	A074477 002	Feb 13, 1996	Jun	DISC
>D>	AB		50MG	A074477 003	Feb 13, 1996	Jun	DISC
>A>		@	50MG	A074477 003	Feb 13, 1996	Jun	DISC
>D>	AB		100MG	A074477 004	Feb 13, 1996	Jun	DISC
>A>		@	100MG	A074477 004	Feb 13, 1996	Jun	DISC
>D>	AB	TEVA	12.5MG	A074483 001	Feb 13, 1996	Jun	DISC
>A>		@	12.5MG	A074483 001	Feb 13, 1996	Jun	DISC
>D>	AB		25MG	A074483 002	Feb 13, 1996	Jun	DISC
>A>		@	25MG	A074483 002	Feb 13, 1996	Jun	DISC
>D>	AB		50MG	A074483 003	Feb 13, 1996	Jun	DISC
>A>		@	50MG	A074483 003	Feb 13, 1996	Jun	DISC
>D>	AB		100MG	A074483 004	Feb 13, 1996	Jun	DISC
>A>		@	100MG	A074483 004	Feb 13, 1996	Jun	DISC

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

>A>	AB	TARO	100MG	A201106 001	Jun 21, 2013	Jun	NEWA
>A>	AB		200MG	A201106 002	Jun 21, 2013	Jun	NEWA
>A>	AB		300MG	A201106 003	Jun 21, 2013	Jun	NEWA

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE; ORAL

CARBIDOPA AND LEVODOPA

AB	ACCORD HLTHCARE	25MG;100MG	A202323 001	Feb 08, 2013	Jan	NEWA
AB		50MG;200MG	A202323 002	Feb 08, 2013	Jan	NEWA

CARBINOXAMINE MALEATE

SUSPENSION, EXTENDED RELEASE; ORAL

KARBINAL ER

+	TRIS PHARMA INC	4MG/5ML	N022556 001	Mar 28, 2013	Mar	NEWA
---	-----------------	---------	-------------	--------------	-----	------

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

@ PLIVA	50MG/VIAL	A076602 001	Nov 16, 2004	Feb	DISC
@	150MG/VIAL	A076602 002	Nov 16, 2004	Feb	DISC
@	450MG/VIAL	A076602 003	Nov 16, 2004	Feb	DISC

INJECTABLE; IV (INFUSION)

CARBOPLATIN

@ FRESENIUS KABI USA	50MG/5ML (10MG/ML)	A077266 001	Feb 15, 2006	Mar	DISC
@	150MG/15ML (10MG/ML)	A077266 002	Feb 15, 2006	Mar	DISC
@ PHARMACHEMIE BV	50MG/5ML (10MG/ML)	A077679 001	Feb 25, 2009	Apr	DISC
@	150MG/15ML (10MG/ML)	A077679 002	Feb 25, 2009	Apr	DISC
@	450MG/45ML (10MG/ML)	A077679 003	Feb 25, 2009	Apr	DISC

PARAPLATIN

@ CORDENPHARMA	50MG/5ML (10MG/ML)	N020452 001	Jul 14, 2003	Mar	CAHN
@	150MG/15ML (10MG/ML)	N020452 002	Jul 14, 2003	Mar	CAHN
@	450MG/45ML (10MG/ML)	N020452 003	Jul 14, 2003	Mar	CAHN
@	600MG/60ML (10MG/ML)	N020452 004	Jan 15, 2004	Mar	CAHN

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

AA	ACCELRX LABS	350MG	A040576 001	Jun 07, 2005	May	CAHN
	@ COREPHARMA	350MG	A040397 001	Sep 21, 2000	Feb	DISC
>D> AA	PROSAM LABS	350MG	A040188 001	Mar 07, 1997	Jun	DISC
>A>	@	350MG	A040188 001	Mar 07, 1997	Jun	DISC

CARMUSTINE

IMPLANT; INTRACRANIAL

GLIADEL

+	ARBOR PHARMS LLC	7.7MG	N020637 001	Sep 23, 1996	Mar	CAHN
---	------------------	-------	-------------	--------------	-----	------

INJECTABLE; INJECTION

BICNU

+	EMCURE PHARMS LTD	100MG/VIAL	N017422 001		Jan	CAHN
---	-------------------	------------	-------------	--	-----	------

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CARTEOLOL HYDROCHLORIDE

@ APOTEX INC	1%	A076097 001	Feb 06, 2002	Apr	DISC
--------------	----	-------------	--------------	-----	------

CARVEDILOL

TABLET; ORAL

CARVEDILOL

@ WOCKHARDT LTD	3.125MG	A078786 001	Dec 22, 2009	Feb	DISC
@	6.25MG	A078786 002	Dec 22, 2009	Feb	DISC
@	12.5MG	A078786 003	Dec 22, 2009	Feb	DISC
@	25MG	A078786 004	Dec 22, 2009	Feb	DISC

CEFADROXIL/CEFADROXIL HEMIHYDRATE

FOR SUSPENSION; ORAL

CEFADROXIL

AB	AUROBINDO	EQ 250MG BASE/5ML	A065349 001	Apr 25, 2013	Apr	NEWA
AB		EQ 500MG BASE/5ML	A065349 002	Apr 25, 2013	Apr	NEWA
	@ TEVA PHARMS USA	EQ 250MG BASE/5ML	A065278 001	Jan 20, 2006	Mar	DISC

FOR SUSPENSION; ORAL

CEFADROXIL

@ TEVA PHARMS USA

EQ 500MG BASE/5ML

A065278 002 Jan 20, 2006 Mar DISC

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

AP + HOSPIRA INC

EQ 500MG BASE/VIAL

A065226 001 Apr 21, 2005 Feb CRLD

AP +

EQ 1GM BASE/VIAL

A065226 002 Apr 21, 2005 Feb CRLD

AP +

EQ 1GM BASE/VIAL

A065244 001 Aug 12, 2005 Feb CRLD

AP +

EQ 10GM BASE/VIAL

A065247 001 Aug 12, 2005 Feb CRLD

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME HYDROCHLORIDE

@ SANDOZ

EQ 500MG BASE/VIAL

A090291 001 Dec 21, 2010 Mar DISC

@

EQ 1GM BASE/VIAL

A090291 002 Dec 21, 2010 Mar DISC

@

EQ 2GM BASE/VIAL

A090291 003 Dec 21, 2010 Mar DISC

CEFIXIME

FOR SUSPENSION; ORAL

SUPRAX

+ LUPIN LTD

500MG/5ML

N202091 001 Feb 20, 2013 Feb CDFR

LUPIN PHARMS

100MG/5ML

A065129 001 Feb 23, 2004 Feb CDFR

200MG/5ML

A065355 001 Apr 10, 2007 Feb CDFR

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME SODIUM

>D> AP

AUROBINDO PHARMA

EQ 10GM BASE/VIAL

A065516 001 Nov 06, 2009 Jun DISC

>A>

@ AUROBINDO PHARMA LTD

EQ 10GM BASE/VIAL

A065516 001 Nov 06, 2009 Jun DISC

CEFTAZIDIME

INJECTABLE; INJECTION

CEFTAZIDIME

>D> AP

AUROBINDO PHARMA

500MG/VIAL

A065481 001 May 28, 2010 Jun DISC

>D> AP

1GM/VIAL

A065481 002 May 28, 2010 Jun DISC

>D> AP

2GM/VIAL

A065481 003 May 28, 2010 Jun DISC

>D> AP

6GM/VIAL

A065482 001 May 28, 2010 Jun DISC

>A>

@ AUROBINDO PHARMA LTD

500MG/VIAL

A065481 001 May 28, 2010 Jun DISC

>A>

@

1GM/VIAL

A065481 002 May 28, 2010 Jun DISC

>A>

@

2GM/VIAL

A065481 003 May 28, 2010 Jun DISC

>A>

@

6GM/VIAL

A065482 001 May 28, 2010 Jun DISC

CEFTRIAZONE SODIUM

INJECTABLE; IM-IV

CEFTRIAZONE

@ AUROBINDO PHARMA LTD

EQ 250MG BASE/VIAL

A065505 001 Jul 31, 2008 May DISC

@

EQ 500MG BASE/VIAL

A065505 002 Jul 31, 2008 May DISC

@

EQ 1GM BASE/VIAL

A065505 003 Jul 31, 2008 May DISC

@

EQ 2GM BASE/VIAL

A065505 004 Jul 31, 2008 May DISC

AP TEVA PHARMS USA

EQ 250MG BASE/VIAL

A065227 001 Mar 15, 2007 May CAHN

AP

EQ 500MG BASE/VIAL

A065227 002 Mar 15, 2007 May CAHN

AP

EQ 1GM BASE/VIAL

A065227 003 Mar 15, 2007 May CAHN

AP

EQ 2GM BASE/VIAL

A065227 004 Mar 15, 2007 May CAHN

INJECTABLE; INJECTION

CEFTRIAZONE

@ AUROBINDO PHARMA LTD EQ 10GM BASE/VIAL

A065504 001 Jul 31, 2008 May DISC

CEFUROXIME SODIUM

INJECTABLE; INJECTION

>D> ZINACEF IN PLASTIC CONTAINER

>D> + COVIS PHARMA EQ 15MG BASE/ML

N050643 001 Apr 28, 1989 Jun DISC

>A> @ COVIS PHARMA SARL EQ 15MG BASE/ML

N050643 001 Apr 28, 1989 Jun DISC

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

ALKEM LABS LTD

EQ 333MG BASE

A090836 003 Mar 29, 2013 Mar NEWA

AB EQ 750MG BASE

A090836 004 Mar 29, 2013 Mar NEWA

KEFLEX

AB + SHIONOGI INC EQ 750MG BASE

N050405 005 May 12, 2006 Mar CTEC

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

@ APOTEX INC 5MG/5ML

A078412 001 Jun 18, 2008 Apr DISC

@ AUROBINDO PHARMA LTD 5MG/5ML

A090751 001 Dec 16, 2009 Feb DISC

AA BIO PHARM INC 5MG/5ML

A078870 001 Apr 27, 2009 May CAHN

>A> AA CARACO 5MG/5ML

A090191 001 Nov 12, 2009 Jun CAHN

>D> AA SUN PHARM INDS INC 5MG/5ML

A090191 001 Nov 12, 2009 Jun CAHN

CETRORELIX

INJECTABLE; INJECTION

CETROTIDE

>D> + EMD SERONO EQ 3MG BASE/ML

N021197 002 Aug 11, 2000 Jun DISC

>A> @ EMD SERONO INC EQ 3MG BASE/ML

N021197 002 Aug 11, 2000 Jun DISC

CEVIMELINE HYDROCHLORIDE

CAPSULE; ORAL

CEVIMELINE HYDROCHLORIDE

>A> AB ROXANE 30MG

A091591 001 Jul 08, 2013 Jun NEWA

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

CHLORHEXIDINE GLUCONATE

@ APOTEX INC 0.12%

A075561 001 Nov 14, 2000 Apr DISC

PAROEX

AT SUNSTAR AMERICAS 0.12%

A076434 001 Nov 29, 2005 Apr CTNA

CHLOROTHIAZIDE

TABLET; ORAL

DIURIL

@ OAK PHARMS AKORN 250MG

N011145 004 Jan CAHN

@ 500MG

N011145 002 Jan CAHN

CHLOROTHIAZIDE SODIUM

INJECTABLE; INJECTION

CHLOROTHIAZIDE SODIUM

>A> AP LUITPOLD EQ 500MG BASE/VIAL

A202561 001 Apr 22, 2013 Jun CAHN

INJECTABLE; INJECTION

CHLOROTHIAZIDE SODIUM

>D>	AP	PHARMAFORCE	EQ 500MG BASE/VIAL	A202561 001	Apr 22, 2013	Jun	CAHN
	AP		EQ 500MG BASE/VIAL	A202561 001	Apr 22, 2013	Apr	NEWA

DIURIL

AP	+	OAK PHARMS AKORN	EQ 500MG BASE/VIAL	N011145 005		Jan	CAHN
----	---	------------------	--------------------	-------------	--	-----	------

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

SOLUTION; ORAL

VITUZ

+	CYPRESS PHARM	4MG/5ML;5MG/5ML	N204307 001	Feb 20, 2013	Feb	NEWA
---	---------------	-----------------	-------------	--------------	-----	------

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

@	WATSON LABS INC	100MG	A088852 001	Sep 26, 1984	Jan	DISC
---	-----------------	-------	-------------	--------------	-----	------

@		250MG	A088826 001	Sep 26, 1984	Jan	DISC
---	--	-------	-------------	--------------	-----	------

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL

FENOFIBRIC ACID

AB	MYLAN PHARMS INC	EQ 45MG FENOFIBRIC ACID	A200913 001	Mar 25, 2013	Mar	NEWA
----	------------------	-------------------------	-------------	--------------	-----	------

AB		EQ 135MG FENOFIBRIC ACID	A200913 002	Mar 25, 2013	Mar	NEWA
----	--	--------------------------	-------------	--------------	-----	------

TRILIPIX

AB	ABBVIE	EQ 45MG FENOFIBRIC ACID	N022224 001	Dec 15, 2008	Mar	CFTG
----	--------	-------------------------	-------------	--------------	-----	------

AB	+	EQ 135MG FENOFIBRIC ACID	N022224 002	Dec 15, 2008	Mar	CFTG
----	---	--------------------------	-------------	--------------	-----	------

CICLOPIROX

SOLUTION; TOPICAL

CICLOPIROX

@	APOTEX INC	8%	A078172 001	Sep 18, 2007	Apr	DISC
---	------------	----	-------------	--------------	-----	------

@	TEVA PHARMS	8%	A078079 001	Sep 18, 2007	Jan	DISC
---	-------------	----	-------------	--------------	-----	------

PENLAC

AT	+	VALEANT BERMUDA	8%	N021022 001	Dec 17, 1999	May	CAHN
----	---	-----------------	----	-------------	--------------	-----	------

AT	+	VALEANT INTL	8%	N021022 001	Dec 17, 1999	Feb	CAHN
----	---	--------------	----	-------------	--------------	-----	------

CIMETIDINE

TABLET; ORAL

CIMETIDINE

>D>	AB	WATSON LABS	800MG	A074316 001	Feb 28, 1996	Jun	DISC
-----	----	-------------	-------	-------------	--------------	-----	------

		@ WATSON LABS INC	200MG	A074349 001	Aug 30, 1996	May	DISC
--	--	-------------------	-------	-------------	--------------	-----	------

		@	300MG	A074349 002	Aug 30, 1996	May	DISC
--	--	---	-------	-------------	--------------	-----	------

		@	400MG	A074349 003	Aug 30, 1996	May	DISC
--	--	---	-------	-------------	--------------	-----	------

>A>		@	800MG	A074316 001	Feb 28, 1996	Jun	DISC
-----	--	---	-------	-------------	--------------	-----	------

CIMETIDINE HYDROCHLORIDE

SOLUTION; ORAL

CIMETIDINE HYDROCHLORIDE

@	APOTEX INC	EQ 300MG BASE/5ML	A075560 001	Mar 15, 2000	Apr	DISC
---	------------	-------------------	-------------	--------------	-----	------

CIPROFLOXACIN

INJECTABLE; INJECTION

CIPROFLOXACIN

@	TEVA PHARMS USA	400MG/40ML (10MG/ML)	A077782 002	Aug 28, 2006	Apr	CAHN
---	-----------------	----------------------	-------------	--------------	-----	------

@		200MG/20ML (10MG/ML)	A077782 001	Aug 28, 2006	Apr	CAHN
---	--	----------------------	-------------	--------------	-----	------

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CIPROFLOXACIN HYDROCHLORIDE

@ APOTEX INC

EQ 0.3% BASE

A075928 001 Jun 09, 2004 Apr DISC

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPRO XR

@ BAYER HLTHCARE

212.6MG;EQ 287.5MG BASE

N021473 001 Dec 13, 2002 May DISC

@

425.2MG;EQ 574.9MG BASE

N021473 002 Aug 28, 2003 May DISC

CIPROFLOXACIN EXTENDED RELEASE

>D> AB DR REDDYS LABS LTD

212.6MG;EQ 287.5MG BASE

A077701 002 Oct 31, 2007 Jun DISC

>A> @

212.6MG;EQ 287.5MG BASE

A077701 002 Oct 31, 2007 Jun DISC

AB + MYLAN PHARMS INC

212.6MG;EQ 287.5MG BASE

A078183 001 Mar 22, 2007 May CRLD

AB +

425.2MG;EQ 574.9MG BASE

A078183 002 Mar 22, 2007 May CRLD

CISPLATIN

INJECTABLE; INJECTION

PLATINOL

@ HQ SPCLT PHARMA

10MG/VIAL

N018057 001 Jan CAHN

@

50MG/VIAL

N018057 002 Jan CAHN

PLATINOL-AQ

@ HQ SPCLT PHARMA

0.5MG/ML

N018057 003 Jul 18, 1984 Jan CAHN

@

1MG/ML

N018057 004 Nov 08, 1988 Jan CAHN

CITALOPRAM HYDROBROMIDE

SOLUTION; ORAL

CITALOPRAM HYDROBROMIDE

@ APOTEX INC

EQ 10MG BASE/5ML

A077601 001 Nov 15, 2005 Apr DISC

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

@ COREPHARMA

EQ 10MG BASE

A077036 001 Oct 28, 2004 Feb DISC

@

EQ 20MG BASE

A077036 002 Oct 28, 2004 Feb DISC

@

EQ 40MG BASE

A077036 003 Oct 28, 2004 Feb DISC

>D> AB NATCO PHARMA LTD

EQ 20MG BASE

A077141 002 Apr 10, 2008 Jun DISC

>A> @

EQ 20MG BASE

A077141 002 Apr 10, 2008 Jun DISC

>D> AB

EQ 40MG BASE

A077141 001 Apr 10, 2008 Jun DISC

>A> @

EQ 40MG BASE

A077141 001 Apr 10, 2008 Jun DISC

CLARITHROMYCIN

TABLET; ORAL

CLARITHROMYCIN

AB ALLIED PHARMA INC

250MG

A202710 001 Jun 10, 2013 May NEWA

AB

500MG

A202710 002 Jun 10, 2013 May NEWA

CLEMASTINE FUMARATE

SYRUP; ORAL

CLEMASTINE FUMARATE

@ APOTEX INC

EQ 0.5MG BASE/5ML

A075703 001 Nov 27, 2000 Apr DISC

@ SILARX

EQ 0.5MG BASE/5ML

A074884 001 Dec 17, 1997 Mar DISC

CLEVIDIPINE

EMULSION; INTRAVENOUS

CLEVIPREX

+	MEDICINES CO	25MG/50ML (0.5MG/ML)	N022156 001	Aug 01, 2008	Feb	CAIN
+		50MG/100ML (0.5MG/ML)	N022156 002	Aug 01, 2008	Feb	CAIN

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA	AUROBINDO PHARMA LTD	EQ 75MG BASE/5ML	A202409 001	Apr 30, 2013	Apr	NEWA
----	----------------------	------------------	-------------	--------------	-----	------

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER

AP	AKORN INC	EQ 6MG BASE/ML	A203048 001	Apr 04, 2013	Mar	NEWA
AP		EQ 12MG BASE/ML	A203048 002	Apr 04, 2013	Mar	NEWA
AP		EQ 18MG BASE/ML	A203048 003	Apr 04, 2013	Mar	NEWA

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

@	ACTAVIS MID ATLANTIC	EQ 1% BASE	A062811 001	Sep 01, 1988	May	CAHN
@	PERRIGO NEW YORK	EQ 1% BASE	A064050 001	Nov 30, 1995	Feb	DISC

CLOBETASOL PROPIONATE

AEROSOL, FOAM; TOPICAL

OLUX E

>A>	AB2 +	DELCOR ASSET	0.05%	N022013 001	Jan 12, 2007	Jun	CAHN
>D>	AB2 +	STIEFEL LABS INC	0.05%	N022013 001	Jan 12, 2007	Jun	CAHN

CREAM; TOPICAL

CLOBETASOL PROPIONATE

>D>	AB1	TEVA PHARMS	0.05%	A074087 001	Feb 16, 1994	Jun	DISC
>A>		@ TEVA PHARMS USA	0.05%	A074087 001	Feb 16, 1994	Jun	DISC

CLONAZEPAM

TABLET; ORAL

CLONAZEPAM

AB	ACCORD HLTHCARE	0.5MG	A077147 001	May 02, 2005	Apr	CAHN
AB		1MG	A077147 002	May 02, 2005	Apr	CAHN
AB		2MG	A077147 003	May 02, 2005	Apr	CAHN
	@ APOTEX INC	0.5MG	A075468 001	Oct 06, 2000	Feb	DISC
	@	1MG	A075468 002	Oct 06, 2000	Feb	DISC
	@	2MG	A075468 003	Oct 06, 2000	Feb	DISC

CLONIDINE HYDROCHLORIDE

TABLET; ORAL

CLONIDINE HYDROCHLORIDE

AB	CARLSBAD	0.1MG	A202297 001	Jun 13, 2013	May	NEWA
AB		0.2MG	A202297 002	Jun 13, 2013	May	NEWA
AB		0.3MG	A202297 003	Jun 13, 2013	May	NEWA

TABLET, EXTENDED RELEASE; ORAL

JENLOGA

@	CONCORDIA PHARMS INC	0.1MG	N022331 001	Sep 30, 2009	May	CAHN
@		0.2MG	N022331 002	May 25, 2010	May	CAHN

KAPVAY

+	CONCORDIA PHARMS INC	0.1MG	N022331 003	Sep 28, 2010	May	CAHN
---	----------------------	-------	-------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

KAPVAY

CONCORDIA PHARMS INC 0.2MG

N022331 004 Sep 28, 2010 May CAHN

CLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

AB	ACCORD HLTHCARE	EQ 75MG BASE	A202925 001	Mar 27, 2013	Mar	NEWA
AB		EQ 300MG BASE	A202925 002	Mar 27, 2013	Mar	NEWA
AB	ACTAVIS TOTOWA	EQ 75MG BASE	A090307 001	May 28, 2013	May	NEWA
AB	MUTUAL PHARM	EQ 75MG BASE	A078133 001	Jun 10, 2013	May	NEWA

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL

TRANXENE

@ RECORDATI RARE

3.75MG

N017105 001

May CAHN

@

7.5MG

N017105 002

May CAHN

@

15MG

N017105 003

May CAHN

TABLET; ORAL

TRANXENE

AB	RECORDATI RARE	3.75MG	N017105 006		May	CAHN
AB		7.5MG	N017105 007		May	CAHN
AB	+	15MG	N017105 008		May	CAHN

TRANXENE SD

@ RECORDATI RARE

11.25MG

N017105 005

May CAHN

@

22.5MG

N017105 004

May CAHN

CLOZAPINE

SUSPENSION; ORAL

VERSACLOZ

+ DOUGLAS PHARMS 50MG/ML

N203479 001 Feb 06, 2013 Feb NEWA

+ JAZZ PHARMS III 50MG/ML

N203479 001 Feb 06, 2013 Mar CAHN

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

AA	AMNEAL PHARMS	10MG/5ML;6.25MG/5ML	A200894 001	Apr 24, 2013	Apr	NEWA
AA	CARACO	10MG/5ML;6.25MG/5ML	A090180 001	Mar 17, 2010	May	CAHN

COSYNTROPIN

INJECTABLE; INJECTION

COSYNTROPIN

AP	MYLAN LLC	0.25MG/VIAL	A090574 001	Dec 17, 2009	Feb	CAHN
----	-----------	-------------	-------------	--------------	-----	------

CROMOLYN SODIUM

CONCENTRATE; ORAL

CROMOLYN SODIUM

AA	MICRO LABS LTD INDIA	100MG/5ML	A202745 001	Apr 04, 2013	Mar	NEWA
----	----------------------	-----------	-------------	--------------	-----	------

SOLUTION; INHALATION

CROMOLYN SODIUM

@ APOTEX INC

10MG/ML

A075333 001 Apr 30, 2002 Apr DISC

SOLUTION/DROPS; OPHTHALMIC

CROMOLYN SODIUM

@ APOTEX INC

4%

A075615 001 Jan 26, 2001 Apr DISC

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

AMRIX

AB	IVAX INTL	15MG	N021777	001	Feb 01, 2007	Jan	CAHN
AB	+	30MG	N021777	002	Feb 01, 2007	Jan	CAHN

CYCLOBENZAPRINE HYDROCHLORIDE

AB	TWI PHARMS INC	15MG	A091281	001	Jan 31, 2013	Jan	NEWA
AB		30MG	A091281	002	Jan 31, 2013	Jan	NEWA

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB	MYLAN PHARMS INC	7.5MG	A073144	003	Mar 25, 2013	Mar	NEWA
	@ PROSAM LABS	5MG	A077291	001	Feb 03, 2006	Mar	DISC
	@ SANDOZ	5MG	A072854	002	Feb 03, 2006	Apr	DISC
	@	10MG	A072854	001	Nov 19, 1991	Apr	DISC

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AKPENTOLATE

@ AKORN	2%	A040165	001	Jan 13, 1997	Mar	DISC
---------	----	---------	-----	--------------	-----	------

CYCLOGYL

+	ALCON LABS INC	2%	A084108	001		Mar	CTEC
---	----------------	----	---------	-----	--	-----	------

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

CYTOXAN (LYOPHILIZED)

AP	+	BAXTER HLTHCARE	500MG/VIAL	N012142	003		Mar	CTNA
	@		500MG/VIAL	N012142	008	Jan 04, 1984	Jan	CTNA
AP	+		1GM/VIAL	N012142	004	Aug 30, 1982	Mar	CTNA
	@		1GM/VIAL	N012142	010	Sep 24, 1985	Jan	CTNA
AP	+		2GM/VIAL	N012142	005	Aug 30, 1982	Mar	CTNA
	@		2GM/VIAL	N012142	009	Dec 10, 1985	Jan	CTNA

CYCLOSPORINE

SOLUTION; ORAL

CYCLOSPORINE

@ APOTEX INC	100MG/ML	A065167	001	Jan 05, 2005	Apr	DISC
--------------	----------	---------	-----	--------------	-----	------

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL

CYPROHEPTADINE HYDROCHLORIDE

AA	PHARM ASSOC	2MG/5ML	A091295	001	Mar 28, 2013	Mar	NEWA
----	-------------	---------	---------	-----	--------------	-----	------

CYSTEAMINE BITARTRATE

CAPSULE, DELAYED RELEASE; ORAL

PROCYSBI

	RAPTOR PHARMS	EQ 25MG BASE	N203389	001	Apr 30, 2013	Apr	NEWA
+		EQ 75MG BASE	N203389	002	Apr 30, 2013	Apr	NEWA

CYTARABINE

INJECTABLE; INJECTION

CYTOSAR-U

>D>	AP	TEVA PARENTERAL	100MG/VIAL	A075206	001	Dec 30, 1998	Jun	CAHN
>D>	AP	+	500MG/VIAL	A075206	002	Dec 30, 1998	Jun	CAHN
>D>	AP	+	1GM/VIAL	A075206	004	Dec 30, 1998	Jun	CAHN

INJECTABLE; INJECTIONCYTOSAR-U

>D>	AP	+	TEVA PARENTERAL	2GM/VIAL	A075206 003	Dec 30,	1998	Jun	CAHN
>A>	AP		TEVA PHARMS USA	100MG/VIAL	A075206 001	Dec 30,	1998	Jun	CAHN
>A>	AP	+		500MG/VIAL	A075206 002	Dec 30,	1998	Jun	CAHN
>A>	AP	+		1GM/VIAL	A075206 004	Dec 30,	1998	Jun	CAHN
>A>	AP	+		2GM/VIAL	A075206 003	Dec 30,	1998	Jun	CAHN

DABRAFENIB MESYLATECAPSULE; ORALTAFINLARGLAXOSMITHKLINE

+

EQ 50MG BASE

N202806 001 May 29, 2013 May NEWA

EQ 75MG BASE

N202806 002 May 29, 2013 May NEWA

DACARBAZINEINJECTABLE; INJECTIONDACARBAZINE

AP TEVA PHARMS USA

200MG/VIAL

A075259 002 Aug 27, 1998 Apr CAHN

AP +

500MG/VIAL

A075259 001 Sep 22, 2000 Apr CAHN

DACTINOMYCININJECTABLE; INJECTIONCOSMEGEN

AP + RECORDATI RARE

0.5MG/VIAL

N050682 001

May CAHN

DALTEPARIN SODIUMINJECTABLE; SUBCUTANEOUSFRAGMIN

>D> EISAI INC

10,000IU/0.4ML (25,000IU/ML)

N020287 002 May 01, 2007 Jun DISC

>A> @

10,000IU/0.4ML (25,000IU/ML)

N020287 002 May 01, 2007 Jun DISC

>D>

95,000IU/9.5ML (10,000IU/ML)

N020287 007 Apr 04, 2002 Jun DISC

>A> @

95,000IU/9.5ML (10,000IU/ML)

N020287 007 Apr 04, 2002 Jun DISC

DAUNORUBICIN HYDROCHLORIDEINJECTABLE; INJECTIONDAUNORUBICIN HYDROCHLORIDE

AP TEVA PHARMS USA

EQ 5MG BASE/ML

A065035 001 Jan 24, 2000 Apr CAHN

DESMOPRESSIN ACETATEINJECTABLE; INJECTIONDESMOPRESSIN ACETATE

AP SUN PHARM INDS LTD

0.004MG/ML

A091280 001 Jan 25, 2013 Jan NEWA

AP TEVA PHARMS USA

0.004MG/ML

A074888 001 Oct 15, 1997 Apr CAHN

DESOGESTREL; ETHINYL ESTRADIOLTABLET; ORAL-28ENSKYCE

AB LUPIN LTD

0.15MG;0.03MG

A201887 001 Mar 07, 2013 Feb NEWA

DESONIDEGEL; TOPICALDESONATE

>A> + BAYER HLTHCARE

0.05%

N021844 001 Oct 20, 2006 Jun CAHN

>D> + BHP DERMATOLOGY

0.05%

N021844 001 Oct 20, 2006 Jun CAHN

DESOXIMETASONE

SPRAY; TOPICAL

TOPICORT

+	TARO	0.25%	N204141	001	Apr 11, 2013	Apr	NEWA
---	------	-------	---------	-----	--------------	-----	------

DESVENLAFAXINE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE

+	ALEMBIC PHARMS LTD	50MG	N204150	001	Mar 04, 2013	Apr	CRLD
		50MG	N204150	001	Mar 04, 2013	Mar	NEWA
+		100MG	N204150	002	Mar 04, 2013	Mar	NEWA

DEXAMETHASONE

ELIXIR; ORAL

DEXAMETHASONE

AA	WOCKHARDT EU OPERATN	0.5MG/5ML	A088254	001	Jul 27, 1983	May	CRLD
----	----------------------	-----------	---------	-----	--------------	-----	------

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

>D>	AT	FERA PHARMS	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062938	001	Jul 31, 1989	Jun	CAHN
-----	----	-------------	---------------------------------------	---------	-----	--------------	-----	------

>A>	AT	PERRIGO CO TENNESSEE	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062938	001	Jul 31, 1989	Jun	CAHN
-----	----	----------------------	---------------------------------------	---------	-----	--------------	-----	------

SUSPENSION/DROPS; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

@	ALCON PHARMS LTD	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062721	001	Nov 17, 1986	Jan	DISC
---	------------------	---------------------------------------	---------	-----	--------------	-----	------

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

PRECEDEX

+	HOSPIRA	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	N021038	002	Mar 13, 2013	Mar	NEWA
---	---------	---------------------------------------	---------	-----	--------------	-----	------

+		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	N021038	003	Mar 13, 2013	Mar	NEWA
---	--	--	---------	-----	--------------	-----	------

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION

TOTECT

+	BIOCODEX INC	EQ 500MG BASE/VIAL	N022025	001	Sep 06, 2007	May	CAHN
---	--------------	--------------------	---------	-----	--------------	-----	------

DEXTROAMPHETAMINE SULFATE

SOLUTION; ORAL

DEXTROAMPHETAMINE SULFATE

AA	+	OUTLOOK PHARMS	5MG/5ML	A040776	001	Jan 29, 2008	May	CFTG
----	---	----------------	---------	---------	-----	--------------	-----	------

AA		TRIS PHARMA INC	5MG/5ML	A203644	001	May 29, 2013	May	NEWA
----	--	-----------------	---------	---------	-----	--------------	-----	------

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER

@	B BRAUN	5GM/100ML;220MG/100ML	N018744	003	Nov 09, 1982	Jan	DISC
---	---------	-----------------------	---------	-----	--------------	-----	------

DIAZEPAM

INJECTABLE; INJECTION

DIAZEPAM

>D>	AP	WATSON LABS	5MG/ML	A070296	001	Feb 12, 1986	Jun	DISC
-----	----	-------------	--------	---------	-----	--------------	-----	------

		INJECTABLE; INJECTION				
		DIAZEPAM				
>A>		@ WATSON LABS	5MG/ML	A070296 001	Feb 12, 1986	Jun DISC
<u>DIAZOXIDE</u>						
		SUSPENSION; ORAL				
		PROGLYCEM				
	+	TEVA BRANDED PHARM	50MG/ML	N017453 001		Apr CAHN
<u>DICLOFENAC SODIUM</u>						
		SOLUTION/DROPS; OPTHALMIC				
		DICLOFENAC SODIUM				
		@ APOTEX INC	0.1%	A077600 001	Nov 13, 2008	Apr DISC
<u>DICLOFENAC SODIUM; MISOPROSTOL</u>						
		TABLET, DELAYED RELEASE; ORAL				
		DICLOFENAC SODIUM AND MISOPROSTOL				
AB		SANDOZ	50MG;0.2MG	A200158 001	May 09, 2013	Apr NEWA
AB			75MG;0.2MG	A200158 002	May 09, 2013	Apr NEWA
<u>DIDANOSINE</u>						
		TABLET, FOR SUSPENSION; ORAL				
		DIDANOSINE				
		AUROBINDO	100MG	A077275 001	Aug 14, 2012	Apr CDFR
			150MG	A077275 002	Aug 14, 2012	Apr CDFR
	+		200MG	A077275 003	Aug 14, 2012	Apr CDFR
<u>DIFLORASONE DIACETATE</u>						
		CREAM; TOPICAL				
		DIFLORASONE DIACETATE				
		@ FOUGERA PHARMS	0.05%	A075187 001	Mar 30, 1998	May DISC
BX	+	TARO	0.05%	A075508 001	Apr 24, 2000	May CRLD
		PSORCON				
>D>		@ TARO	0.05%	N020205 001	Nov 20, 1992	Jun CAHN
>A>		@ TARO PHARMS NORTH	0.05%	N020205 001	Nov 20, 1992	Jun CAHN
<u>DIGOXIN</u>						
		TABLET; ORAL				
		DIGOXIN				
>D>	AB	CARACO	0.125MG	A076363 001	Jan 31, 2003	Jun DISC
>A>		@	0.125MG	A076363 001	Jan 31, 2003	Jun DISC
>D>	AB		0.25MG	A076363 002	Jan 31, 2003	Jun DISC
>A>		@	0.25MG	A076363 002	Jan 31, 2003	Jun DISC
<u>DILTIAZEM HYDROCHLORIDE</u>						
		CAPSULE, EXTENDED RELEASE; ORAL				
		DILTIAZEM HYDROCHLORIDE				
AB3		PAR PHARM	120MG	A074984 001	Dec 20, 1999	Jan CAHN
AB3			180MG	A074984 002	Dec 20, 1999	Jan CAHN
AB3			240MG	A074984 003	Dec 20, 1999	Jan CAHN
AB3			300MG	A074984 004	Dec 20, 1999	Jan CAHN
AB4		SANDOZ	120MG	A091022 001	Sep 28, 2012	Feb CAHN
AB4			180MG	A091022 002	Sep 28, 2012	Feb CAHN
AB4			240MG	A091022 003	Sep 28, 2012	Feb CAHN
AB4			300MG	A091022 004	Sep 28, 2012	Feb CAHN

CAPSULE, EXTENDED RELEASE; ORAL

DILTIAZEM HYDROCHLORIDE

AB4	SANDOZ	360MG	A091022 005	Sep 28, 2012	Feb	CAHN
AB4		420MG	A091022 006	Sep 28, 2012	Feb	CAHN

INJECTABLE; INJECTION

DILTIAZEM HYDROCHLORIDE

	@ APOTEX INC	5MG/ML	A075375 001	Sep 30, 1999	Apr	DISC
	@ TEVA PHARMS USA	5MG/ML	A074894 001	Aug 26, 1997	Apr	CAHN
+		10MG/ML	A074894 002	Apr 19, 2002	Apr	CAHN

TABLET; ORAL

DILTIAZEM HYDROCHLORIDE

	@ DAVA PHARMS INC	30MG	A074093 001	Nov 05, 1992	Jan	DISC
	@	60MG	A074093 002	Nov 05, 1992	Jan	DISC
	@	90MG	A074093 003	Nov 05, 1992	Jan	DISC
	@	120MG	A074093 004	Nov 05, 1992	Jan	DISC

DIMENHYDRINATE

INJECTABLE; INJECTION

DIMENHYDRINATE

+	FRESENIUS KABI USA	50MG/ML	A040519 001	Jun 23, 2004	Apr	CRLD
	@ WATSON LABS	50MG/ML	A080615 001		Apr	DISC

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE; ORAL

TECFIDERA

	BIOGEN IDEC INC	120MG	N204063 001	Mar 27, 2013	Mar	NEWA
+		240MG	N204063 002	Mar 27, 2013	Mar	NEWA

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DIPHENHYDRAMINE HYDROCHLORIDE

	@ WATSON LABS INC	10MG/ML	A080873 001		Mar	DISC
	@	50MG/ML	A080873 002		Mar	DISC

DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE

AP	BD RX	50MG/ML	A091526 001	Mar 26, 2013	Mar	NEWA
	@ WATSON LABS INC	50MG/ML	A080873 003		Mar	DISC

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

	@ APOTEX INC	5MG/ML	A075769 001	Nov 27, 2002	Apr	DISC
	@ TEVA PHARMS USA	5MG/ML	A074952 001	Nov 26, 1997	May	CAHN

TABLET; ORAL

DIPYRIDAMOLE

>D>	AB	PROSAM LABS	25MG	A040542 001	Apr 21, 2006	Jun	DISC
>A>		@	25MG	A040542 001	Apr 21, 2006	Jun	DISC
>D>	AB		50MG	A040542 002	Apr 21, 2006	Jun	DISC
>A>		@	50MG	A040542 002	Apr 21, 2006	Jun	DISC
>D>	AB		75MG	A040542 003	Apr 21, 2006	Jun	DISC
>A>		@	75MG	A040542 003	Apr 21, 2006	Jun	DISC

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE; ORAL

DIVALPROEX SODIUM

	@ TEVA PHARMS USA	EQ 500MG VALPROIC ACID	A078700 001	Aug 03, 2009	Mar	DISC
--	-------------------	------------------------	-------------	--------------	-----	------

DOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

AP	ACTAVIS INC	20MG/ML (20MG/ML)	N203551 001	Apr 12, 2013	Apr	NEWA
AP		80MG/4ML (20MG/ML)	N203551 002	Apr 12, 2013	Apr	NEWA
		140MG/7ML (20MG/ML)	N203551 003	Apr 12, 2013	Apr	NEWA
	@ APOTEX INC	20MG/0.5ML (40MG/ML)	N022312 001	Jan 11, 2012	May	DISC
	@	80MG/2ML (40MG/ML)	N022312 002	Jan 11, 2012	May	DISC

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

	@ ACCORD HLTHCARE	5MG	A201335 001	Aug 29, 2011	Jan	DISC
	@	10MG	A201335 002	Aug 29, 2011	Jan	DISC
AB	ACTAVIS GRP PTC	5MG	A090551 001	May 31, 2011	Apr	CAHN
AB		10MG	A090551 002	May 31, 2011	Apr	CAHN
AB	ALEMBIC PHARMS LTD	5MG	A201724 001	Feb 25, 2013	Feb	NEWA
AB		10MG	A201724 002	Feb 25, 2013	Feb	NEWA
>A>	AB ALVOGEN PINE BROOK	5MG	A202114 001	Jul 05, 2013	Jun	NEWA
>A>	AB	10MG	A202114 002	Jul 05, 2013	Jun	NEWA

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

@ APOTEX INC	EQ 2% BASE	A078395 001	Oct 28, 2008	Apr	DISC
--------------	------------	-------------	--------------	-----	------

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

@ APOTEX INC	EQ 2% BASE;EQ 0.5% BASE	A078201 001	Oct 28, 2008	Apr	DISC
--------------	-------------------------	-------------	--------------	-----	------

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

@ WATSON LABS INC	EQ 1MG BASE	A075426 001	Oct 18, 2000	Jan	DISC
@	EQ 2MG BASE	A075426 002	Oct 18, 2000	Jan	DISC
@	EQ 4MG BASE	A075426 003	Oct 18, 2000	Jan	DISC
@	EQ 8MG BASE	A075426 004	Oct 18, 2000	Jan	DISC

DOXEPIH HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIH HYDROCHLORIDE

>D>	AB + MYLAN PHARMS INC	EQ 10MG BASE	A070791 002	May 13, 1986	Jun	CRLD
>A>	AB	EQ 10MG BASE	A070791 002	May 13, 1986	Jun	CRLD
	AB +	EQ 10MG BASE	A070791 002	May 13, 1986	May	CRLD
>D>	AB	EQ 25MG BASE	A070791 003	May 13, 1986	Jun	CRLD
>A>	AB +	EQ 25MG BASE	A070791 003	May 13, 1986	Jun	CRLD
	@ PAR PHARM	EQ 10MG BASE	A071697 001	Nov 09, 1987	May	DISC
	@	EQ 25MG BASE	A071437 001	Nov 09, 1987	May	DISC
	@	EQ 50MG BASE	A071595 001	Nov 09, 1987	May	DISC
	@	EQ 75MG BASE	A071608 001	Nov 09, 1987	May	DISC
	@	EQ 100MG BASE	A071422 001	Nov 09, 1987	May	DISC
	@ WATSON LABS	EQ 10MG BASE	A071485 001	Apr 30, 1987	May	DISC
	@	EQ 25MG BASE	A071486 001	Apr 30, 1987	May	DISC

CAPSULE; ORAL

DOXEPIN HYDROCHLORIDE

@ WATSON LABS

EQ 50MG BASE

A071238 001 Apr 30, 1987 May DISC

@

EQ 75MG BASE

A071326 001 Apr 30, 1987 May DISC

@

EQ 100MG BASE

A071239 001 Apr 30, 1987 May DISC

CONCENTRATE; ORAL

DOXEPIN HYDROCHLORIDE

@ PHARM ASSOC

EQ 10MG BASE/ML

A075924 001 Jan 15, 2004 Mar DISC

TABLET; ORAL

SILENOR

PERNIX THERAPS LLC

EQ 3MG BASE

N022036 001 Mar 17, 2010 Apr CAHN

+

EQ 6MG BASE

N022036 002 Mar 17, 2010 Apr CAHN

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DOXORUBICIN HYDROCHLORIDE

AP SAGENT PHARMS

2MG/ML

A091495 001 Mar 18, 2013 Mar NEWA

>D> AP TEVA PARENTERAL

2MG/ML

A064140 001 Jul 28, 1995 Jun CAHN

>D> AP

200MG/100ML

A064140 002 Jul 28, 1995 Jun CAHN

>A> AP TEVA PHARMS USA

2MG/ML

A064140 001 Jul 28, 1995 Jun CAHN

>A> AP

200MG/100ML

A064140 002 Jul 28, 1995 Jun CAHN

INJECTABLE, LIPOSOMAL; INJECTION

DOXIL

AB + JANSSEN RES AND DEV

20MG/10ML (2MG/ML)

N050718 001 Nov 17, 1995 Jan CFTG

AB +

50MG/25ML (2MG/ML)

N050718 002 Jun 13, 2000 Jan CFTG

DOXIL (LIPOSOMAL)

>D> AB + JANSSEN RES AND DEV

20MG/10ML (2MG/ML)

N050718 001 Nov 17, 1995 Jun CRLD

>A> AB

20MG/10ML (2MG/ML)

N050718 001 Nov 17, 1995 Jun CRLD

AB +

20MG/10ML (2MG/ML)

N050718 001 Nov 17, 1995 Apr CTNA

>D> AB +

50MG/25ML (2MG/ML)

N050718 002 Jun 13, 2000 Jun CRLD

>A> AB

50MG/25ML (2MG/ML)

N050718 002 Jun 13, 2000 Jun CRLD

AB +

50MG/25ML (2MG/ML)

N050718 002 Jun 13, 2000 Apr CTNA

DOXORUBICIN HYDROCHLORIDE

AB SUN PHARMA GLOBAL

20MG/10ML (2MG/ML)

A203263 001 Feb 04, 2013 Jan NEWA

AB

50MG/25ML (2MG/ML)

A203263 002 Feb 04, 2013 Jan NEWA

DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

>D> AB SUN PHARMA GLOBAL

20MG/10ML (2MG/ML)

A203263 001 Feb 04, 2013 Jun CRLD

>A> AB +

20MG/10ML (2MG/ML)

A203263 001 Feb 04, 2013 Jun CRLD

AB

20MG/10ML (2MG/ML)

A203263 001 Feb 04, 2013 Apr CTNA

>D> AB

50MG/25ML (2MG/ML)

A203263 002 Feb 04, 2013 Jun CRLD

>A> AB +

50MG/25ML (2MG/ML)

A203263 002 Feb 04, 2013 Jun CRLD

AB

50MG/25ML (2MG/ML)

A203263 002 Feb 04, 2013 Apr CTNA

DOXYCYCLINE

FOR SUSPENSION; ORAL

DOXYCYCLINE

AB LUPIN LTD

EQ 25MG BASE/5ML

A201678 001 Mar 18, 2013 Mar NEWA

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXYCYCLINE HYCLATE

AB HIKMA PHARMS

EQ 50MG BASE

A062396 002 Nov 07, 1984 May CAHN

AB

EQ 100MG BASE

A062396 001 May 07, 1984 May CAHN

TABLET; ORAL

DOXYCYCLINE HYCLATE

@ BLU CARIBE INC

EQ 50MG BASE

A062269 003 Mar CAHN

	TABLET; ORAL					
	DOXYCYCLINE HYCLATE					
	@ BLU CARIBE INC	EQ 100MG BASE	A062269	002	Nov 08, 1982	Mar CAHN
AB	+ HIKMA PHARMS	EQ 100MG BASE	A065095	001	Jul 02, 2003	May CAHN
	TABLET, DELAYED RELEASE; ORAL					
	DORYX					
	MAYNE PHARMA	EQ 80MG BASE	N050795	004	Apr 11, 2013	Apr NEWA
		EQ 200MG BASE	N050795	005	Apr 11, 2013	Apr NEWA
	DOXYCYCLINE HYCLATE					
AB	HERITAGE PHARMS INC	EQ 75MG BASE	A200856	001	Apr 30, 2013	Apr NEWA
AB		EQ 100MG BASE	A200856	002	Apr 30, 2013	Apr NEWA
AB		EQ 150MG BASE	A200856	003	Apr 30, 2013	Apr NEWA
	<u>DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE</u>					
	TABLET, DELAYED RELEASE; ORAL					
	DICLEGIS					
	+ DUCHESNAY	10MG;10MG	N021876	001	Apr 08, 2013	Apr NEWA
	<u>DUTASTERIDE</u>					
	CAPSULE; ORAL					
	DUTASTERIDE					
AB	BANNER PHARMACAPS	0.5MG	A200899	001	May 30, 2013	May NEWA
	<u>ECONAZOLE NITRATE</u>					
	CREAM; TOPICAL					
	ECONAZOLE NITRATE					
AB	IGI LABS INC	1%	A076574	001	Dec 17, 2004	Mar CAHN
	<u>ENALAPRILAT</u>					
	INJECTABLE; INJECTION					
	ENALAPRILAT					
AP	TEVA PHARMS USA	1.25MG/ML	A075578	001	Aug 22, 2000	May CAHN
	<u>ENTACAPONE</u>					
	TABLET; ORAL					
	ENTACAPONE					
AB	MYLAN PHARMS INC	200MG	A202394	001	May 13, 2013	Apr NEWA
	<u>EPIRUBICIN HYDROCHLORIDE</u>					
	INJECTABLE; INJECTION					
	EPIRUBICIN HYDROCHLORIDE					
	@ MYLAN LLC	50MG/25ML (2MG/ML)	A065371	001	Nov 28, 2007	Feb DISC
	@	200MG/100ML (2MG/ML)	A065371	002	Nov 28, 2007	Feb DISC
AP	TEVA PHARMS USA	50MG/25ML (2MG/ML)	A065331	001	Aug 09, 2007	Apr CAHN
AP		200MG/100ML (2MG/ML)	A065331	002	Aug 09, 2007	Apr CAHN
	<u>EPOPROSTENOL SODIUM</u>					
	INJECTABLE; INJECTION					
	EPOPROSTENOL SODIUM					
AP	TEVA PHARMS USA	EQ 0.5MG BASE/VIAL	A078396	001	Apr 23, 2008	Apr CAHN
AP		EQ 1.5MG BASE/VIAL	A078396	002	Apr 23, 2008	Apr CAHN

ERTAPENEM SODIUM

INJECTABLE; INTRAMUSCULAR, IV (INFUSION)
INVANZ

>D>	+	MERCK	EQ 1GM BASE/VIAL	N021337 001	Nov 21, 2001	Jun	CAHN
>A>	+	MERCK SHARP DOHME	EQ 1GM BASE/VIAL	N021337 001	Nov 21, 2001	Jun	CAHN

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL
ERYC

AB	+	MAYNE PHARMA	250MG	N050536 001		Mar	CAHN
		@ WARNER CHILCOTT LLC	250MG	A062338 001		Apr	DISC

OINTMENT; OPHTHALMIC
ERYTHROMYCIN

>D>	AT	+	FERA PHARMS	0.5%	A062447 001	Sep 26, 1983	Jun	CAHN
>A>	AT	+	PERRIGO CO TENNESSEE	0.5%	A062447 001	Sep 26, 1983	Jun	CAHN

SOLUTION; TOPICAL
SANSAC

		@ DOW PHARM	2%	A062522 001	Jan 24, 1985	Apr	CAHN
--	--	-------------	----	-------------	--------------	-----	------

ESCITALOPRAM OXALATE

SOLUTION; ORAL
ESCITALOPRAM OXALATE

AA		SILARX PHARMS INC	EQ 5MG BASE/5ML	A090477 001	Jun 12, 2013	May	NEWA
----	--	-------------------	-----------------	-------------	--------------	-----	------

ESOMEPRAZOLE SODIUM

INJECTABLE; INTRAVENOUS
ESOMEPRAZOLE SODIUM

AP		SUN PHARMA GLOBAL	EQ 20MG BASE/VIAL	A200882 001	Mar 18, 2013	Mar	NEWA
AP			EQ 40MG BASE/VIAL	A200882 002	Mar 18, 2013	Mar	NEWA

NEXIUM IV

AP	+	ASTRAZENECA	EQ 20MG BASE/VIAL	N021689 001	Mar 31, 2005	Mar	CFTG
AP	+		EQ 40MG BASE/VIAL	N021689 002	Mar 31, 2005	Mar	CFTG

ESTRADIOL VALERATE

INJECTABLE; INJECTION
ESTRADIOL VALERATE

>D>	AO		WATSON LABS	20MG/ML	A083547 001		Jun	DISC
>D>	AO			40MG/ML	A083714 001		Jun	DISC
>A>		@		40MG/ML	A083714 001		Jun	DISC
>A>		@ WATSON LABS INC		20MG/ML	A083547 001		Jun	DISC

ESTRONE

INJECTABLE; INJECTION
ESTRONE

>D>	+	WATSON LABS	5MG/ML	A085239 001		Jun	DISC
>A>		@	5MG/ML	A085239 001		Jun	DISC

ESTROPIPATE

TABLET; ORAL
ORTHO-EST

	@	CARACO	0.75MG	A089567 001	Feb 27, 1991	Apr	DISC
	@		1.5MG	A089582 001	Jul 17, 1991	Apr	DISC

ESZOPICLONE

TABLET; ORAL

ESZOPICLONE

AB	MYLAN PHARMS INC	1MG	A091151 001	Mar 26, 2013	Mar	NEWA
AB		2MG	A091151 002	Mar 26, 2013	Mar	NEWA
AB		3MG	A091151 003	Mar 26, 2013	Mar	NEWA
AB	SUN PHARMA GLOBAL	1MG	A091103 001	Apr 03, 2013	Mar	NEWA
AB		2MG	A091103 002	Apr 03, 2013	Mar	NEWA
AB		3MG	A091103 003	Apr 03, 2013	Mar	NEWA
LUNESTA						
AB	SUNOVION PHARMS INC	1MG	N021476 001	Dec 15, 2004	Mar	CTEC
AB		2MG	N021476 002	Dec 15, 2004	Mar	CTEC
AB	+	3MG	N021476 003	Dec 15, 2004	Mar	CTEC

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

DAYSEE

AB	LUPIN LTD	0.03MG,0.01MG;0.15MG,N/A	A091467 001	Apr 10, 2013	Mar	NEWA
QUARTETTE						
+	TEVA BRANDED PHARM	0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A	N204061 001	Mar 28, 2013	Mar	NEWA

TABLET; ORAL-28

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB1	LUPIN LTD	0.02MG;0.1MG	A091425 001	Jan 18, 2013	Jan	NEWA
-----	-----------	--------------	-------------	--------------	-----	------

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

PIRMELLA 1/35

AB	LUPIN LTD	0.035MG;1MG	A201512 001	Apr 24, 2013	Apr	NEWA
PIRMELLA 7/7/7						
AB	LUPIN LTD	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A201510 001	Apr 24, 2013	Apr	NEWA

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

CAPSULE; ORAL

MINASTRIN 24 FE

+	WARNER CHILCOTT	0.02MG;1MG	N204426 001	Apr 19, 2013	Apr	NEWA
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE						
@	WARNER CHILCOTT	0.02MG;1MG	N204426 001	Apr 19, 2013	May	DISC

TABLET; ORAL

FEMHRT

@	WARNER CHILCOTT LLC	0.005MG;1MG	N021065 002	Oct 15, 1999	Jan	DISC
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL						
+	BARR LABS INC	0.005MG;1MG	A076221 001	Nov 06, 2009	Jan	CRLD

TABLET, CHEWABLE; ORAL

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

+	WARNER CHILCOTT LLC	0.02MG;1MG	N203667 001	May 08, 2003	May	NEWA
---	---------------------	------------	-------------	--------------	-----	------

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

ESTARYLLA

AB	SANDOZ	0.035MG;0.25MG	A090794 001	Jan 30, 2013	Jan	NEWA
TRI LO SPRINTC						
@	BARR LABS INC	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A076784 001	Jun 29, 2009	Apr	DISC

TABLET; ORAL-28									
TRI-ESTARYLLA									
AB	SANDOZ	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A090793	001	Jan 30, 2013	Jan	NEWA		
<u>ETHOTOIN</u>									
TABLET; ORAL									
PEGANONE									
+	RECORDATI RARE	250MG	N010841	001		May	CAHN		
<u>ETODOLAC</u>									
TABLET; ORAL									
ETODOLAC									
	@ PROSAM LABS	400MG	A074819	001	Feb 28, 1997	Mar	DISC		
	@	500MG	A074819	002	Apr 28, 1998	Mar	DISC		
<u>ETOPOSIDE</u>									
INJECTABLE; INJECTION									
ETOPOSIDE									
AP	ACCORD HLTHCARE	20MG/ML	A074513	001	Mar 14, 1996	Apr	CAHN		
	@ PHARMACHEMIE	20MG/ML	A074227	001	Feb 22, 1996	Apr	DISC		
AP	TEVA PHARMS USA	20MG/ML	A074284	001	Feb 10, 1994	May	CAHN		
AP		20MG/ML	A074529	001	Jul 24, 1996	Apr	CAHN		
<u>FAMOTIDINE</u>									
INJECTABLE; INJECTION									
FAMOTIDINE									
	@ APOTEX INC	10MG/ML	A075942	001	Aug 02, 2002	Apr	DISC		
FAMOTIDINE PRESERVATIVE FREE									
AP	AKORN INC	10MG/ML	A076324	001	Nov 27, 2002	Mar	CAHN		
	@ APOTEX INC	10MG/ML	A076324	001	Nov 27, 2002	Apr	DISC		
FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK)									
AP	AKORN INC	10MG/ML	A076322	001	Nov 27, 2002	Mar	CAHN		
	@ APOTEX INC	10MG/ML	A076322	001	Nov 27, 2002	Apr	DISC		
PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER									
	@ MERCK SHARP DOHME	0.4MG/ML	N020249	001	Feb 18, 1994	Apr	CAHN		
<u>FENOFIBRIC ACID</u>									
TABLET; ORAL									
FIBRICOR									
	MUTUAL PHARM CO INC	35MG	N022418	001	Aug 14, 2009	Feb	CAHN		
+		105MG	N022418	002	Aug 14, 2009	Feb	CAHN		
<u>FENOPROFEN CALCIUM</u>									
TABLET; ORAL									
FENOPROFEN CALCIUM									
	@ IVAX SUB TEVA PHARMS	EQ 600MG BASE	A072557	001	Aug 29, 1988	Mar	DISC		
+	MYLAN PHARMS INC	EQ 600MG BASE	A072267	001	Aug 17, 1988	Mar	CTEC		
<u>FENTANYL CITRATE</u>									
FILM; BUCCAL									
ONSOLIS									
	@ MEDA PHARMS	EQ 0.2MG BASE	N022266	001	Jul 16, 2009	May	DISC		
	@	EQ 0.4MG BASE	N022266	002	Jul 16, 2009	May	DISC		
	@	EQ 0.6MG BASE	N022266	003	Jul 16, 2009	May	DISC		
	@	EQ 0.8MG BASE	N022266	004	Jul 16, 2009	May	DISC		

FILM; BUCCAL

ONSOLIS

@ MEDA PHARMS

EQ 1.2MG BASE

N022266 005 Jul 16, 2009 May DISC

TABLET; BUCCAL, SUBLINGUAL

FENTORA

AB CEPHALON

EQ 0.1MG BASE

N021947 001 Sep 25, 2006 Feb CDFR

AB

EQ 0.2MG BASE

N021947 002 Sep 25, 2006 Feb CDFR

@

EQ 0.3MG BASE

N021947 006 Mar 02, 2007 Feb CDFR

AB +

EQ 0.4MG BASE

N021947 003 Sep 25, 2006 Feb CDFR

AB

EQ 0.6MG BASE

N021947 004 Sep 25, 2006 Feb CDFR

AB

EQ 0.8MG BASE

N021947 005 Sep 25, 2006 Feb CDFR

TABLET; SUBLINGUAL

ABSTRAL

GALENA BIOPHARMA

EQ 0.1MG BASE

N022510 001 Jan 07, 2011 May CAHN

EQ 0.2MG BASE

N022510 002 Jan 07, 2011 May CAHN

EQ 0.3MG BASE

N022510 003 Jan 07, 2011 May CAHN

+

EQ 0.4MG BASE

N022510 004 Jan 07, 2011 May CAHN

EQ 0.6MG BASE

N022510 005 Jan 07, 2011 May CAHN

EQ 0.8MG BASE

N022510 006 Jan 07, 2011 May CAHN

FERUMOXASIL

SUSPENSION; ORAL

GASTROMARK

@ AMAG PHARMS INC

EQ 0.175MG IRON/ML

N020410 001 Dec 06, 1996 Feb DISC

FINASTERIDE

TABLET; ORAL

FINASTERIDE

AB ACCORD HLTHCARE

5MG

A090121 001 Feb 23, 2010 Apr CAHN

>A>

AB HETERO LABS LTD III

1MG

A090060 001 Jul 01, 2013 Jun NEWA

AB

5MG

A090061 001 Jun 07, 2010 Apr CAHN

>A>

AB SUN PHARMA GLOBAL

1MG

A090508 001 Jul 01, 2013 Jun NEWA

FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE

@ APOTEX INC

50MG

A079164 001 Jul 09, 2009 Apr DISC

@

100MG

A079164 002 Jul 09, 2009 Apr DISC

@

150MG

A079164 003 Jul 09, 2009 Apr DISC

AB +

ROXANE

150MG

A076278 003 Jan 14, 2003 May CRLD

TAMBOCOR

@ MEDICIS

50MG

N018830 004 Aug 23, 1988 May DISC

@

100MG

N018830 001 Oct 31, 1985 May DISC

@

150MG

N018830 003 Jun 03, 1988 May DISC

FLUCONAZOLE

FOR SUSPENSION; ORAL

FLUCONAZOLE

@ TARO PHARM INDS

50MG/5ML

A076918 001 Dec 18, 2006 Mar DISC

@

200MG/5ML

A076918 002 Dec 18, 2006 Mar DISC

INJECTABLE; INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

@ APOTEX INC

200MG/100ML (2MG/ML)

A076888 001 Mar 25, 2005 Apr DISC

@

400MG/200ML (2MG/ML)

A076888 002 Mar 25, 2005 Apr DISC

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

AP

TEVA PHARMS USA

200MG/100ML (2MG/ML)

A076653 001 Jul 29, 2004 May CAHN

INJECTABLE; INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%							
AP	TEVA PHARMS USA	400MG/200ML (2MG/ML)	A076653	002	Jul 29, 2004	May	CAHN
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
	@ APOTEX INC	200MG/100ML (2MG/ML)	A076889	001	Mar 25, 2005	Apr	DISC
	@	400MG/200ML (2MG/ML)	A076889	002	Mar 25, 2005	Apr	DISC

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARABINE PHOSPHATE							
AP	+ FRESENIUS KABI USA	50MG/2ML (25MG/ML)	A078393	001	Oct 15, 2007	Jan	CRLD
AP	TEVA PARENTERAL	50MG/2ML (25MG/ML)	A076661	001	Apr 28, 2004	Jan	CRLD
AP	TEVA PHARMS USA	50MG/2ML (25MG/ML)	A076661	001	Apr 28, 2004	Apr	CAHN
AP		50MG/VIAL	A076349	001	Aug 28, 2003	Apr	CAHN

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18							
>D>	HOUSTON CYCLOTRON	20-500mCi/ML	A203665	001	Feb 14, 2013	Jun	CRLD
>A>	+	20-500mCi/ML	A203665	001	Feb 14, 2013	Jun	CRLD
		20-500mCi/ML	A203665	001	Feb 14, 2013	Jan	NEWA
>A>	+ UCLA BIOMEDICAL	4-40mCi/ML	A203811	001	Jun 27, 2013	Jun	NEWA

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL							
	@ APOTEX INC	0.5MG/5ML (0.1MG/ML)	A076755	002	Oct 12, 2004	Apr	DISC
	@	1MG/10ML (0.1MG/ML)	A076755	001	Oct 12, 2004	Apr	DISC
	@ TEVA PHARMS USA	0.5MG/5ML (0.1MG/ML)	A076589	002	Oct 12, 2004	Apr	CAHN
	@	1MG/10ML (0.1MG/ML)	A076589	001	Oct 12, 2004	Apr	CAHN

FLUOCINONIDE

CREAM; TOPICAL

LIDEX							
	@ CNTY LINE PHARMS	0.05%	N016908	002		Jan	CAHN
LIDEX-E							
	@ CNTY LINE PHARMS	0.05%	N016908	003		Jan	CAHN

GEL; TOPICAL

FLUOCINONIDE							
AB	+ TARO	0.05%	A074935	001	Jul 29, 1997	Jan	CRLD
LIDEX							
	@ CNTY LINE PHARMS	0.05%	N017373	001		Jan	CAHN

OINTMENT; TOPICAL

FLUOCINONIDE							
AB	+ TARO	0.05%	A075008	001	Jun 30, 1999	Jan	CRLD
LIDEX							
	@ CNTY LINE PHARMS	0.05%	N016909	002		Jan	CAHN

SOLUTION; TOPICAL

FLUOCINONIDE							
AT	ACTAVIS MID ATLANTIC	0.05%	A071535	001	Dec 02, 1988	May	CAHN
AT	+ TARO	0.05%	A074799	001	Dec 31, 1996	Jan	CRLD
LIDEX							
	@ CNTY LINE PHARMS	0.05%	N018849	001	Apr 06, 1984	May	CAHN
	@ MEDICIS	0.05%	N018849	001	Apr 06, 1984	Jan	DISC

FLUOROURACIL

INJECTABLE; INJECTION

FLUOROURACIL

AP	+	MYLAN LLC	500MG/10ML (50MG/ML)	A040743	002	Apr 26, 2007	Feb	CAHN
AP	+		1GM/20ML (50MG/ML)	A040743	001	Apr 26, 2007	Feb	CAHN
AP	+	TEVA PHARMS USA	500MG/10ML (50MG/ML)	A040333	001	Jan 27, 2000	May	CAHN
AP	+		2.5GM/50ML (50MG/ML)	A040334	001	Feb 25, 2000	May	CAHN
AP	+		5GM/100ML (50MG/ML)	A040334	002	Feb 25, 2000	May	CAHN

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

		@ CARLSBAD	EQ 10MG BASE	A076022	001	Jan 30, 2002	Mar	DISC
		@	EQ 20MG BASE	A076022	002	Jan 30, 2002	Mar	DISC
		@ CR DOUBLE CRANE	EQ 10MG BASE	A076165	001	Feb 01, 2002	Apr	DISC
AB1			EQ 10MG BASE	A076165	001	Feb 01, 2002	Mar	CAHN
		@	EQ 20MG BASE	A076165	002	Feb 01, 2002	Apr	DISC
AB1			EQ 20MG BASE	A076165	002	Feb 01, 2002	Mar	CAHN
		@ WOCKHARDT LTD	EQ 10MG BASE	A078143	001	Jan 16, 2008	Feb	DISC
		@	EQ 20MG BASE	A078143	002	Jan 16, 2008	Feb	DISC
		@	EQ 40MG BASE	A078143	003	Jan 16, 2008	Feb	DISC

SOLUTION; ORAL

FLUOXETINE HYDROCHLORIDE

		@ APOTEX INC	EQ 20MG BASE/5ML	A075292	001	Feb 07, 2002	Apr	DISC
--	--	--------------	------------------	---------	-----	--------------	-----	------

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE; ORAL

OLANZAPINE AND FLUOXETINE HYDROCHLORIDE

AB		TEVA PHARMS	EQ 25MG BASE;EQ 3MG BASE	A202074	001	Mar 25, 2013	Mar	NEWA
----	--	-------------	--------------------------	---------	-----	--------------	-----	------

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE

		@ APOTEX INC	25MG/ML	A075918	001	Aug 17, 2001	Apr	DISC
--	--	--------------	---------	---------	-----	--------------	-----	------

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE

POWDER; INHALATION

BREO ELLIPTA

+		GLAXO GRP LTD	0.1MG/INH;EQ 0.025MG BASE/INH	N204275	001	May 10, 2013	May	NEWA
---	--	---------------	-------------------------------	---------	-----	--------------	-----	------

FLUTICASONE PROPIONATE

POWDER; INHALATION

FLOVENT DISKUS 100

+		GLAXO GRP LTD	0.1MG/INH	N020833	002	Sep 29, 2000	May	CAHN
---	--	---------------	-----------	---------	-----	--------------	-----	------

FLOVENT DISKUS 250

+		GLAXO GRP LTD	0.25MG/INH	N020833	003	Sep 29, 2000	May	CAHN
---	--	---------------	------------	---------	-----	--------------	-----	------

FLOVENT DISKUS 50

+		GLAXO GRP LTD	0.05MG/INH	N020833	001	Sep 29, 2000	May	CAHN
---	--	---------------	------------	---------	-----	--------------	-----	------

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

AEROSOL, METERED; INHALATION

ADVAIR HFA

+		GLAXO GRP LTD	0.045MG/INH;EQ 0.021MG BASE/INH	N021254	001	Jun 08, 2006	May	CAHN
---	--	---------------	---------------------------------	---------	-----	--------------	-----	------

+			0.115MG/INH;EQ 0.021MG BASE/INH	N021254	002	Jun 08, 2006	May	CAHN
---	--	--	---------------------------------	---------	-----	--------------	-----	------

AEROSOL, METERED; INHALATION

ADVAIR HFA

+	GLAXO GRP LTD	0.23MG/INH;EQ 0.021MG BASE/INH	N021254	003	Jun 08, 2006	May	CAHN
---	---------------	--------------------------------	---------	-----	--------------	-----	------

POWDER; INHALATION

ADVAIR DISKUS 100/50

+	GLAXO GRP LTD	0.1MG/INH;EQ 0.05MG BASE/INH	N021077	001	Aug 24, 2000	May	CAHN
---	---------------	------------------------------	---------	-----	--------------	-----	------

ADVAIR DISKUS 250/50

+	GLAXO GRP LTD	0.25MG/INH;EQ 0.05MG BASE/INH	N021077	002	Aug 24, 2000	May	CAHN
---	---------------	-------------------------------	---------	-----	--------------	-----	------

ADVAIR DISKUS 500/50

+	GLAXO GRP LTD	0.5MG/INH;EQ 0.05MG BASE/INH	N021077	003	Aug 24, 2000	May	CAHN
---	---------------	------------------------------	---------	-----	--------------	-----	------

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

FLUVOXAMINE MALEATE

AB	ACTAVIS ELIZABETH	100MG	A091482	001	Apr 23, 2013	Apr	NEWA
----	-------------------	-------	---------	-----	--------------	-----	------

AB	ANCHEN PHARMS	100MG	A091476	001	Mar 13, 2013	Mar	NEWA
----	---------------	-------	---------	-----	--------------	-----	------

AB		150MG	A091476	002	Mar 13, 2013	Mar	NEWA
----	--	-------	---------	-----	--------------	-----	------

LUVOX CR

AB	JAZZ PHARMS	100MG	N022033	001	Feb 28, 2008	Mar	CFTG
----	-------------	-------	---------	-----	--------------	-----	------

AB	+	150MG	N022033	002	Feb 28, 2008	Mar	CFTG
----	---	-------	---------	-----	--------------	-----	------

TABLET; ORAL

FLUVOXAMINE MALEATE

>D>	AB	CARACO	25MG	A075900	001	Feb 23, 2006	Jun	DISC
-----	----	--------	------	---------	-----	--------------	-----	------

>A>		@	25MG	A075900	001	Feb 23, 2006	Jun	DISC
-----	--	---	------	---------	-----	--------------	-----	------

>D>	AB		50MG	A075900	002	Feb 23, 2006	Jun	DISC
-----	----	--	------	---------	-----	--------------	-----	------

>A>		@	50MG	A075900	002	Feb 23, 2006	Jun	DISC
-----	--	---	------	---------	-----	--------------	-----	------

>D>	AB		100MG	A075900	003	Feb 23, 2006	Jun	DISC
-----	----	--	-------	---------	-----	--------------	-----	------

>A>		@	100MG	A075900	003	Feb 23, 2006	Jun	DISC
-----	--	---	-------	---------	-----	--------------	-----	------

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

	@ WATSON LABS	10MG	A076987	001	Dec 23, 2004	Mar	DISC
--	---------------	------	---------	-----	--------------	-----	------

	@	20MG	A076987	002	Dec 23, 2004	Mar	DISC
--	---	------	---------	-----	--------------	-----	------

	@	40MG	A076987	003	Dec 23, 2004	Mar	DISC
--	---	------	---------	-----	--------------	-----	------

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

AP	AMNEAL PHARMS	EQ 50MG PNENYTOIN NA/ML	A078476	001	Mar 18, 2008	May	CAHN
----	---------------	-------------------------	---------	-----	--------------	-----	------

	@ APOTEX INC	EQ 50MG PHENYTOIN NA/ML	A078126	001	Aug 06, 2007	Apr	DISC
--	--------------	-------------------------	---------	-----	--------------	-----	------

	@ TEVA PHARMS USA	EQ 50MG PHENYTOIN NA/ML	A076886	001	Aug 06, 2007	May	CAHN
--	-------------------	-------------------------	---------	-----	--------------	-----	------

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

	@ INTL MEDICATION	10MG/ML	N018025	001		Jan	DISC
--	-------------------	---------	---------	-----	--	-----	------

TABLET; ORAL

FUROSEMIDE

	@ DAVA PHARMS INC	20MG	N018415	001	Jul 27, 1982	Feb	DISC
--	-------------------	------	---------	-----	--------------	-----	------

	@	40MG	N018415	002	Jul 27, 1982	Feb	DISC
--	---	------	---------	-----	--------------	-----	------

	@	80MG	N018415	003	Nov 26, 1984	Feb	DISC
--	---	------	---------	-----	--------------	-----	------

GABAPENTINSOLUTION; ORAL
GABAPENTIN

>A>	AA	TARO	250MG/5ML	A076672	001	Jul 03, 2013	Jun	NEWA
-----	----	------	-----------	---------	-----	--------------	-----	------

GABAPENTIN ENACARBILTABLET, EXTENDED RELEASE; ORAL
HORIZANT

		XENOPORT INC	300MG	N022399	002	Dec 13, 2011	May	CAHN
		+	600MG	N022399	001	Apr 06, 2011	May	CAHN

GADOTERATE MEGLUMINESOLUTION; INTRAVENOUS
DOTAREM

+	GUERBET	37.69GM/100ML (376.9MG/ML)	N204781	001	Mar 20, 2013	Mar	NEWA
+		3.769GM/10ML (376.9MG/ML)	N204781	002	Mar 20, 2013	Mar	NEWA
+		5.6535GM/15ML (376.9MG/ML)	N204781	003	Mar 20, 2013	Mar	NEWA
+		7.538GM/20ML (376.9MG/ML)	N204781	004	Mar 20, 2013	Mar	NEWA

GADOXETATE DISODIUMSOLUTION; INTRAVENOUS
EOVIST

	BAYER HLTHCARE	2.72145GM/15ML (181.43MG/ML)	N022090	002	Feb 04, 2013	Feb	NEWA
--	----------------	------------------------------	---------	-----	--------------	-----	------

GANCICLOVIRIMPLANT; IMPLANTATION
VITRASERT

@	BAUSCH AND LOMB	4.5MG	N020569	001	Mar 04, 1996	May	DISC
---	-----------------	-------	---------	-----	--------------	-----	------

GATIFLOXACINSOLUTION/DROPS; OPHTHALMIC
GATIFLOXACIN
@ APOTEX INC

		0.3%	A079084	001	Aug 19, 2011	Apr	DISC
--	--	------	---------	-----	--------------	-----	------

GEMCITABINE HYDROCHLORIDEINJECTABLE; INJECTION
GEMCITABINE HYDROCHLORIDE

AP	DR REDDYS LABS LTD	EQ 2GM BASE/VIAL	A202997	001	May 07, 2013	Apr	NEWA
AP	JIANGSU HANSON PHARM	EQ 200MG BASE/VIAL	A202485	001	May 07, 2013	Apr	NEWA
AP		EQ 1GM BASE/VIAL	A202485	002	May 07, 2013	Apr	NEWA
AP	PHARMAFORCE	EQ 200MG BASE/VIAL	A202031	001	May 07, 2013	Apr	NEWA
AP		EQ 1GM BASE/VIAL	A202031	002	May 07, 2013	Apr	NEWA
AP	SAGENT PHARMS	EQ 200MG BASE/VIAL	A091597	001	May 07, 2013	Apr	NEWA
AP		EQ 1GM BASE/VIAL	A091597	002	May 07, 2013	Apr	NEWA

GEMFIBROZILTABLET; ORAL
GEMFIBROZIL

>A>	AB	CARACO	600MG	A079239	001	Dec 29, 2008	Jun	CAHN
>D>	AB	SUN PHARM INDS INC	600MG	A079239	001	Dec 29, 2008	Jun	CAHN

GENTAMICIN SULFATE

OINTMENT; OPHTHALMIC

GENTAMICIN SULFATE

>D>	AT	FERA PHARMS	EQ 0.3% BASE	A065024 001	Jul 30, 2004	Jun	CAHN
>A>	AT	PERRIGO CO TENNESSEE	EQ 0.3% BASE	A065024 001	Jul 30, 2004	Jun	CAHN

SOLUTION/DROPS; OPHTHALMIC

GENTAMICIN SULFATE

>D>	AT	FERA PHARMS	EQ 0.3% BASE	A065121 001	Jan 30, 2004	Jun	CAHN
>A>	AT	PERRIGO CO TENNESSEE	EQ 0.3% BASE	A065121 001	Jan 30, 2004	Jun	CAHN

GLATIRAMER ACETATE

FOR SOLUTION; SUBCUTANEOUS

COPAXONE

@	TEVA PHARMS USA	20MG/VIAL	N020622 001	Dec 20, 1996	Apr	CAHN
---	-----------------	-----------	-------------	--------------	-----	------

INJECTABLE; SUBCUTANEOUS

COPAXONE

+	TEVA PHARMS USA	20MG/ML	N020622 002	Feb 12, 2002	Apr	CAHN
---	-----------------	---------	-------------	--------------	-----	------

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

@	COREPHARMA	1MG	A077274 001	Oct 06, 2005	Feb	DISC
---	------------	-----	-------------	--------------	-----	------

@		2MG	A077274 002	Oct 06, 2005	Feb	DISC
---	--	-----	-------------	--------------	-----	------

@		4MG	A077274 003	Oct 06, 2005	Feb	DISC
---	--	-----	-------------	--------------	-----	------

AB	INDOCO REMEDIES	1MG	A202112 001	Apr 17, 2013	Apr	NEWA
----	-----------------	-----	-------------	--------------	-----	------

AB		2MG	A202112 002	Apr 17, 2013	Apr	NEWA
----	--	-----	-------------	--------------	-----	------

AB		4MG	A202112 003	Apr 17, 2013	Apr	NEWA
----	--	-----	-------------	--------------	-----	------

GLIPIZIDE

TABLET; ORAL

GLIPIZIDE

AB	ACCORD HLTHCARE	5MG	A074550 001	Sep 11, 1997	Apr	CAHN
----	-----------------	-----	-------------	--------------	-----	------

AB		10MG	A074550 002	Sep 11, 1997	Apr	CAHN
----	--	------	-------------	--------------	-----	------

@	BARR LABS INC	5MG	A074619 001	Apr 04, 1997	May	CAHN
---	---------------	-----	-------------	--------------	-----	------

@		10MG	A074619 002	Apr 04, 1997	May	CAHN
---	--	------	-------------	--------------	-----	------

GLYCEROL PHENYLBUTYRATE

LIQUID; ORAL

RAVICTI

+	HYPERION THERAP INC	1.1GM/ML	N203284 001	Feb 01, 2013	Feb	NEWA
---	---------------------	----------	-------------	--------------	-----	------

GLYCOPYRROLATE

INJECTABLE; INJECTION

ROBINUL

AP	+	HIKMA MAPLE	0.2MG/ML	N017558 001		Apr	CAHN
----	---	-------------	----------	-------------	--	-----	------

TABLET; ORAL

GLYCOPYRROLATE

AA	AUROLIFE PHARMA LLC	1MG	A202675 001	Apr 15, 2013	Apr	NEWA
----	---------------------	-----	-------------	--------------	-----	------

@	COREPHARMA	1MG	A040568 001	Dec 22, 2004	Mar	DISC
---	------------	-----	-------------	--------------	-----	------

@		2MG	A040568 002	Dec 22, 2004	Mar	DISC
---	--	-----	-------------	--------------	-----	------

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

		@ APOTEX INC	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078197	001	Dec 31, 2007	Apr	DISC
		@	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078198	001	Jun 30, 2008	Apr	DISC
		@	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078198	002	Jun 30, 2008	Apr	DISC
		@ EBEWE PHARMA	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078808	001	Apr 29, 2008	Feb	DISC
AP	+	TEVA PHARMS USA	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078392	001	Dec 31, 2007	May	CAHN
AP	+		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077963	001	Jan 03, 2008	May	CAHN
AP	+		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077297	001	Jun 30, 2008	May	CAHN
			GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE					
		@ TEVA PHARMS USA	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077165	001	Dec 31, 2007	May	CAHN

GRISEOFULVIN, MICROSIZE

SUSPENSION; ORAL

GRIFULVIN V

AB	+	VALEANT LUXEMBOURG	125MG/5ML	A062483	001	Jan 26, 1984	Apr	CAHN
----	---	--------------------	-----------	---------	-----	--------------	-----	------

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

GUANFACINE HYDROCHLORIDE

>D>	AB	EPIC PHARMA	EQ 1MG BASE	A074673	001	Feb 28, 1997	Jun	DISC
>D>	AB		EQ 2MG BASE	A074673	002	Feb 28, 1997	Jun	DISC
>A>		@ EPIC PHARMA LLC	EQ 1MG BASE	A074673	001	Feb 28, 1997	Jun	DISC
>A>		@	EQ 2MG BASE	A074673	002	Feb 28, 1997	Jun	DISC

HALOBETASOL PROPIONATE

OINTMENT; TOPICAL

HALOBETASOL PROPIONATE

		@ FOUGERA PHARMS	0.05%	A076903	001	Dec 16, 2004	Apr	DISC
>A>		@ G AND W LABS INC	0.05%	A077109	001	Jun 14, 2005	Jun	CAHN
		@ TARO	0.05%	A076994	001	Dec 16, 2004	Mar	DISC
>D>		@ VENUS PHARMS	0.05%	A077109	001	Jun 14, 2005	Jun	CAHN

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALOPERIDOL DECANOATE

		@ APOTEX INC	EQ 50MG BASE/ML	A075440	001	Feb 28, 2000	Apr	DISC
		@	EQ 100MG BASE/ML	A075440	002	Feb 28, 2000	Apr	DISC
>D>	AO	TEVA PARENTERAL	EQ 50MG BASE/ML	A075393	001	May 11, 1999	Jun	CAHN
>D>	AO		EQ 100MG BASE/ML	A075393	002	May 11, 1999	Jun	CAHN
>A>	AO	TEVA PHARMS USA	EQ 50MG BASE/ML	A075393	001	May 11, 1999	Jun	CAHN
>A>	AO		EQ 100MG BASE/ML	A075393	002	May 11, 1999	Jun	CAHN

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

HALOPERIDOL

		@ APOTEX INC	EQ 5MG BASE/ML	A076791	001	Aug 25, 2004	Apr	DISC
		@	EQ 5MG BASE/ML	A076828	001	Aug 25, 2004	Apr	DISC
>D>	AP	TEVA PARENTERAL	EQ 5MG BASE/ML	A076035	001	Aug 29, 2001	Jun	CAHN
>A>	AP	TEVA PHARMS USA	EQ 5MG BASE/ML	A076035	001	Aug 29, 2001	Jun	CAHN

HYALURONIDASE

INJECTABLE; INJECTION
VITRASE

+	BAUSCH AND LOMB	200 UNITS/VIAL	N021640	002	Dec 02, 2004	May	CAHN
@		6,200 UNITS/VIAL	N021640	001	May 05, 2004	May	CAHN

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HYDROCHLORIDE

AP	NAVINTA LLC	20MG/ML	A202938	001	Mar 28, 2013	Mar	NEWA
----	-------------	---------	---------	-----	--------------	-----	------

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

AA	ACTAVIS GRP PTC	10MG	A091679	001	Mar 04, 2013	Apr	CAHN
AA		25MG	A091679	002	Mar 04, 2013	Apr	CAHN
AA		50MG	A091679	003	Mar 04, 2013	Apr	CAHN
AA		100MG	A091679	004	Mar 04, 2013	Apr	CAHN
AA	ACTAVIS PHARMA	10MG	A091679	001	Mar 04, 2013	Feb	NEWA
AA		25MG	A091679	002	Mar 04, 2013	Feb	NEWA
AA		50MG	A091679	003	Mar 04, 2013	Feb	NEWA
AA		100MG	A091679	004	Mar 04, 2013	Feb	NEWA
AA	ALKEM LABS LTD	10MG	A200737	001	Dec 07, 2012	Apr	CTEC
AA		25MG	A200737	002	Dec 07, 2012	Apr	CTEC
AA		50MG	A200737	003	Dec 07, 2012	Apr	CTEC
AA		100MG	A200737	004	Dec 07, 2012	Apr	CTEC
AA	HETERO LABS LTD III	10MG	A040901	001	Sep 12, 2008	Apr	CAHN
AA		25MG	A040901	002	Sep 12, 2008	Apr	CAHN
AA		50MG	A040901	003	Sep 12, 2008	Apr	CAHN
AA		100MG	A040901	004	Sep 12, 2008	Apr	CAHN
AA	STRIDES ARCOLAB LTD	25MG	A200770	001	May 03, 2013	Apr	NEWA
AA		50MG	A200770	002	May 03, 2013	Apr	NEWA
AA		100MG	A200770	003	May 03, 2013	Apr	NEWA
>D>	AA	ZYDUS PHARMS USA	A040858	001	Feb 26, 2010	Jun	DISC
>A>	@	10MG	A040858	001	Feb 26, 2010	Jun	DISC
>D>	AA	25MG	A040858	002	Feb 26, 2010	Jun	DISC
>A>	@	25MG	A040858	002	Feb 26, 2010	Jun	DISC
>D>	AA	50MG	A040858	003	Feb 26, 2010	Jun	DISC
>A>	@	50MG	A040858	003	Feb 26, 2010	Jun	DISC
>D>	AA	100MG	A040858	004	Feb 26, 2010	Jun	DISC
>A>	@	100MG	A040858	004	Feb 26, 2010	Jun	DISC

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

@	WATSON LABS	25MG	A081189	001	Jan 24, 1992	Mar	DISC
---	-------------	------	---------	-----	--------------	-----	------

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB	AUROBINDO PHARMA LTD	12.5MG;150MG	A203630	001	Feb 22, 2013	Feb	NEWA
AB		12.5MG;300MG	A203630	002	Feb 22, 2013	Feb	NEWA
AB	LUPIN LTD	12.5MG;150MG	A201524	001	Feb 27, 2013	Feb	NEWA
AB		12.5MG;300MG	A201524	002	Feb 27, 2013	Feb	NEWA

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB	IPCA LABS LTD	12.5MG;50MG	A201682 001	Mar 01, 2013	Feb	NEWA
AB		12.5MG;100MG	A201682 002	Mar 01, 2013	Feb	NEWA
AB		25MG;100MG	A201682 003	Mar 01, 2013	Feb	NEWA

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	APOTEX CORP	12.5MG;EQ 10MG BASE	A091524 001	Mar 12, 2013	Mar	NEWA
AB		12.5MG;EQ 20MG BASE	A091524 002	Mar 12, 2013	Mar	NEWA
AB		25MG;EQ 20MG BASE	A091524 003	Mar 12, 2013	Mar	NEWA

HYDROCHLOROTHIAZIDE; TRIAMTERENE

TABLET; ORAL

MAXZIDE

AB	+ MYLAN PHARMS INC	50MG;75MG	N019129 001	Oct 22, 1984	May	CAHN
	MAXZIDE-25					
AB	MYLAN PHARMS INC	25MG;37.5MG	N019129 003	May 13, 1988	May	CAHN
	TRIAMTERENE AND HYDROCHLOROTHIAZIDE					
	@ WATSON LABS	50MG;75MG	A071969 001	Apr 17, 1988	Jan	DISC

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

AB	ALEMBIC LTD	12.5MG;80MG	A201662 001	Mar 21, 2013	Mar	NEWA
AB		12.5MG;160MG	A201662 002	Mar 21, 2013	Mar	NEWA
AB		12.5MG;320MG	A201662 003	Mar 21, 2013	Mar	NEWA
AB		25MG;160MG	A201662 004	Mar 21, 2013	Mar	NEWA
AB		25MG;320MG	A201662 005	Mar 21, 2013	Mar	NEWA
AB	APOTEX INC	12.5MG;80MG	A203026 001	Mar 21, 2013	Mar	NEWA
AB		12.5MG;160MG	A203026 002	Mar 21, 2013	Mar	NEWA
AB		12.5MG;320MG	A203026 003	Mar 21, 2013	Mar	NEWA
AB		25MG;160MG	A203026 004	Mar 21, 2013	Mar	NEWA
AB		25MG;320MG	A203026 005	Mar 21, 2013	Mar	NEWA
AB	AUROBINDO PHARMA LTD	12.5MG;80MG	A202519 001	Mar 21, 2013	Mar	NEWA
AB		12.5MG;160MG	A202519 002	Mar 21, 2013	Mar	NEWA
AB		12.5MG;320MG	A202519 003	Mar 21, 2013	Mar	NEWA
AB		25MG;160MG	A202519 004	Mar 21, 2013	Mar	NEWA
AB		25MG;320MG	A202519 005	Mar 21, 2013	Mar	NEWA
AB	LUPIN LTD	12.5MG;80MG	A078946 003	Mar 21, 2013	Mar	NEWA
AB		12.5MG;160MG	A078946 004	Mar 21, 2013	Mar	NEWA
AB		12.5MG;320MG	A078946 001	Mar 21, 2013	Mar	NEWA
AB		25MG;160MG	A078946 005	Mar 21, 2013	Mar	NEWA
AB		25MG;320MG	A078946 002	Mar 21, 2013	Mar	NEWA
AB	MACLEODS PHARMS LTD	12.5MG;80MG	A203145 001	Apr 19, 2013	Apr	NEWA
AB		12.5MG;160MG	A203145 002	Apr 19, 2013	Apr	NEWA
AB		12.5MG;320MG	A203145 003	Apr 19, 2013	Apr	NEWA
AB		25MG;160MG	A203145 004	Apr 19, 2013	Apr	NEWA
AB		25MG;320MG	A203145 005	Apr 19, 2013	Apr	NEWA
AB	WATSON LABS INC	12.5MG;80MG	A091519 001	Mar 21, 2013	Mar	NEWA
AB		12.5MG;160MG	A091519 002	Mar 21, 2013	Mar	NEWA
AB		12.5MG;320MG	A091519 003	Mar 21, 2013	Mar	NEWA
AB		25MG;160MG	A091519 004	Mar 21, 2013	Mar	NEWA

TABLET; ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

AB	WATSON LABS INC	25MG;320MG	A091519	005	Mar 21, 2013	Mar	NEWA
----	-----------------	------------	---------	-----	--------------	-----	------

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

AB	SUN PHARM INDS INC	2.5MG;200MG	A091633	001	May 28, 2013	May	NEWA
AB		5MG;200MG	A091633	002	May 28, 2013	May	NEWA
AB		7.5MG;200MG	A091633	003	May 28, 2013	May	NEWA
AB		10MG;200MG	A091633	004	May 28, 2013	May	NEWA

REPREXAIN

AB	AMNEAL PHARMS NY	2.5MG;200MG	A076642	003	Oct 19, 2007	May	CFTG
AB		10MG;200MG	A076642	004	Oct 19, 2007	May	CFTG

HYDROCORTISONE

LOTION; TOPICAL

STIE-CORT

@	PERRIGO CO	1%	A089066	001	Nov 25, 1985	Feb	DISC
---	------------	----	---------	-----	--------------	-----	------

OINTMENT; TOPICAL

HYDROCORTISONE

@	TARO	2.5%	A040310	001	Dec 29, 2000	Mar	DISC
---	------	------	---------	-----	--------------	-----	------

HYDROCORTISONE ACETATE

PASTE; TOPICAL

ORABASE HCA

@	COLGATE	0.5%	A083205	001		Mar	DISC
---	---------	------	---------	-----	--	-----	------

HYDROCORTISONE VALERATE

OINTMENT; TOPICAL

HYDROCORTISONE VALERATE

@	FOUGERA PHARMS	0.2%	A075085	001	Jul 31, 2001	Feb	DISC
---	----------------	------	---------	-----	--------------	-----	------

+	TARO	0.2%	A075043	001	Aug 25, 1998	Feb	CRLD
---	------	------	---------	-----	--------------	-----	------

WESTCORT

@	RANBAXY	0.2%	N018726	001	Aug 08, 1983	Feb	DISC
---	---------	------	---------	-----	--------------	-----	------

HYDROMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

EXALGO

	MALLINCKRODT INC	16MG	N021217	003	Mar 01, 2010	Jan	CRLD
--	------------------	------	---------	-----	--------------	-----	------

+		32MG	N021217	004	Aug 24, 2012	Jan	CRLD
---	--	------	---------	-----	--------------	-----	------

HYDROXYUREA

CAPSULE; ORAL

HYDROXYUREA

>A>	@	BARR LABS INC	250MG	A075020	002	Jun 26, 2000	Jun	CAHN
-----	---	---------------	-------	---------	-----	--------------	-----	------

>A>	@		500MG	A075020	001	Jul 30, 1998	Jun	CAHN
-----	---	--	-------	---------	-----	--------------	-----	------

>D>	@	DURAMED PHARMS BARR	250MG	A075020	002	Jun 26, 2000	Jun	CAHN
-----	---	---------------------	-------	---------	-----	--------------	-----	------

>D>	@		500MG	A075020	001	Jul 30, 1998	Jun	CAHN
-----	---	--	-------	---------	-----	--------------	-----	------

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

>A>	AB	CARACO	10MG	A040899	001	Jun 10, 2008	Jun	CAHN
-----	----	--------	------	---------	-----	--------------	-----	------

>A>	AB		25MG	A040899	002	Jun 10, 2008	Jun	CAHN
-----	----	--	------	---------	-----	--------------	-----	------

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

>A>	AB	CARACO	50MG	A040899	003	Jun 10, 2008	Jun	CAHN
	AB	HETERO LABS LTD III	10MG	A040805	001	May 29, 2008	Apr	CAHN
	AB		25MG	A040805	002	May 29, 2008	Apr	CAHN
	AB		50MG	A040805	003	May 29, 2008	Apr	CAHN
>D>	AB	SUN PHARM INDS INC	10MG	A040899	001	Jun 10, 2008	Jun	CAHN
>D>	AB		25MG	A040899	002	Jun 10, 2008	Jun	CAHN
>D>	AB		50MG	A040899	003	Jun 10, 2008	Jun	CAHN

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

AB	EMCURE PHARMS USA	25MG	A201507	001	Jun 03, 2013	May	NEWA
AB		50MG	A201507	002	Jun 03, 2013	May	NEWA

IBUPROFEN

SOLUTION; INTRAVENOUS

CALDOLOR

@ CUMBERLAND PHARMS	400MG/4ML (100MG/ML)	N022348	001	Jun 11, 2009	May	DISC
---------------------	----------------------	---------	-----	--------------	-----	------

IBUPROFEN LYSINE

INJECTABLE; INTRAVENOUS

NEOPROFEN

+ RECORDATI RARE	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N021903	001	Apr 13, 2006	May	CAHN
------------------	------------------------------------	---------	-----	--------------	-----	------

>A> ICOSAPENT ETHYL

>A> CAPSULE; ORAL

>A> VASCEPA

>A>	+	AMARIN PHARMS	1GM	N202057	001	Jul 26, 2012	Jun	NEWA
>A>	+		1GM	N202057	001	Jul 26, 2012	Jun	NEWA

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDARUBICIN HYDROCHLORIDE PFS

AP	TEVA PHARMS USA	1MG/ML	A065036	001	May 01, 2002	Apr	CAHN
----	-----------------	--------	---------	-----	--------------	-----	------

IFOSFAMIDE

INJECTABLE; INJECTION

IFOSFAMIDE

AP	+	TEVA PHARMS USA	1GM/20ML (50MG/ML)	A076657	001	Apr 04, 2007	May	CAHN
AP	+		3GM/60ML (50MG/ML)	A076657	002	Apr 04, 2007	May	CAHN

IFOSFAMIDE; MESNA

INJECTABLE; INTRAVENOUS

IFOSFAMIDE/MESNA KIT

+	TEVA PHARMS USA	1GM/20ML;1GM/10ML (50MG/ML;100MG/ML)	A075874	001	Feb 26, 2002	May	CAHN
+		3GM/60ML;1GM/10ML (50MG/ML;100MG/ML)	A075874	002	Feb 26, 2002	May	CAHN

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

@ PROSAM LABS	10MG	A040753	001	Feb 28, 2008	Mar	DISC
@	25MG	A040752	001	Feb 28, 2008	Mar	DISC

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

@ PROSAM LABS

50MG

A040751 001 Feb 28, 2008 Mar DISC

IMIPRAMINE PAMOATE

CAPSULE; ORAL

IMIPRAMINE PAMOATE

>A> AB MYLAN PHARMS INC

EQ 75MG HCL

A202338 001 Jun 28, 2013 Jun NEWA

>A> AB

EQ 100MG HCL

A202338 002 Jun 28, 2013 Jun NEWA

>A> AB

EQ 125MG HCL

A202338 003 Jun 28, 2013 Jun NEWA

>A> AB

EQ 150MG HCL

A202338 004 Jun 28, 2013 Jun NEWA

INDINAVIR SULFATE

CAPSULE; ORAL

CRIXIVAN

>D> MERCK SHARP DOHME

EQ 100MG BASE

N020685 006 Apr 19, 2000 Jun DISC

>A> @

EQ 100MG BASE

N020685 006 Apr 19, 2000 Jun DISC

INDOMETHACIN

CAPSULE; ORAL

INDOCIN

@ ICEUTICA OPERATIONS

25MG

N016059 001

Mar CAHN

@

50MG

N016059 002

Mar CAHN

INDOMETHACIN

>A> AB CARACO

25MG

A091401 001 Mar 28, 2013 Jun CAHN

>A> AB

50MG

A091401 002 Mar 28, 2013 Jun CAHN

AB HETERO LABS LTD III

25MG

A091240 001 Apr 12, 2011 Apr CAHN

AB

50MG

A091240 002 Apr 12, 2011 Apr CAHN

>D> AB SUN PHARM INDS INC

25MG

A091401 001 Mar 28, 2013 Jun CAHN

AB

25MG

A091401 001 Mar 28, 2013 Mar NEWA

>D> AB

50MG

A091401 002 Mar 28, 2013 Jun CAHN

AB

50MG

A091401 002 Mar 28, 2013 Mar NEWA

INDOMETHACIN SODIUM

INJECTABLE; INJECTION

INDOCIN

AP + RECORDATI RARE

EQ 1MG BASE/VIAL

N018878 001 Jan 30, 1985 May CAHN

IPRATROPIUM BROMIDE

SOLUTION; INHALATION

IPRATROPIUM BROMIDE

@ APOTEX INC

0.02%

A075441 001 Mar 28, 2001 Apr DISC

@ TEVA PHARMS USA

0.02%

A075313 001 Feb 07, 2000 Mar DISC

SPRAY, METERED; NASAL

IPRATROPIUM BROMIDE

@ APOTEX INC

0.021MG/SPRAY

A076156 001 Apr 18, 2003 Apr DISC

@

0.042MG/SPRAY

A076155 001 Apr 18, 2003 Apr DISC

IRON SUCROSE

INJECTABLE; INTRAVENOUS

VENOFER

LUITPOLD

EQ 65MG BASE/3.25ML (EQ 20MG
BASE/ML)

N021135 005 Mar 29, 2013 Mar NEWA

ISONIAZID

TABLET; ORAL

ISONIAZID

>D>	AA	WATSON LABS	300MG	A080521 001		Jun	DISC
>A>		@	300MG	A080521 001		Jun	DISC

ISONIAZID; RIFAMPIN

CAPSULE; ORAL

RIFAMATE

+	SANOFI AVENTIS US	150MG;300MG	A061884 001		Apr	CTEC
---	-------------------	-------------	-------------	--	-----	------

RIFAMPIN AND ISONIAZID

@	WEST WARD PHARM CORP	150MG;300MG	A065221 001	Jul 29, 2005	Apr	DISC
---	----------------------	-------------	-------------	--------------	-----	------

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION

ISOPROTERENOL HYDROCHLORIDE

@	INTL MEDICATION	0.2MG/ML	A083724 001		Mar	DISC
---	-----------------	----------	-------------	--	-----	------

ISUPREL

+	HOSPIRA	0.2MG/ML	N010515 001		Mar	CTEC
---	---------	----------	-------------	--	-----	------

ISOSORBIDE DINITRATE

CAPSULE, EXTENDED RELEASE; ORAL

DILATRATE-SR

+	ACTIENT PHARMS	40MG	N019790 001	Sep 02, 1988	May	CAHN
---	----------------	------	-------------	--------------	-----	------

TABLET; ORAL

ISORDIL

AB	VALEANT BERMUDA	5MG	N012093 007	Jul 29, 1988	Apr	CAHN
----	-----------------	-----	-------------	--------------	-----	------

AB		10MG	N012093 002	Jul 29, 1988	Apr	CAHN
----	--	------	-------------	--------------	-----	------

AB		20MG	N012093 006	Jul 29, 1988	Apr	CAHN
----	--	------	-------------	--------------	-----	------

AB	+	30MG	N012093 005	Jul 29, 1988	Apr	CAHN
----	---	------	-------------	--------------	-----	------

+		40MG	N012093 001	Jul 29, 1988	Apr	CAHN
---	--	------	-------------	--------------	-----	------

AB	VALEANT PHARM NORTH	5MG	N012093 007	Jul 29, 1988	Mar	CAHN
----	---------------------	-----	-------------	--------------	-----	------

AB		10MG	N012093 002	Jul 29, 1988	Mar	CAHN
----	--	------	-------------	--------------	-----	------

AB		20MG	N012093 006	Jul 29, 1988	Mar	CAHN
----	--	------	-------------	--------------	-----	------

AB	+	30MG	N012093 005	Jul 29, 1988	Mar	CAHN
----	---	------	-------------	--------------	-----	------

+		40MG	N012093 001	Jul 29, 1988	Mar	CAHN
---	--	------	-------------	--------------	-----	------

ISOSORBIDE DINITRATE

AB	PAR PHARM	5MG	A086923 001	Mar 12, 1987	Apr	CMFD
----	-----------	-----	-------------	--------------	-----	------

@		5MG	A086923 001	Mar 12, 1987	Feb	DISC
---	--	-----	-------------	--------------	-----	------

@	WATSON LABS	5MG	A086034 001	Jan 06, 1988	Apr	DISC
---	-------------	-----	-------------	--------------	-----	------

@		10MG	A086032 001	Jan 07, 1988	Apr	DISC
---	--	------	-------------	--------------	-----	------

TABLET; SUBLINGUAL

ISOSORBIDE DINITRATE

>D>	AB	WATSON LABS	2.5MG	A086033 001	Feb 26, 1988	Jun	DISC
-----	----	-------------	-------	-------------	--------------	-----	------

>A>		@	2.5MG	A086033 001	Feb 26, 1988	Jun	DISC
-----	--	---	-------	-------------	--------------	-----	------

>D>	AB	+	5MG	A086031 001	Sep 29, 1987	Jun	DISC
-----	----	---	-----	-------------	--------------	-----	------

>A>		@	5MG	A086031 001	Sep 29, 1987	Jun	DISC
-----	--	---	-----	-------------	--------------	-----	------

>D>	AB	WEST WARD	5MG	A086055 001	Nov 02, 1987	Jun	CRLD
-----	----	-----------	-----	-------------	--------------	-----	------

>A>	AB	+	WEST WARD PHARM CORP	5MG	A086055 001	Nov 02, 1987	Jun	CRLD
-----	----	---	----------------------	-----	-------------	--------------	-----	------

ISOTRETINOIN

CAPSULE; ORAL

ABSORICA

BX	RANBAXY	10MG	N021951 001	May 25, 2012	Feb	CAHN
----	---------	------	-------------	--------------	-----	------

BX		20MG	N021951 002	May 25, 2012	Feb	CAHN
----	--	------	-------------	--------------	-----	------

CAPSULE; ORAL

ABSORICA

BX	RANBAXY	30MG	N021951 003	May 25, 2012	Feb	CAHN
BX		40MG	N021951 004	May 25, 2012	Feb	CAHN
AMNESTEEM						
AB	MYLAN PHARMS INC	20MG	A075945 002	Nov 08, 2002	Apr	CRLD
CLARAVIS						
AB	TEVA PHARMS USA	10MG	A076356 001	Apr 11, 2003	May	CAHN
AB		30MG	A076135 003	May 11, 2006	Apr	CRLD
AB	+	40MG	A076135 001	Apr 11, 2003	Apr	CRLD
ZENATANE						
AB	DR REDDYS LABS LTD	10MG	A202099 001	Mar 25, 2013	Mar	NEWA
AB		20MG	A202099 002	Mar 25, 2013	Mar	NEWA
AB		40MG	A202099 003	Mar 25, 2013	Mar	NEWA

ISRADIPINE

TABLET, EXTENDED RELEASE; ORAL

DYNACIRC CR

>D>	GLAXOSMITHKLINE LLC	5MG	N020336 001	Jun 01, 1994	Jun	DISC
>A>	@	5MG	N020336 001	Jun 01, 1994	Jun	DISC
>D>	+	10MG	N020336 002	Jun 01, 1994	Jun	DISC
>A>	@	10MG	N020336 002	Jun 01, 1994	Jun	DISC

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

	@	APOTEX INC	15MG/ML	A075631 002	Jun 29, 2001	Apr	DISC
	@		30MG/ML	A075626 001	Jul 24, 2001	Apr	DISC
	@		30MG/ML	A077201 001	Oct 14, 2005	Apr	DISC
	@		30MG/ML	A075631 001	Jun 29, 2001	Apr	DISC
>D>	AP	LUITPOLD	15MG/ML	A078145 001	Jan 14, 2008	Jun	DISC
>A>	@		15MG/ML	A078145 001	Jan 14, 2008	Jun	DISC
>D>	AP		30MG/ML	A078145 002	Jan 14, 2008	Jun	DISC
>A>	@		30MG/ML	A078145 002	Jan 14, 2008	Jun	DISC

SOLUTION/DROPS; OPHTHALMIC

ACULAR PRESERVATIVE FREE

	@ ALLERGAN	0.5%	N020811 001	Nov 03, 1997	May	DISC
--	------------	------	-------------	--------------	-----	------

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HYDROCHLORIDE

	@ APOTEX INC	5MG/ML	A076051 001	Jul 05, 2002	Apr	DISC
--	--------------	--------	-------------	--------------	-----	------

TABLET; ORAL

LABETALOL HYDROCHLORIDE

AB	+	SANDOZ	200MG	A075113 002	Aug 04, 1998	Jan	CRLD
TRANDATE							
	@	PROMETHEUS LABS	100MG	N018716 001	May 24, 1985	Jan	DISC
	@		200MG	N018716 002	Aug 01, 1984	Jan	DISC

LACTULOSE

SOLUTION; ORAL

LACTULOSE

	@ APOTEX INC	10GM/15ML	A075911 001	Feb 21, 2002	Apr	DISC
--	--------------	-----------	-------------	--------------	-----	------

SOLUTION; ORAL, RECTAL

LACTULOSE

	@ APOTEX INC	10GM/15ML	A076645 001	Jul 28, 2003	Apr	DISC
--	--------------	-----------	-------------	--------------	-----	------

LAMOTRIGINE

TABLET; ORAL

LAMICTAL

AB	+	GLAXOSMITHKLINE LLC	25MG	N020241	005	Dec 27, 1994	Mar	CAHN
		@	50MG	N020241	006	Dec 27, 1994	Mar	CAHN
AB			100MG	N020241	001	Dec 27, 1994	Mar	CAHN
AB			150MG	N020241	002	Dec 27, 1994	Mar	CAHN
AB			200MG	N020241	003	Dec 27, 1994	Mar	CAHN
		@	250MG	N020241	004	Dec 27, 1994	Mar	CAHN

LAMOTRIGINE

>A>	AB	ALKEM LABS LTD	25MG	A200694	001	Jun 14, 2013	Jun	NEWA
>A>	AB		100MG	A200694	002	Jun 14, 2013	Jun	NEWA
>A>	AB		150MG	A200694	003	Jun 14, 2013	Jun	NEWA
>A>	AB		200MG	A200694	004	Jun 14, 2013	Jun	NEWA

TABLET, CHEWABLE; ORAL

LAMICTAL CD

AB		GLAXOSMITHKLINE LLC	2MG	N020764	004	Sep 08, 2000	Mar	CAHN
AB			5MG	N020764	001	Aug 24, 1998	Mar	CAHN
AB	+		25MG	N020764	002	Aug 24, 1998	Mar	CAHN
		@	100MG	N020764	003	Aug 24, 1998	Mar	CAHN

TABLET, EXTENDED RELEASE; ORAL

LAMICTAL XR

AB		GLAXOSMITHKLINE LLC	25MG	N022115	001	May 29, 2009	Mar	CAHN
AB	+		50MG	N022115	002	May 29, 2009	Mar	CAHN
AB			100MG	N022115	003	May 29, 2009	Mar	CAHN
AB			200MG	N022115	004	May 29, 2009	Mar	CAHN
AB			250MG	N022115	006	Jun 21, 2011	Mar	CAHN
AB			300MG	N022115	005	Apr 14, 2010	Mar	CAHN

LAMOTRIGINE

>A>	AB	DR REDDYS LABS LTD	25MG	A202383	001	Jun 19, 2013	Jun	NEWA
>A>	AB		50MG	A202383	002	Jun 19, 2013	Jun	NEWA
>A>	AB		100MG	A202383	003	Jun 19, 2013	Jun	NEWA
>A>	AB		200MG	A202383	004	Jun 19, 2013	Jun	NEWA
>A>	AB		300MG	A202383	005	Jun 19, 2013	Jun	NEWA
	AB	PAR PHARM	25MG	A201791	001	Jan 18, 2013	Jan	NEWA
	AB		50MG	A201791	002	Jan 18, 2013	Jan	NEWA
	AB		100MG	A201791	003	Jan 18, 2013	Jan	NEWA
	AB		200MG	A201791	004	Jan 18, 2013	Jan	NEWA
	AB		250MG	A201791	005	Jan 18, 2013	Jan	NEWA
	AB		300MG	A201791	006	Jan 18, 2013	Jan	NEWA
>A>	AB	WILSHIRE PHARMS INC	25MG	A202887	001	Jun 17, 2013	Jun	NEWA
>A>	AB		50MG	A202887	002	Jun 17, 2013	Jun	NEWA
>A>	AB		100MG	A202887	003	Jun 17, 2013	Jun	NEWA
>A>	AB		200MG	A202887	004	Jun 17, 2013	Jun	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

LAMICTAL ODT

		GLAXOSMITHKLINE LLC	25MG	N022251	001	May 08, 2009	Mar	CAHN
	+		50MG	N022251	002	May 08, 2009	Mar	CAHN
			100MG	N022251	003	May 08, 2009	Mar	CAHN
			200MG	N022251	004	May 08, 2009	Mar	CAHN

LATANOPROST

SOLUTION/DROPS; OPHTHALMIC

LATANOPROST

	@	APOTEX INC	0.005%	A077697	001	Mar 22, 2011	Apr	DISC
--	---	------------	--------	---------	-----	--------------	-----	------

SOLUTION/DROPS; OPHTHALMIC

LATANOPROST

AT	DR REDDYS LABS LTD	0.005%	A202077 001	Feb 11, 2013	Jan	NEWA
----	--------------------	--------	-------------	--------------	-----	------

LENALIDOMIDE

CAPSULE; ORAL

REVLIMID

>A>	CELGENE	20MG	N021880 006	Jun 05, 2013	Jun	NEWA
-----	---------	------	-------------	--------------	-----	------

>D> LEPIRUDIN RECOMBINANT

>D> INJECTABLE; INJECTION

>D> REFLUDAN

>D>	+ BAYER HLTHCARE	50MG/VIAL	N020807 001	Mar 06, 1998	Jun	DISC
-----	------------------	-----------	-------------	--------------	-----	------

>A>	@	50MG/VIAL	N020807 001	Mar 06, 1998	Jun	DISC
-----	---	-----------	-------------	--------------	-----	------

LETROZOLE

TABLET; ORAL

LETROZOLE

AB	JIANGSU HENG Rui MED	2.5MG	A202716 001	May 16, 2013	Apr	NEWA
----	----------------------	-------	-------------	--------------	-----	------

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM

AP	TEVA PHARMS USA	EQ 100MG BASE/VIAL	A081277 001	Sep 28, 1993	Mar	CAHN
----	-----------------	--------------------	-------------	--------------	-----	------

AP		EQ 350MG BASE/VIAL	A040174 001	Jun 12, 1997	Mar	CAHN
----	--	--------------------	-------------	--------------	-----	------

LEUCOVORIN CALCIUM PRESERVATIVE FREE

>D>	AP	LUITPOLD	EQ 50MG BASE/VIAL	A040338 001	Jan 31, 2001	Jun	DISC
-----	----	----------	-------------------	-------------	--------------	-----	------

>A>	@	EQ 50MG BASE/VIAL	A040338 001	Jan 31, 2001	Jun	DISC
-----	---	-------------------	-------------	--------------	-----	------

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

LEUPROLIDE ACETATE

AP	TEVA PHARMS USA	1MG/0.2ML	A075471 001	Oct 25, 2000	Mar	CAHN
----	-----------------	-----------	-------------	--------------	-----	------

LUPRON DEPOT

+	ABBVIE ENDOCRINE INC	3.75MG/VIAL	N020011 001	Oct 22, 1990	Apr	CAHN
---	----------------------	-------------	-------------	--------------	-----	------

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

LEVALBUTEROL HYDROCHLORIDE

AN	DEY	EQ 0.0103% BASE	A077800 001	Mar 15, 2013	Mar	NEWA
----	-----	-----------------	-------------	--------------	-----	------

AN		EQ 0.021% BASE	A077800 002	Mar 15, 2013	Mar	NEWA
----	--	----------------	-------------	--------------	-----	------

AN		EQ 0.042% BASE	A077800 003	Mar 15, 2013	Mar	NEWA
----	--	----------------	-------------	--------------	-----	------

AN	TEVA PHARMS USA	EQ 0.0103% BASE	A090297 001	Apr 26, 2013	Apr	NEWA
----	-----------------	-----------------	-------------	--------------	-----	------

AN		EQ 0.021% BASE	A090297 002	Apr 26, 2013	Apr	NEWA
----	--	----------------	-------------	--------------	-----	------

AN		EQ 0.042% BASE	A090297 003	Apr 26, 2013	Apr	NEWA
----	--	----------------	-------------	--------------	-----	------

LEVETIRACETAM

INJECTABLE; IV (INFUSION)

LEVETIRACETAM

>A>	AP	SAGENT PHARMS	500MG/5ML (100MG/ML)	A091627 001	Jun 26, 2013	Jun	NEWA
-----	----	---------------	----------------------	-------------	--------------	-----	------

SOLUTION; ORAL

LEVETIRACETAM

@	APOTEX INC	100MG/ML	A090187 001	Aug 05, 2011	Apr	DISC
---	------------	----------	-------------	--------------	-----	------

AA	HETERO DRUGS LTD	100MG/ML	A203052 001	Feb 28, 2013	Feb	NEWA
----	------------------	----------	-------------	--------------	-----	------

AA	HETERO LABS LTD III	100MG/ML	A203052 001	Feb 28, 2013	Apr	CAHN
----	---------------------	----------	-------------	--------------	-----	------

SOLUTION; ORAL

LEVETIRACETAM

AA	ORIT LABS LLC	100MG/ML	A203067	001	May 09, 2013	Apr	NEWA
----	---------------	----------	---------	-----	--------------	-----	------

TABLET; ORAL

LEVETIRACETAM

AB	HETERO LABS LTD III	250MG	A090515	001	Oct 08, 2010	Apr	CAHN
AB		500MG	A090515	002	Oct 08, 2010	Apr	CAHN
AB		750MG	A090515	003	Oct 08, 2010	Apr	CAHN
AB		1GM	A090515	004	Oct 08, 2010	Apr	CAHN
AB	PRINSTON INC	250MG	A078106	001	Feb 10, 2009	Apr	CAHN
AB		500MG	A078106	002	Feb 10, 2009	Apr	CAHN
AB		750MG	A078106	003	Feb 10, 2009	Apr	CAHN
AB		1GM	A078106	004	Feb 10, 2009	Apr	CAHN

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

	@ SANDOZ	500MG	A091668	001	Nov 01, 2012	Mar	DISC
	@	750MG	A091668	002	Nov 01, 2012	Mar	DISC
AB	VINTAGE PHARMS LLC	500MG	A202533	001	Jul 20, 2012	Jan	NEWA
AB		750MG	A202533	002	Jul 20, 2012	Jan	NEWA

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

LEVOBUNOLOL HYDROCHLORIDE

	@ APOTEX INC	0.25%	A075473	001	Aug 03, 2000	Apr	DISC
	@	0.5%	A075475	001	Aug 03, 2000	Apr	DISC

LEVOCARNITINE

INJECTABLE; INJECTION

LEVOCARNITINE

AP	TEVA PHARMS USA	200MG/ML	A075881	001	Mar 29, 2001	May	CAHN
----	-----------------	----------	---------	-----	--------------	-----	------

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AB	SANDOZ	5MG	A090486	001	Mar 26, 2013	Mar	NEWA
AB	SUN PHARMA GLOBAL	5MG	A090362	001	Jan 31, 2013	Jan	NEWA

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVOFLOXACIN

AP	AUROBINDO PHARMA LTD	EQ 500MG/20ML (EQ 25MG/ML)	A202328	001	Jan 24, 2013	Jan	NEWA
AP		EQ 750MG/30ML (EQ 25MG/ML)	A202328	002	Jan 24, 2013	Jan	NEWA
AP	CLARIS LIFESCIENCES	EQ 500MG/20ML (EQ 25MG/ML)	A091436	001	Jun 05, 2013	May	NEWA
AP	EMCURE PHARMS LTD	EQ 500MG/20ML (EQ 25MG/ML)	A202590	001	Jan 24, 2013	Jan	NEWA
AP		EQ 750MG/30ML (EQ 25MG/ML)	A202590	002	Jan 24, 2013	Jan	NEWA

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

>A>	AP	FRESENIUS KABI USA	EQ 250MG/50ML (EQ 5MG/ML)	A200674	001	Jun 19, 2013	Jun	NEWA
>A>	AP		EQ 500MG/100ML (EQ 5MG/ML)	A200674	002	Jun 19, 2013	Jun	NEWA
>A>	AP		EQ 750MG/150ML (EQ 5MG/ML)	A200674	003	Jun 19, 2013	Jun	NEWA

SOLUTION/DROPS; OPHTHALMIC

LEVOFLOXACIN

	@ APOTEX INC	0.5%	A078282	001	Dec 20, 2010	Apr	DISC
--	--------------	------	---------	-----	--------------	-----	------

LEVONORDEFIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

>D>	ISOCAINE HYDROCHLORIDE W/ LEVONORDEFIN					
>D>	AP NOVOCOL	0.05MG/ML;2%	A084697	001	Jun	DISC
>A>	@	0.05MG/ML;2%	A084697	001	Jun	DISC
	SCANDONEST L					
>D>	AP DEPROCO	0.05MG/ML;2%	A088388	001	Oct 10, 1984	Jun CRLD
>A>	+	0.05MG/ML;2%	A088388	001	Oct 10, 1984	Jun CRLD

LEVONORGESTREL

INTRAUTERINE DEVICE; INTRAUTERINE

SKYLA

+	BAYER HLTHCARE	13.5MG	N203159	001	Jan 09, 2013	Jan NEWA
---	----------------	--------	---------	-----	--------------	----------

TABLET; ORAL

LEVONORGESTREL

AB	LUPIN LTD	0.75MG	A091328	001	Jan 23, 2013	Jan NEWA
AB	NOVEL LABS INC	1.5MG	A202508	001	Feb 22, 2013	Feb NEWA
	PLAN B ONE-STEP					
AB	+ TEVA BRANDED PHARM	1.5MG	N021998	001	Jul 10, 2009	Apr CAHN

LEVOTHYROXINE SODIUM**

**Refer to Annual Edition Preface Section 1.8 Levothyroxine Sodium for amplifying information

TABLET; ORAL

LEVOXYL

AB1,	KING PHARMS R AND D	0.025MG	N021301	001	May 25, 2001	Mar CAHN
AB3						
AB1,		0.05MG	N021301	002	May 25, 2001	Mar CAHN
AB3						
AB1,		0.075MG	N021301	003	May 25, 2001	Mar CAHN
AB3						
AB1,		0.088MG	N021301	004	May 25, 2001	Mar CAHN
AB3						
AB1,		0.1MG	N021301	005	May 25, 2001	Mar CAHN
AB3						
AB1,		0.112MG	N021301	006	May 25, 2001	Mar CAHN
AB3						
AB1,		0.125MG	N021301	007	May 25, 2001	Mar CAHN
AB3						
AB1,		0.137MG	N021301	008	May 25, 2001	Mar CAHN
AB3						
AB1,		0.15MG	N021301	009	May 25, 2001	Mar CAHN
AB3						
AB1,		0.175MG	N021301	010	May 25, 2001	Mar CAHN
AB3						
AB1, +		0.2MG	N021301	011	May 25, 2001	Mar CAHN
AB3						
	@	0.3MG	N021301	012	May 25, 2001	Mar CAHN

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE

@ LUITPOLD

2%

A083198	001	Mar	DISC
---------	-----	-----	------

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE

AP	AUROBINDO PHARMA LTD	1%	A203040	001	Mar 14, 2013	Mar NEWA
AP		1%	A203082	001	Mar 14, 2013	Mar NEWA
AP		2%	A203040	002	Mar 14, 2013	Mar NEWA
AP		2%	A203082	002	Mar 14, 2013	Mar NEWA

JELLY; TOPICAL

ANESTACON

@ POLYMEDICA

2%

A080429 001

May DISC

LIDOCAINE HYDROCHLORIDE

>D> AT

TEVA PHARMS

2%

A081318 001 Apr 29, 1993 Jun DISC

>A>

@ TEVA PHARMS USA

2%

A081318 001 Apr 29, 1993 Jun DISC

LIOTHYRONINE SODIUM

TABLET; ORAL

CYTOMEL

AB KING PHARMS R AND D

EQ 0.005MG BASE

N010379 001

Mar CAHN

AB

EQ 0.025MG BASE

N010379 002

Mar CAHN

AB +

EQ 0.05MG BASE

N010379 003

Mar CAHN

LISINOPRIL

TABLET; ORAL

LISINOPRIL

@ SANDOZ

2.5MG

A075999 001 Jul 01, 2002 Jan CAHN

@

5MG

A075999 002 Jul 01, 2002 Jan CAHN

@

10MG

A075999 003 Jul 01, 2002 Jan CAHN

@

20MG

A075999 004 Jul 01, 2002 Jan CAHN

@

30MG

A075999 005 Jul 01, 2002 Jan CAHN

@

40MG

A075999 006 Jul 01, 2002 Jan CAHN

LITHIUM CARBONATE

CAPSULE; ORAL

LITHIUM CARBONATE

@ APOTEX INC

300MG

A076795 001 Nov 22, 2004 Feb DISC

AB HETERO LABS LTD III

150MG

A090702 001 Sep 25, 2009 Apr CAHN

AB

300MG

A090702 002 Sep 25, 2009 Apr CAHN

AB

600MG

A090702 003 Sep 25, 2009 Apr CAHN

LOMUSTINE

CAPSULE; ORAL

CEENU

CORDEN PHARMA

10MG

N017588 001

Apr CAHN

40MG

N017588 002

Apr CAHN

+

100MG

N017588 003

Apr CAHN

LORAZEPAM

CONCENTRATE; ORAL

LORAZEPAM

AA LUPIN LTD

2MG/ML

A091407 001 Feb 19, 2013 Feb NEWA

TABLET; ORAL

LORAZEPAM

@ SANDOZ

0.5MG

A071193 001 Apr 15, 1988 Apr DISC

@

1MG

A071194 001 Apr 15, 1988 Apr DISC

@

2MG

A071195 001 Apr 15, 1988 Apr DISC

LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM

AB ACTAVIS GRP PTC

25MG

A090382 001 Oct 06, 2010 Mar CAHN

AB

50MG

A090382 002 Oct 06, 2010 Mar CAHN

AB

100MG

A090382 003 Oct 06, 2010 Mar CAHN

LOVASTATIN

TABLET; ORAL									
LOVASTATIN									
AB	+ CARLSBAD	40MG	A075991	003	Jun 05, 2002	Feb	CRLD		
MEVACOR									
	@ MERCK	20MG	N019643	003	Aug 31, 1987	Feb	DISC		
	@	40MG	N019643	004	Dec 14, 1988	Feb	DISC		

LOXAPINE SUCCINATE

CAPSULE; ORAL									
LOXAPINE SUCCINATE									
AB	MIKAH PHARMA	EQ 5MG BASE	A076868	001	Aug 04, 2005	May	CMFD		
AB		EQ 10MG BASE	A076868	002	Aug 04, 2005	May	CMFD		
AB		EQ 25MG BASE	A076868	003	Aug 04, 2005	May	CMFD		
AB		EQ 50MG BASE	A076868	004	Aug 04, 2005	May	CMFD		

MAFENIDE ACETATE

CREAM; TOPICAL									
SULFAMYLN									
	+ MYLAN INSTITUTIONAL	EQ 85MG BASE/GM	N016763	001		May	CAHN		
FOR SOLUTION; TOPICAL									
MAFENIDE ACETATE									
AB	PAR FORM	5%	A201511	001	Feb 12, 2013	Jan	NEWA		
SULFAMYLN									
AB	+ MYLAN INSTITUTIONAL	5%	N019832	003	Jun 05, 1998	May	CAHN		
AB	+ MYLAN LLC	5%	N019832	003	Jun 05, 1998	Jan	CFTG		

MAGNESIUM SULFATE, POTASSIUM SULFATE, SODIUM SULFATE; POLYETHYLENE GLYCOL 3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE

SOLUTION, FOR SOLUTION; ORAL, ORAL									
SUCLEAR									
	+ BRAINTREE LABS	1.6GM/BOT, 3.13GM/BOT, 17.5GM/BOT, N/A, N/A, N/A, N/A; N/A, N/A, N/A, 210GM, 0.74GM, 2.86GM, 5.6GM	N203595	001	Jan 18, 2013	Jan	NEWA		

MANNITOL

INJECTABLE; INJECTION									
MANNITOL 20%									
	@ B BRAUN	20GM/100ML	N014738	001		Jan	DISC		

MECAMYLAMINE HYDROCHLORIDE

TABLET; ORAL									
MECAMYLAMINE HYDROCHLORIDE									
	NEXGEN PHARMA	2.5MG	A204054	001	Mar 19, 2013	Mar	NEWA		

MECHLORETHAMINE HYDROCHLORIDE

INJECTABLE; INJECTION									
MUSTARGEN									
	+ RECORDATI RARE	10MG/VIAL	N006695	001		May	CAHN		

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION									
MEDROXYPROGESTERONE ACETATE									
AB	TEVA PHARMS USA	150MG/ML	A076553	001	Jul 28, 2004	May	CAHN		
	@	150MG/ML	A076552	001	Oct 27, 2004	May	CAHN		

MEFENAMIC ACID

CAPSULE; ORAL

MEFENAMIC ACID

AB	CYPRESS PHARM	250MG	A090359	001	Feb 05, 2013	Jan	NEWA
----	---------------	-------	---------	-----	--------------	-----	------

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

MEFLOQUINE HYDROCHLORIDE

>D>	AB	WEST WARD	250MG	A077699	001	Apr 21, 2010	Jun	DISC
>A>		@ WEST WARD PHARM CORP	250MG	A077699	001	Apr 21, 2010	Jun	DISC

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGESTROL ACETATE

	@ APOTEX INC	40MG/ML	A077404	001	Feb 16, 2006	Apr	DISC
--	--------------	---------	---------	-----	--------------	-----	------

MELOXICAM

TABLET; ORAL

MELOXICAM

	@ COREPHARMA	7.5MG	A077930	001	Jul 19, 2006	Feb	DISC
	@	15MG	A077930	002	Jul 19, 2006	Feb	DISC
	@ CR DOUBLE CRANE	7.5MG	A078039	001	Dec 14, 2006	Apr	DISC
AB		7.5MG	A078039	001	Dec 14, 2006	Mar	CAHN
	@	15MG	A078039	002	Dec 14, 2006	Apr	DISC
AB		15MG	A078039	002	Dec 14, 2006	Mar	CAHN

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

	@ TARO	200MG	A200998	001	May 23, 2011	Jan	DISC
	@	400MG	A200998	002	May 23, 2011	Jan	DISC

MESALAMINE

CAPSULE, DELAYED RELEASE; ORAL

DELZICOL

+	WARNER CHILCOTT LLC	400MG	N204412	001	Feb 01, 2013	Feb	NEWA
---	---------------------	-------	---------	-----	--------------	-----	------

SUPPOSITORY; RECTAL

CANASA

+	APTALIS PHARMA US	1GM	N021252	002	Nov 05, 2004	Feb	CRLD
---	-------------------	-----	---------	-----	--------------	-----	------

MESNA

INJECTABLE; INTRAVENOUS

MESNA

AP	TEVA PHARMS USA	100MG/ML	A075764	001	Apr 27, 2001	May	CAHN
----	-----------------	----------	---------	-----	--------------	-----	------

METAPROTERENOL SULFATE

SOLUTION; INHALATION

METAPROTERENOL SULFATE

	@ APOTEX INC	0.4%	A075402	001	Feb 28, 2001	Apr	DISC
	@	0.6%	A075403	001	Feb 28, 2001	Apr	DISC

SYRUP; ORAL

METAPROTERENOL SULFATE

	@ APOTEX INC	10MG/5ML	A075235	001	Jan 27, 2000	Apr	DISC
	@ NOVEX	10MG/5ML	A075235	001	Jan 27, 2000	Feb	DISC

SYRUP; ORAL

METAPROTERENOL SULFATE

+	SILARX	10MG/5ML	A073632	001	Jul 22, 1992	Feb	CTEC
---	--------	----------	---------	-----	--------------	-----	------

TABLET; ORAL

METAPROTERENOL SULFATE

	PAR PHARM	10MG	A072024	001	Jun 28, 1988	Mar	CTEC
+		20MG	A072025	001	Jun 28, 1988	Mar	CTEC
	@ WATSON LABS	10MG	A073013	001	Jan 31, 1991	Mar	DISC
	@	20MG	A072795	001	Jan 31, 1991	Mar	DISC

METAXALONE

TABLET; ORAL

METAXALONE

>A>	AB	AMNEAL PHARMS	800MG	A203399	001	Jun 21, 2013	Jun	NEWA
-----	----	---------------	-------	---------	-----	--------------	-----	------

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

AB	SANDOZ	500MG	A075965	001	Jan 25, 2002	May	CMFD
	@	500MG	A075965	001	Jan 25, 2002	Mar	DISC
AB		850MG	A075965	002	Jan 25, 2002	May	CMFD
	@	850MG	A075965	002	Jan 25, 2002	Mar	DISC
AB		1GM	A075965	003	Jan 25, 2002	May	CMFD
	@	1GM	A075965	003	Jan 25, 2002	Mar	DISC

TABLET, EXTENDED RELEASE; ORAL

METFORMIN HYDROCHLORIDE

>D>	AB	TORRENT PHARMS	750MG	A079226	001	Feb 18, 2010	Jun	DISC
>A>		@ TORRENT PHARMS LTD	750MG	A079226	001	Feb 18, 2010	Jun	DISC
		@ WATSON LABS INC	500MG	A076818	001	Dec 14, 2004	Mar	DISC

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	500MG;EQ 15MG BASE	A200823	001	Feb 13, 2013	Jan	NEWA
AB		850MG;EQ 15MG BASE	A200823	002	Feb 13, 2013	Jan	NEWA
AB	SANDOZ	500MG;EQ 15MG BASE	A091273	001	Apr 16, 2013	Apr	NEWA
AB		850MG;EQ 15MG BASE	A091273	002	Apr 16, 2013	Apr	NEWA
AB	TORRENT PHARMS LTD	500MG;EQ 15MG BASE	A202001	001	Feb 13, 2013	Jan	NEWA
AB		850MG;EQ 15MG BASE	A202001	002	Feb 13, 2013	Jan	NEWA

METHADONE HYDROCHLORIDE

TABLET, FOR SUSPENSION; ORAL

METHADONE HYDROCHLORIDE

AA	MALLINCKRODT INC	40MG	A077142	001	Jul 12, 2005	Mar	CDFR
AA	+	ROXANE	N017058	001		Mar	CDFR
AA	SANDOZ	40MG	A075082	001	Mar 25, 1998	Mar	CDFR
	METHADOSE						
AA	MALLINCKRODT	40MG	A074184	001	Apr 29, 1993	Mar	CDFR

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL

DESOXYN

AA	+	RECORDATI RARE	5MG	N005378	002	May	CAHN
----	---	----------------	-----	---------	-----	-----	------

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

AA	AUSTARPHARMA LLC	500MG	A200958 001	Oct 21, 2011	May	CMFD
	@	500MG	A200958 001	Oct 21, 2011	Jan	DISC
AA		750MG	A200958 002	Oct 21, 2011	May	CMFD
	@	750MG	A200958 002	Oct 21, 2011	Jan	DISC
AA	HETERO LABS LTD III	500MG	A090200 001	Nov 06, 2009	Apr	CAHN
AA		750MG	A090200 002	Nov 06, 2009	Apr	CAHN
AA	PRINSTON INC	500MG	A086989 001		Feb	CMFD
AA		750MG	A086988 001		Feb	CAHN
	@ SOLCO HLTHCARE	500MG	A086989 001		Jan	DISC

METHOXSALLEN

CAPSULE; ORAL

OXSORALEN-ULTRA

+	DOW PHARM	10MG	N019600 001	Oct 30, 1986	Apr	CAHN
---	-----------	------	-------------	--------------	-----	------

METHYCLOTHIAZIDE

TABLET; ORAL

METHYCLOTHIAZIDE

+	MYLAN PHARMS INC	5MG	A087672 001	Aug 17, 1982	Jan	CTEC
	@ WATSON LABS	5MG	A088724 001	Sep 06, 1984	Jan	DISC

>D> METHYL AMINOLEVULINATE HYDROCHLORIDE

>D> CREAM; TOPICAL

>D> METVIXIA

>D>	+	GALDERMA LABS LP	EQ 16.8% BASE	N021415 001	Jul 27, 2004	Jun	DISC
>A>		@	EQ 16.8% BASE	N021415 001	Jul 27, 2004	Jun	DISC

METHYLDOPA

TABLET; ORAL

METHYLDOPA

	@ ACCORD HLTHCARE	125MG	A070070 003	Oct 15, 1985	Apr	CAHN
AB		250MG	A070084 001	Oct 15, 1985	Apr	CAHN
AB		500MG	A070085 001	Oct 15, 1985	Apr	CAHN

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB1	WATSON LABS INC	20MG	A078458 001	Dec 01, 2011	Apr	CAHN
AB1		30MG	A078458 002	Dec 01, 2011	Apr	CAHN
AB1		40MG	A078458 003	Dec 01, 2011	Apr	CAHN

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB	CARACO	5MG	A090710 001	Mar 15, 2012	May	CAHN
AB		10MG	A090710 002	Mar 15, 2012	May	CAHN
AB		20MG	A090710 003	Mar 15, 2012	May	CAHN

TABLET, EXTENDED RELEASE; ORAL

CONCERTA

>D>	JANSSEN PHARMS	18MG	N021121 001	Aug 01, 2000	Jun	CTEC
>A>	AB	18MG	N021121 001	Aug 01, 2000	Jun	CTEC
	METHYLIN ER					
	MALLINCKRODT INC	10MG	A075629 001	May 09, 2000	Feb	CTEC

TABLET, EXTENDED RELEASE; ORAL
METHYLPHENIDATE HYDROCHLORIDE

>A>	AB	KUDCO IRELAND	18MG	A091695 001	Jul 09, 2013	Jun	NEWA
>A>	AB		27MG	A091695 002	Jul 09, 2013	Jun	NEWA

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION
METHYLPREDNISOLONE ACETATE

AB	TEVA PHARMS USA	40MG/ML	A040557 001	Feb 23, 2005	May	CAHN
AB		40MG/ML	A040620 001	Oct 27, 2006	May	CAHN
AB		80MG/ML	A040557 002	Feb 23, 2005	May	CAHN
AB		80MG/ML	A040620 002	Oct 27, 2006	May	CAHN

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
METOCLOPRAMIDE HYDROCHLORIDE

AP	BD RX	EQ 5MG BASE/ML	A091392 001	Apr 19, 2013	Apr	NEWA
	@ TEVA PARENTERAL	EQ 5MG BASE/ML	A073135 001	Nov 27, 1991	Feb	DISC
	@ TEVA PHARMS USA	EQ 5MG BASE/ML	A073135 001	Nov 27, 1991	May	CAHN

METOLAZONE

TABLET; ORAL
METOLAZONE

	@ TEVA	2.5MG	A076600 001	Jan 06, 2004	Mar	DISC
>D>	AB	5MG	A076833 001	Mar 01, 2004	Jun	DISC
>A>	@	5MG	A076833 001	Mar 01, 2004	Jun	DISC
	@	10MG	A075543 003	Dec 24, 2003	May	DISC

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL
METOPROLOL SUCCINATE

	@ NESHER PHARMS	EQ 25MG TARTRATE	A077779 001	Mar 20, 2008	Feb	DISC
	@	EQ 50MG TARTRATE	A077176 001	May 14, 2008	May	DISC

METOPROLOL TARTRATE

INJECTABLE; INJECTION
METOPROLOL TARTRATE

AP	CLARIS LIFESCIENCES	1MG/ML	A078950 001	Apr 29, 2013	Apr	NEWA
	@ WATSON LABS	1MG/ML	A074032 001	Dec 21, 1993	Mar	DISC

TABLET; ORAL

METOPROLOL TARTRATE

AB	ALEMBIC PHARMS LTD	25MG	A202871 001	May 28, 2013	May	NEWA
AB		50MG	A202871 002	May 28, 2013	May	NEWA
AB		100MG	A202871 003	May 28, 2013	May	NEWA
	@ PRINSTON INC	50MG	A074453 001	Apr 27, 1995	Mar	CAHN
	@	100MG	A074453 002	Apr 27, 1995	Mar	CAHN

METRONIDAZOLE

TABLET; ORAL
METRONIDAZOLE

AB	TEVA PHARMS USA	250MG	A070027 001	Nov 06, 1984	Mar	CAHN
----	-----------------	-------	-------------	--------------	-----	------

METYROSLINE

CAPSULE; ORAL

DEMSEER

>A>	+	ATON PHARMA VPNA	250MG	N017871 001		Jun	CAHN
>D>	+	BIOVAIL TECHNOLOGIES	250MG	N017871 001		Jun	CAHN

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

	@	APOTEX INC	EQ 1MG BASE/ML	A075637 001	Oct 31, 2000	Apr	DISC
	@		EQ 5MG BASE/ML	A075637 002	Oct 31, 2000	Apr	DISC
	@	CLARIS LIFESCIENCES	EQ 1MG BASE/ML	A075637 001	Oct 31, 2000	Jan	DISC
	@		EQ 5MG BASE/ML	A075637 002	Oct 31, 2000	Jan	DISC
>D>	AP	INTL MEDICATED	EQ 1MG BASE/ML	A076144 001	Jan 26, 2005	Jun	DISC
>A>	@		EQ 1MG BASE/ML	A076144 001	Jan 26, 2005	Jun	DISC
>D>	AP		EQ 5MG BASE/ML	A076144 002	Jan 26, 2005	Jun	DISC
>A>	@		EQ 5MG BASE/ML	A076144 002	Jan 26, 2005	Jun	DISC
	@	INTL MEDICATION	EQ 1MG BASE/ML	A076020 001	Jul 16, 2004	May	DISC
	@		EQ 5MG BASE/ML	A076020 002	Jul 16, 2004	May	DISC

SYRUP; ORAL

MIDAZOLAM HYDROCHLORIDE

@	APOTEX INC	EQ 2MG BASE/ML	A077115 001	Sep 09, 2005	Apr	DISC
---	------------	----------------	-------------	--------------	-----	------

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

@	APOTEX INC	EQ 1MG BASE/ML	A076427 001	Sep 21, 2004	Apr	DISC
---	------------	----------------	-------------	--------------	-----	------

MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER

@	APOTEX INC	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A077151 001	Jul 20, 2005	Apr	DISC
---	------------	---------------------------------------	-------------	--------------	-----	------

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

MINOCYCLINE HYDROCHLORIDE

AB		CARACO	EQ 50MG BASE	A090867 001	May 13, 2013	Apr	NEWA
AB			EQ 75MG BASE	A090867 002	May 13, 2013	Apr	NEWA
AB			EQ 100MG BASE	A090867 003	May 13, 2013	Apr	NEWA

CAPSULE, EXTENDED RELEASE; ORAL

XIMINO

@	RANBAXY LABS LTD	EQ 45MG BASE	N201922 001	Jul 11, 2012	May	DISC
@		EQ 67.5MG BASE	N201922 002	Jul 11, 2012	May	DISC
@		EQ 90MG BASE	N201922 003	Jul 11, 2012	May	DISC
@		EQ 112.5MG BASE	N201922 004	Jul 11, 2012	May	DISC
@		EQ 135MG BASE	N201922 005	Jul 11, 2012	May	DISC

TABLET, EXTENDED RELEASE; ORAL

SOLODYN

@	MEDICIS	EQ 45MG BASE	N050808 001	May 08, 2006	Apr	DISC
+		EQ 55MG BASE	N050808 008	Aug 27, 2010	Apr	CRLD
+		EQ 80MG BASE	N050808 007	Aug 27, 2010	Apr	CRLD
@		EQ 135MG BASE	N050808 003	May 08, 2006	Apr	DISC

MIPOMERSEN SODIUM

SOLUTION; SUBCUTANEOUS

KYNAMRO

+	GENZYME CORP	200MG/ML (200MG/ML)	N203568 001	Jan 29, 2013	Jan	NEWA
---	--------------	---------------------	-------------	--------------	-----	------

MIRTAZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL
MIRTAZAPINE

>D>	AB	ACTAVIS ELIZABETH	15MG	A077959 001	Feb 14, 2011	Jun	DISC
>A>		@	15MG	A077959 001	Feb 14, 2011	Jun	DISC
>D>	AB		30MG	A077959 002	Feb 14, 2011	Jun	DISC
>A>		@	30MG	A077959 002	Feb 14, 2011	Jun	DISC
>D>	AB		45MG	A077959 003	Feb 14, 2011	Jun	DISC
>A>		@	45MG	A077959 003	Feb 14, 2011	Jun	DISC

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

AP	ONCO THERAPIES LTD	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A201014 001	Dec 11, 2012	Mar	CAIN
AP	TEVA PHARMS USA	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A077356 001	Apr 11, 2006	May	CAHN
AP		EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	A077356 002	Apr 11, 2006	May	CAHN
AP		EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A077356 003	Apr 11, 2006	May	CAHN

MOMETASONE FUROATE

CREAM; TOPICAL

ELOCON

AB	MERCK SHARP DOHME	0.1%	N019625 002	Apr 19, 2013	Apr	NEWA
----	-------------------	------	-------------	--------------	-----	------

OINTMENT; TOPICAL

MOMETASONE FUROATE

@ TARO

0.1%

A076624 001	Dec 03, 2004	May	DISC
-------------	--------------	-----	------

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

KADIAN

AB1 +	WATSON LABS INC	10MG	N020616 008	Apr 20, 2007	May	CTEC
+		10MG	N020616 008	Apr 20, 2007	Apr	CAHN
AB1		20MG	N020616 001	Jul 03, 1996	Apr	CAHN
AB1		30MG	N020616 004	Mar 09, 2001	Apr	CAHN
		40MG	N020616 009	Jul 09, 2012	Apr	CAHN
AB1		50MG	N020616 002	Jul 03, 1996	Apr	CAHN
AB1		60MG	N020616 005	Mar 09, 2001	Apr	CAHN
		70MG	N020616 010	Jul 09, 2012	Apr	CAHN
AB1		80MG	N020616 006	Oct 27, 2006	Apr	CAHN
AB1 +		100MG	N020616 003	Jul 03, 1996	Apr	CAHN
		130MG	N020616 011	Jul 09, 2012	Apr	CAHN
		150MG	N020616 012	Jul 09, 2012	Apr	CAHN
AB1 +		200MG	N020616 007	Feb 27, 2007	May	CTEC
+		200MG	N020616 007	Feb 27, 2007	Apr	CAHN

MORPHINE SULFATE

AB1	PAR PHARM INC	20MG	A200812 001	Nov 10, 2011	Apr	CTEC
AB1		30MG	A200812 002	Nov 10, 2011	Apr	CTEC
AB1		50MG	A200812 003	Nov 10, 2011	Apr	CTEC
AB1		60MG	A200812 004	Nov 10, 2011	Apr	CTEC
AB1		80MG	A200812 005	Nov 10, 2011	Apr	CTEC
AB1		100MG	A200812 006	Nov 10, 2011	Apr	CTEC
AB1	UPSHER SMITH	10MG	A202104 001	Jun 03, 2013	May	NEWA
AB1		20MG	A202104 002	Jun 03, 2013	May	NEWA

CAPSULE, EXTENDED RELEASE; ORALMORPHINE SULFATE

AB1	UPSHER SMITH	30MG	A202104 003	Jun 03, 2013	May	NEWA
AB1		50MG	A202104 004	Jun 03, 2013	May	NEWA
AB1		60MG	A202104 005	Jun 03, 2013	May	NEWA
AB1		80MG	A202104 006	Jun 03, 2013	May	NEWA
AB1		100MG	A202104 007	Jun 03, 2013	May	NEWA

MUPIROCIIN CALCIUMCREAM; TOPICALBACTROBAN

AB	+	GLAXOSMITHKLINE	EQ 2% BASE	N050746 001	Dec 11, 1997	Jan	CFTG
----	---	-----------------	------------	-------------	--------------	-----	------

MUPIROCIIN

AB		GLENMARK GENERICS	EQ 2% BASE	A201587 001	Jan 24, 2013	Jan	NEWA
----	--	-------------------	------------	-------------	--------------	-----	------

MYCOPHENOLATE MOFETILCAPSULE; ORALMYCOPHENOLATE MOFETIL

AB		ACCORD HLTHCARE	250MG	A090253 001	May 04, 2009	Apr	CAHN
>A>	AB	ALKEM LABS LTD	250MG	A200197 001	Jun 13, 2013	Jun	NEWA

NABUMETONETABLET; ORALNABUMETONE

	@	DR REDDYS LABS LTD	500MG	A078420 001	Sep 24, 2008	Apr	DISC
	@		750MG	A078420 002	Sep 24, 2008	Apr	DISC
	@	PROSAM LABS	500MG	A079093 001	Feb 27, 2009	Mar	DISC
	@		750MG	A079093 002	Feb 27, 2009	Mar	DISC

NAFTIFINE HYDROCHLORIDEGEL; TOPICALNAFTIN

>A>	+	MERZ PHARMS	2%	N204286 001	Jun 27, 2013	Jun	NEWA
-----	---	-------------	----	-------------	--------------	-----	------

NALTREXONE HYDROCHLORIDETABLET; ORALNALTREXONE HYDROCHLORIDE

	@	SANDOZ	50MG	A075434 001	Mar 08, 2000	Apr	DISC
--	---	--------	------	-------------	--------------	-----	------

NAPROXENTABLET; ORALNAPROXEN

AB		WEST WARD PHARM CORP	250MG	A076494 001	Jan 14, 2004	Apr	CAHN
AB			375MG	A076494 002	Jan 14, 2004	Apr	CAHN
AB			500MG	A076494 003	Jan 14, 2004	Apr	CAHN

NARATRIPTAN HYDROCHLORIDETABLET; ORALAMERGE

AB		GLAXOSMITHKLINE LLC	EQ 1MG BASE	N020763 002	Feb 10, 1998	Mar	CAHN
AB	+		EQ 2.5MG BASE	N020763 001	Feb 10, 1998	Mar	CAHN

NELFINAVIR MESYLATE

>D>	POWDER; ORAL							
>D>	VIRACEPT							
>D>	+ AGOURON	EQ 50MG BASE/SC00PFUL	N020778	001	Mar 14, 1997	Jun	DISC	
>A>	@	EQ 50MG BASE/SC00PFUL	N020778	001	Mar 14, 1997	Jun	DISC	

NEOMYCIN SULFATE

POWDER; FOR RX COMPOUNDING

NEO-RX

@ X GEN PHARMS	100%	A061579	001		Mar	DISC
----------------	------	---------	-----	--	-----	------

NEOMYCIN SULFATE; POLYMYXIN B SULFATE; PREDNISOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC

POLY-PRED

@ ALLERGAN	EQ 0.35% BASE;10,000 UNITS/ML;0.5%	N050081	002		May	DISC
------------	---------------------------------------	---------	-----	--	-----	------

NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS

BLOXIVERZ

+ ECLAT PHARMS LLC	5MG/10ML (0.5MG/ML)	N204078	001	May 31, 2013	May	NEWA
+	10MG/10ML (1MG/ML)	N204078	002	May 31, 2013	May	NEWA

NIFEDIPINE

CAPSULE; ORAL

NIFEDIPINE

AB	ACTAVIS ELIZABETH	20MG	A072556	001	Sep 20, 1990	Apr	CTEC
	@ CATALENT	10MG	A073250	001	Oct 08, 1991	Apr	DISC
AB	EMCURE PHARMS USA	10MG	A202644	001	Apr 25, 2013	Apr	NEWA
AB		20MG	A202644	002	Apr 25, 2013	Apr	NEWA

NILUTAMIDE

TABLET; ORAL

NILANDRON

@ COVIS PHARMA SARL	50MG	N020169	001	Sep 19, 1996	Apr	CAHN
+	150MG	N020169	002	Apr 30, 1999	Apr	CAHN

NIMODIPINE

SOLUTION; ORAL

NYMALIZE

+ ARBOR PHARMS INC	60MG/20ML	N203340	001	May 10, 2013	May	NEWA
--------------------	-----------	---------	-----	--------------	-----	------

NITISINONE

CAPSULE; ORAL

ORFADIN

SWEDISH ORPHAN	2MG	N021232	001	Jan 18, 2002	May	CAHN
	5MG	N021232	002	Jan 18, 2002	May	CAHN
+	10MG	N021232	003	Jan 18, 2002	May	CAHN

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

MACRODANTIN

	ALVOGEN INC	25MG	N016620	003		Mar	CTEC
AB		25MG	N016620	003		Feb	CAHN
AB		50MG	N016620	001		Feb	CAHN

CAPSULE; ORAL

MACRODANTIN

AB	+	ALVOGEN INC	100MG	N016620 002		Feb	CAHN
		NITROFURANTOIN					
		@ WATSON LABS	25MG	A073696 001	Dec 31, 1992	Mar	DISC
		@	50MG	A073696 002	Dec 31, 1992	Mar	DISC
		@	100MG	A073696 003	Dec 31, 1992	Mar	DISC

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

MACROBID

AB	+	ALVOGEN INC	75MG;25MG	N020064 001	Dec 24, 1991	Mar	CAHN
----	---	-------------	-----------	-------------	--------------	-----	------

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL

NITRO-DUR

AB1	+	MERCK SHARP DOHME	0.1MG/HR	N020145 001	Apr 04, 1995	Mar	CAHN
AB1	+		0.2MG/HR	N020145 002	Apr 04, 1995	Mar	CAHN
	+		0.3MG/HR	N020145 003	Apr 04, 1995	Mar	CAHN
AB1	+		0.4MG/HR	N020145 004	Apr 04, 1995	Mar	CAHN
AB1	+		0.6MG/HR	N020145 005	Apr 04, 1995	Mar	CAHN
	+		0.8MG/HR	N020145 006	Apr 04, 1995	Mar	CAHN

NIZATIDINE

CAPSULE; ORAL

NIZATIDINE

		@ APOTEX INC	150MG	A076383 001	Jan 23, 2003	Feb	DISC
		@	300MG	A076383 002	Jan 23, 2003	Feb	DISC

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

NOREPINEPHRINE BITARTRATE

AP		TEVA PHARMS USA	EQ 1MG BASE/ML	A040455 001	Mar 03, 2003	May	CAHN
----	--	-----------------	----------------	-------------	--------------	-----	------

NORETHINDRONE

TABLET; ORAL-28

JENCYCLA

AB2		LUPIN LTD	0.35MG	A091323 001	Mar 28, 2013	Apr	CTEC
AB			0.35MG	A091323 001	Mar 28, 2013	Mar	NEWA

NORETHINDRONE

>A>	AB1	FAMY CARE LTD	0.35MG	A201483 001	Jun 24, 2013	Jun	NEWA
	AB2		0.35MG	A200980 001	Jun 12, 2013	May	NEWA

NYSTATIN

SUSPENSION; ORAL

NILSTAT

		@ GLENMARK GENERICS	100,000 UNITS/ML	N050299 001		Feb	DISC
--	--	---------------------	------------------	-------------	--	-----	------

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE

AP		TEVA PHARMS USA	EQ 0.05MG BASE/ML	A075957 001	Oct 03, 2005	May	CAHN
AP			EQ 0.1MG BASE/ML	A075957 002	Oct 03, 2005	May	CAHN
AP			EQ 0.2MG BASE/ML	A075959 001	Nov 21, 2005	May	CAHN
AP			EQ 0.5MG BASE/ML	A075957 003	Oct 03, 2005	May	CAHN

INJECTABLE; INJECTION									
OCTREOTIDE ACETATE									
AP	TEVA PHARMS USA	EQ 1MG BASE/ML	A075959	002	Nov 21, 2005	May	CAHN		
<u>OFLOXACIN</u>									
SOLUTION/DROPS; OPHTHALMIC									
OFLOXACIN									
AT	ALTAIRE PHARMS INC	0.3%	A202692	001	Apr 29, 2013	Apr	NEWA		
	@ APOTEX INC	0.3%	A076513	001	May 14, 2004	Apr	DISC		
<u>OMEPRAZOLE; SODIUM BICARBONATE</u>									
FOR SUSPENSION; ORAL									
OMEPRAZOLE AND SODIUM BICARBONATE									
AB	PAR PHARM	20MG/PACKET;1.68GM/PACKET	A079182	001	Apr 19, 2013	Apr	NEWA		
AB		40MG/PACKET;1.68GM/PACKET	A079182	002	Apr 19, 2013	Apr	NEWA		
ZEGERID									
AB	SANTARUS	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Apr	CFTG		
AB	+	40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Apr	CFTG		
<u>ONDANSETRON HYDROCHLORIDE</u>									
INJECTABLE; INJECTION									
ONDANSETRON HYDROCHLORIDE									
	@ APOTEX INC	EQ 2MG BASE/ML	A077368	001	Dec 26, 2006	Apr	DISC		
AP	CLARIS LIFESCIENCES	2MG/ML	A078288	001	Feb 22, 2013	Feb	NEWA		
	@ LUITPOLD	EQ 2MG BASE/ML	A077582	001	Dec 26, 2006	Mar	DISC		
	@ PLIVA HRVATSKA DOO	EQ 2MG BASE/ML	A077544	001	Dec 26, 2006	Feb	DISC		
ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER									
	@ CLARIS LIFESCIENCES	EQ 0.64MG BASE/ML	A078308	001	Mar 17, 2008	Jan	DISC		
	@ HOSPIRA	EQ 0.64MG BASE/ML	A077348	001	Feb 01, 2007	Jan	DISC		
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE									
	@ APOTEX INC	EQ 2MG BASE/ML	A077343	001	Dec 26, 2006	Apr	DISC		
AP	CLARIS LIFESCIENCES	2MG/ML	A078287	001	Feb 22, 2013	Feb	NEWA		
	@ LUITPOLD	EQ 2MG BASE/ML	A077387	001	Dec 26, 2006	Mar	DISC		
<u>OSPEMIFENE</u>									
TABLET; ORAL									
OSPHENA									
+	SHIONOGI INC	60MG	N203505	001	Feb 26, 2013	Feb	NEWA		
<u>OXACILLIN SODIUM</u>									
INJECTABLE; INJECTION									
OXACILLIN SODIUM									
AP	AUROBINDO PHARMA LTD	EQ 1GM BASE/VIAL	A201539	001	Jan 18, 2013	Jan	NEWA		
AP		EQ 2GM BASE/VIAL	A201539	002	Jan 18, 2013	Jan	NEWA		
AP		EQ 10GM BASE/VIAL	A201538	001	Jan 18, 2013	Jan	NEWA		
<u>OXAPROZIN</u>									
TABLET; ORAL									
OXAPROZIN									
	@ CARACO	600MG	A075844	001	Jan 03, 2002	Jan	DISC		
<u>OXCARBAZEPINE</u>									
TABLET; ORAL									
OXCARBAZEPINE									
	@ TEVA PHARMS USA	150MG	A078005	001	Dec 11, 2007	Mar	DISC		

TABLET; ORAL

OXCARBAZEPINE

@ TEVA PHARMS USA

300MG

A078005 002 Dec 11, 2007 Mar DISC

@

600MG

A078005 003 Dec 11, 2007 Mar DISC

OXYBUTYNIN

GEL, METERED; TRANSDERMAL

>D>

ANTUROL

>D>

+ WATSON LABS INC

3%

N202513 001 Dec 07, 2011 Jun CTNA

>A>

GELNIQUE 3%

>A>

+ WATSON LABS INC

3%

N202513 001 Dec 07, 2011 Jun CTNA

OXYBUTYNIN CHLORIDE

SYRUP; ORAL

OXYBUTYNIN CHLORIDE

@ APOTEX INC

5MG/5ML

A074997 001 Oct 15, 1997 Apr DISC

>D> AA

MIKART

5MG/5ML

A075039 001 Jan 29, 1999 Jun DISC

>A>

@

5MG/5ML

A075039 001 Jan 29, 1999 Jun DISC

TABLET; ORAL

OXYBUTYNIN CHLORIDE

AB

TEVA PHARMS USA

5MG

A071655 001 Nov 14, 1988 Mar CAHN

OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE HYDROCHLORIDE

>D>

@ NESHER PHARMS

5MG

A077290 001 Dec 08, 2005 Jun CMFD

>A> AB

5MG

A077290 001 Dec 08, 2005 Jun CMFD

@

5MG

A077290 001 Dec 08, 2005 Mar DISC

>D>

@

10MG

A077290 002 Dec 08, 2005 Jun CMFD

>A> AB

10MG

A077290 002 Dec 08, 2005 Jun CMFD

@

10MG

A077290 002 Dec 08, 2005 Mar DISC

>D>

@

15MG

A077290 003 Dec 08, 2005 Jun CMFD

>A> AB

15MG

A077290 003 Dec 08, 2005 Jun CMFD

@

15MG

A077290 003 Dec 08, 2005 Mar DISC

>D>

@

20MG

A077290 004 Dec 08, 2005 Jun CMFD

>A> AB

20MG

A077290 004 Dec 08, 2005 Jun CMFD

@

20MG

A077290 004 Dec 08, 2005 Mar DISC

>D>

@

30MG

A077290 005 Dec 08, 2005 Jun CMFD

>A> AB

30MG

A077290 005 Dec 08, 2005 Jun CMFD

@

30MG

A077290 005 Dec 08, 2005 Mar DISC

OXYMORPHONE HYDROCHLORIDE

TABLET; ORAL

OXYMORPHONE HYDROCHLORIDE

AB

AVANTHI INC

5MG

A203601 001 Jan 30, 2013 Jan NEWA

AB

10MG

A203601 002 Jan 30, 2013 Jan NEWA

AB

MALLINCKRODT INC

5MG

A202321 001 Apr 25, 2013 Apr NEWA

AB

10MG

A202321 002 Apr 25, 2013 Apr NEWA

TABLET, EXTENDED RELEASE; ORAL

OXYMORPHONE HYDROCHLORIDE

AB

ACTAVIS ELIZABETH

7.5MG

A079046 001 Dec 13, 2010 Apr CAHN

AB

15MG

A079046 002 Dec 13, 2010 Apr CAHN

OXYTOCIN

INJECTABLE; INJECTION

OXYTOCIN

AP	HIKMA FARMACEUTICA	10USP UNITS/ML (10USP UNITS/ML)	A200219 001	Feb 13, 2013	Jan	NEWA
	@ TEVA PHARMS USA	10USP UNITS/ML (10USP UNITS/ML)	A077453 001	Jan 24, 2008	May	CAHN
	@	100USP UNITS/10ML (10USP UNITS/ML)	A077453 002	Jan 24, 2008	May	CAHN

PACLITAXEL

INJECTABLE; INJECTION

PACLITAXEL

	@ ACCORD HLTHCARE	6MG/ML	A075436 001	Nov 12, 2004	Apr	DISC
	@ TEVA PHARMS USA	6MG/ML	A075297 001	Jan 25, 2002	May	CAHN
	TAXOL					
AP	HQ SPCLT PHARMA	6MG/ML	N020262 001	Dec 29, 1992	Apr	CMFD
	@	6MG/ML	N020262 001	Dec 29, 1992	Jan	CAHN

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

PAMIDRONATE DISODIUM

AP	TEVA PHARMS USA	30MG/10ML (3MG/ML)	A076153 001	Mar 27, 2002	Mar	CAHN
AP		90MG/10ML (9MG/ML)	A076153 002	Mar 27, 2002	Mar	CAHN

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE; ORAL

CREON

	ABBVIE	180,000USP UNITS;36,000USP UNITS;114,000USP UNITS	N020725 005	Mar 14, 2013	Mar	NEWA
--	--------	---	-------------	--------------	-----	------

PANCURONIUM BROMIDE

INJECTABLE; INJECTION

PANCURONIUM BROMIDE

AP	+	TEVA PHARMS USA	1MG/ML	A072759 001	Jul 31, 1990	May	CAHN
AP	+		2MG/ML	A072760 001	Jul 31, 1990	Mar	CAHN

PAROXETINE HYDROCHLORIDE

SUSPENSION; ORAL

PAROXETINE HYDROCHLORIDE

	@ APOTEX INC	EQ 10MG BASE/5ML	A077395 001	Dec 05, 2006	Apr	DISC
--	--------------	------------------	-------------	--------------	-----	------

PAROXETINE MESYLATE

CAPSULE; ORAL

BRISDELLE

>A>	+	NOVEN THERAP	EQ 7.5MG BASE	N204516 001	Jun 28, 2013	Jun	NEWA
-----	---	--------------	---------------	-------------	--------------	-----	------

PEGINESATIDE ACETATE

SOLUTION; INTRAVENOUS, SUBCUTANEOUS

OMONTYS

	@ TAKEDA PHARMS USA	EQ 10MG BASE/ML (EQ 10MG BASE/ML)	N202799 007	Mar 27, 2012	May	DISC
+		EQ 10MG BASE/ML (EQ 10MG BASE/ML)	N202799 007	Mar 27, 2012	Apr	CAHN
	@	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N202799 008	Mar 27, 2012	May	DISC
+		EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N202799 008	Mar 27, 2012	Apr	CAHN

OMONTYS PRESERVATIVE FREE

	@ TAKEDA PHARMS USA	EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML)	N202799 001	Mar 27, 2012	May	DISC
--	---------------------	---------------------------------------	-------------	--------------	-----	------

SOLUTION; INTRAVENOUS, SUBCUTANEOUS

OMONTYS PRESERVATIVE FREE

+	TAKEDA PHARMS USA	EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML)	N202799 001	Mar 27, 2012	Apr	CAHN
@		EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML)	N202799 002	Mar 27, 2012	May	DISC
+		EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML)	N202799 002	Mar 27, 2012	Apr	CAHN
@		EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N202799 003	Mar 27, 2012	May	DISC
+		EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N202799 003	Mar 27, 2012	Apr	CAHN
@		EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML)	N202799 004	Mar 27, 2012	May	DISC
+		EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML)	N202799 004	Mar 27, 2012	Apr	CAHN
@		EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML)	N202799 005	Mar 27, 2012	May	DISC
+		EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML)	N202799 005	Mar 27, 2012	Apr	CAHN
@		EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML)	N202799 006	Mar 27, 2012	May	DISC
+		EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML)	N202799 006	Mar 27, 2012	Apr	CAHN

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

PHENYLEPHRINE HYDROCHLORIDE

	PARAGON BIOTECK	2.5%	N203510 001	Mar 21, 2013	Mar	NEWA
+		10%	N203510 002	Mar 21, 2013	Mar	NEWA

PHENYTOIN SODIUM

INJECTABLE; INJECTION

PHENYTOIN SODIUM

@	HOSPIRA	50MG/ML	A089744 001	Dec 18, 1987	Mar	DISC
---	---------	---------	-------------	--------------	-----	------

PHYTONADIONE

TABLET; ORAL

MEPHYTON

>D>	+	VALEANT PHARMS	5MG	N010104 003		Jun	CAHN
>A>	+		5MG	N010104 003		Jun	CAHN

PINDOLOL

TABLET; ORAL

PINDOLOL

>D>	AB	MYLAN	5MG	A074019 001	Sep 03, 1992	Jun	CTEC
>D>	AB	+	10MG	A074019 002	Sep 03, 1992	Jun	CTEC
>A>		MYLAN PHARMS INC	5MG	A074019 001	Sep 03, 1992	Jun	CTEC
>A>		+	10MG	A074019 002	Sep 03, 1992	Jun	CTEC
>D>	AB	WATSON LABS	5MG	A074437 001	Feb 27, 1995	Jun	DISC
>A>	@		5MG	A074437 001	Feb 27, 1995	Jun	DISC
>D>	AB		10MG	A074437 002	Feb 27, 1995	Jun	DISC
>A>	@		10MG	A074437 002	Feb 27, 1995	Jun	DISC

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

PIOGLITAZONE HYDROCHLORIDE

AB	ACCORD HLTHCARE	EQ 15MG BASE	A200044 001	Feb 13, 2013	Jan	NEWA
AB		EQ 30MG BASE	A200044 002	Feb 13, 2013	Jan	NEWA
AB		EQ 45MG BASE	A200044 003	Feb 13, 2013	Jan	NEWA

TABLET; ORAL

PIOGLITAZONE HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	EQ 15MG BASE	A200268 001	Feb 13, 2013	Jan	NEWA
AB		EQ 30MG BASE	A200268 002	Feb 13, 2013	Jan	NEWA
AB		EQ 45MG BASE	A200268 003	Feb 13, 2013	Jan	NEWA
AB	DR REDDYS LABS LTD	EQ 15MG BASE	A078383 001	Mar 12, 2013	Mar	NEWA
AB		EQ 30MG BASE	A078383 002	Mar 12, 2013	Mar	NEWA
AB		EQ 45MG BASE	A078383 003	Mar 12, 2013	Mar	NEWA
AB	MACLEODS PHARMS LTD	EQ 15MG BASE	A202467 001	Feb 06, 2013	Jan	NEWA
AB		EQ 30MG BASE	A202467 002	Feb 06, 2013	Jan	NEWA
AB		EQ 45MG BASE	A202467 003	Feb 06, 2013	Jan	NEWA
AB	SANDOZ	EQ 15MG BASE	A078670 001	Feb 13, 2013	Jan	NEWA
AB		EQ 30MG BASE	A078670 002	Feb 13, 2013	Jan	NEWA
AB		EQ 45MG BASE	A078670 003	Feb 13, 2013	Jan	NEWA
AB	SYNTHON PHARMS	EQ 15MG BASE	A078472 001	Feb 13, 2013	Jan	NEWA
AB		EQ 30MG BASE	A078472 002	Feb 13, 2013	Jan	NEWA
AB		EQ 45MG BASE	A078472 003	Feb 13, 2013	Jan	NEWA
AB	TORRENT PHARMS LTD	EQ 15MG BASE	A091298 001	Feb 13, 2013	Jan	NEWA
AB		EQ 30MG BASE	A091298 002	Feb 13, 2013	Jan	NEWA
AB		EQ 45MG BASE	A091298 003	Feb 13, 2013	Jan	NEWA
AB	ZYDUS PHARMS USA INC	EQ 15MG BASE	A202456 001	Feb 13, 2013	Jan	NEWA
AB		EQ 30MG BASE	A202456 002	Feb 13, 2013	Jan	NEWA
AB		EQ 45MG BASE	A202456 003	Feb 13, 2013	Jan	NEWA

POLYMYXIN B SULFATE

POWDER; FOR RX COMPOUNDING

POLY-RX

@ X GEN PHARMS	100,000,000 UNITS/BOT	A061578 001		Mar	DISC
----------------	-----------------------	-------------	--	-----	------

POMALIDOMIDE

CAPSULE; ORAL

POMALYST

CELGENE	1MG	N204026 001	Feb 08, 2013	Feb	NEWA
	2MG	N204026 002	Feb 08, 2013	Feb	NEWA
	3MG	N204026 003	Feb 08, 2013	Feb	NEWA
+	4MG	N204026 004	Feb 08, 2013	Feb	NEWA

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

POTASSIUM CHLORIDE

AB	AMNEAL PHARMS	10MEQ	A202128 001	Feb 22, 2013	Feb	NEWA
----	---------------	-------	-------------	--------------	-----	------

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB	ACTAVIS GRP PTC	0.125MG	A091254 001	Nov 30, 2010	Mar	CAHN
AB		0.25MG	A091254 002	Nov 30, 2010	Mar	CAHN
AB		0.5MG	A091254 003	Nov 30, 2010	Mar	CAHN
AB		0.75MG	A091254 004	Nov 30, 2010	Mar	CAHN
AB		1MG	A091254 005	Nov 30, 2010	Mar	CAHN
AB		1.5MG	A091254 006	Nov 30, 2010	Mar	CAHN
AB	SUN PHARM INDS INC	0.125MG	A091683 001	Mar 27, 2013	Mar	NEWA
AB		0.25MG	A091683 002	Mar 27, 2013	Mar	NEWA
AB		0.5MG	A091683 003	Mar 27, 2013	Mar	NEWA
AB		0.75MG	A091683 004	Mar 27, 2013	Mar	NEWA
AB		1MG	A091683 005	Mar 27, 2013	Mar	NEWA

TABLET; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB		SUN PHARM INDS INC	1.5MG		A091683	006	Mar 27, 2013	Mar	NEWA
----	--	--------------------	-------	--	---------	-----	--------------	-----	------

PRAMLintide ACETATE

INJECTABLE; SUBCUTANEOUS

SYMLIN

		AMYLIN PHARMS	EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML)	N021332	002	Sep 25, 2007	Jan	CAHN
>D>			EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML)	N021332	003	Sep 25, 2007	Jun	CRLD
			EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML)	N021332	003	Sep 25, 2007	Jan	CAHN
>D>	+		EQ 3MG BASE/5ML (EQ 600MCG BASE/ML)	N021332	001	Mar 16, 2005	Jun	DISC
	+		EQ 3MG BASE/5ML (EQ 600MCG BASE/ML)	N021332	001	Mar 16, 2005	Jan	CAHN
>A>	+	AMYLIN PHARMS LLC	EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML)	N021332	003	Sep 25, 2007	Jun	CRLD
>A>	@		EQ 3MG BASE/5ML (EQ 600MCG BASE/ML)	N021332	001	Mar 16, 2005	Jun	DISC

PRAZIQUANTEL

TABLET; ORAL

BILTRICIDE

>A>	+	BAYER HLTHCARE	600MG	N018714	001	Dec 29, 1982	Jun	CAHN
>D>	+	BAYER PHARMA AG	600MG	N018714	001	Dec 29, 1982	Jun	CAHN

PREDNISOLONE

SYRUP; ORAL

PREDNISOLONE

@ APOTEX INC

5MG/5ML

A040570 001 Aug 25, 2005 Apr DISC

@

15MG/5ML

A040571 001 Aug 25, 2005 Apr DISC

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

ORAPRED

AA	+	CONCORDIA PHARMS INC	EQ 15MG BASE/5ML	A075117	001	Dec 14, 2000	May	CAHN
		PREDNISOLONE SODIUM PHOSPHATE						
		@ NESHER PHARMS	EQ 15MG BASE/5ML	A076988	001	May 24, 2005	May	DISC
		@ PHARM ASSOC	EQ 5MG BASE/5ML	A076123	001	Dec 23, 2002	Mar	DISC
		@ WE PHARMS	EQ 15MG BASE/5ML	A075250	001	Jul 12, 2002	Mar	DISC

TABLET, ORALLY DISINTEGRATING; ORAL

ORAPRED ODT

AB		CONCORDIA PHARMS INC	EQ 10MG BASE	N021959	001	Jun 01, 2006	May	CAHN
AB			EQ 15MG BASE	N021959	002	Jun 01, 2006	May	CAHN
AB	+		EQ 30MG BASE	N021959	003	Jun 01, 2006	May	CAHN
AB		SHIONOGI INC	EQ 10MG BASE	N021959	001	Jun 01, 2006	Mar	CFTG
AB			EQ 15MG BASE	N021959	002	Jun 01, 2006	Mar	CFTG
AB	+		EQ 30MG BASE	N021959	003	Jun 01, 2006	Mar	CFTG
		PREDNISOLONE SODIUM PHOSPHATE						
AB		MYLAN PHARMS INC	EQ 10MG BASE	A202179	001	Apr 10, 2013	Mar	NEWA
AB			EQ 15MG BASE	A202179	002	Apr 10, 2013	Mar	NEWA
AB			EQ 30MG BASE	A202179	003	Apr 10, 2013	Mar	NEWA

PREDNISONE

TABLET; ORAL

PREDNISONE

AB	HIKMA PHARMS	1MG	A040890	001	Nov 01, 2010	May	CAHN
AB		2.5MG	A040538	001	Jan 08, 2004	May	CAHN
AB		5MG	A080292	001		May	CAHN
AB		10MG	A088832	001	Dec 04, 1985	May	CAHN
AB		20MG	A083677	001		May	CAHN
AB		50MG	A088465	001	Jun 01, 1984	May	CAHN

PRIMIDONE

TABLET; ORAL

PRIMIDONE

@ DR REDDYS LABS LTD

50MG

A040862 001 Oct 03, 2008 Apr DISC

@

250MG

A040862 002 Oct 03, 2008 Apr DISC

PROBENECID

TABLET; ORAL

PROBENECID

@ IVAX SUB TEVA PHARMS 500MG

A083740 001 May 09, 1984 May DISC

PROGESTERONE

CAPSULE; ORAL

PROMETRIUM

AB	ABBVIE INC	100MG	N019781	001	May 14, 1998	May	CAHN
AB	+	200MG	N019781	002	Oct 15, 1999	May	CAHN
	@	300MG	N019781	003	Oct 15, 1999	May	CAHN

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROMETHAZINE HYDROCHLORIDE

AP	+	TEVA PHARMS USA	25MG/ML	A040454	001	Aug 22, 2002	Mar	CAHN
AP	+		50MG/ML	A040454	002	Aug 22, 2002	Mar	CAHN

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE

AA	CARACO	6.25MG/5ML	A040891	001	Mar 13, 2009	May	CAHN
----	--------	------------	---------	-----	--------------	-----	------

TABLET; ORAL

PROMETHAZINE HYDROCHLORIDE

AB	CARACO	12.5MG	A040863	001	Dec 30, 2008	May	CAHN
AB		25MG	A040863	002	Dec 30, 2008	May	CAHN
AB		50MG	A040863	003	Dec 30, 2008	May	CAHN

PROPOFOL

INJECTABLE; INJECTION

PROPOFOL

AB	TEVA PHARMS USA	10MG/ML	A075102	001	Jan 04, 1999	Mar	CAHN
----	-----------------	---------	---------	-----	--------------	-----	------

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPRANOLOL HYDROCHLORIDE

AB	GLATT AIR	60MG	A078065	001	Jan 26, 2007	Feb	CAHN
AB		80MG	A078065	002	Jan 26, 2007	Feb	CAHN
AB		120MG	A078065	003	Jan 26, 2007	Feb	CAHN
AB		160MG	A078065	004	Jan 26, 2007	Feb	CAHN

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

VIVACTIL

@ TEVA WOMENS

5MG

N016012 001

Mar CAHN

@

10MG

N016012 002

Mar CAHN

PYRIMETHAMINE

TABLET; ORAL

DARAPRIM

+ AMEDRA PHARMS

25MG

N008578 001

Apr CAHN

QUAZEPAM

TABLET; ORAL

DORAL

>D> @ QUESTCOR PHARMS

7.5MG

N018708 003 Feb 26, 1987 Jun CAHN

>D> +

15MG

N018708 001 Dec 27, 1985 Jun CAHN

>A> @ SCIECURE PHARMA INC

7.5MG

N018708 003 Feb 26, 1987 Jun CAHN

>A> +

15MG

N018708 001 Dec 27, 1985 Jun CAHN

QUETIAPINE FUMARATE

TABLET; ORAL

QUETIAPINE FUMARATE

AB ACCORD HLTHCARE

EQ 25MG BASE

A202152 001 Mar 27, 2012 Apr CAHN

AB

EQ 50MG BASE

A202152 002 Mar 27, 2012 Apr CAHN

AB

EQ 100MG BASE

A202152 003 Mar 27, 2012 Apr CAHN

AB

EQ 200MG BASE

A202152 004 Mar 27, 2012 Apr CAHN

AB

EQ 300MG BASE

A202152 005 Mar 27, 2012 Apr CAHN

AB

EQ 400MG BASE

A202152 006 Mar 27, 2012 Apr CAHN

AB

ACTAVIS GRP PTC

EQ 25MG BASE

A201762 001 Feb 27, 2013 May CAHN

AB

EQ 50MG BASE

A201762 002 Feb 27, 2013 May CAHN

AB

EQ 100MG BASE

A201762 003 Feb 27, 2013 May CAHN

AB

EQ 150MG BASE

A201762 004 Feb 27, 2013 May CAHN

AB

EQ 200MG BASE

A201762 005 Feb 27, 2013 May CAHN

AB

EQ 300MG BASE

A201762 006 Feb 27, 2013 May CAHN

AB

EQ 400MG BASE

A201762 007 Feb 27, 2013 May CAHN

AB

ACTAVIS PHARMA

EQ 25MG BASE

A201762 001 Feb 27, 2013 Feb NEWA

AB

EQ 50MG BASE

A201762 002 Feb 27, 2013 Feb NEWA

AB

EQ 100MG BASE

A201762 003 Feb 27, 2013 Feb NEWA

AB

EQ 150MG BASE

A201762 004 Feb 27, 2013 Feb NEWA

AB

EQ 200MG BASE

A201762 005 Feb 27, 2013 Feb NEWA

AB

EQ 300MG BASE

A201762 006 Feb 27, 2013 Feb NEWA

AB

EQ 400MG BASE

A201762 007 Feb 27, 2013 Feb NEWA

AB

ALKEM LABS LTD

EQ 25MG BASE

A201504 001 Feb 12, 2013 Jan NEWA

AB

EQ 50MG BASE

A201504 002 Feb 12, 2013 Jan NEWA

AB

EQ 100MG BASE

A201504 003 Feb 12, 2013 Jan NEWA

AB

EQ 150MG BASE

A201504 004 Feb 12, 2013 Jan NEWA

AB

EQ 200MG BASE

A201504 005 Feb 12, 2013 Jan NEWA

AB

EQ 300MG BASE

A201504 006 Feb 12, 2013 Jan NEWA

AB

EQ 400MG BASE

A201504 007 Feb 12, 2013 Jan NEWA

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

@ APOTEX INC

EQ 5MG BASE

A076240 001 Jan 26, 2006 Mar DISC

@

EQ 10MG BASE

A076240 002 Jan 26, 2006 Mar DISC

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

	@ APOTEX INC	EQ 20MG BASE	A076240 003	Jan 26, 2006	Mar	DISC
	@	EQ 40MG BASE	A076240 004	Jan 26, 2006	Mar	DISC
AB	AUROBINDO PHARMA LTD	EQ 5MG BASE	A202725 001	Apr 29, 2013	Apr	NEWA
AB		EQ 10MG BASE	A202725 002	Apr 29, 2013	Apr	NEWA
AB		EQ 20MG BASE	A202725 003	Apr 29, 2013	Apr	NEWA
AB		EQ 40MG BASE	A202725 004	Apr 29, 2013	Apr	NEWA

RABEPRAZOLE SODIUM

CAPSULE, DELAYED RELEASE; ORAL

ACIPHEX SPRINKLE

	EISAI INC	5MG	N204736 001	Mar 26, 2013	Mar	NEWA
+		10MG	N204736 002	Mar 26, 2013	Mar	NEWA

RADIUM RA-223 DICHLORIDE

SOLUTION; INTRAVENOUS

XOFIGO

+	BAYER HLTHCARE	162MCI/6ML (27MCI/ML)	N203971 001	May 15, 2013	May	NEWA
---	----------------	-----------------------	-------------	--------------	-----	------

RANITIDINE HYDROCHLORIDE

GRANULE, EFFERVESCENT; ORAL

ZANTAC 150

>A>	@ GLAXO GRP LTD	EQ 150MG BASE/PACKET	N020251 002	Mar 31, 1994	Jun	CAHN
>D>	@ GLAXOSMITHKLINE	EQ 150MG BASE/PACKET	N020251 002	Mar 31, 1994	Jun	CAHN

INJECTABLE; INJECTION

RANITIDINE HYDROCHLORIDE

AP	ZYDUS PHARMS USA INC	25MG/ML	A091534 001	Feb 22, 2013	Feb	NEWA
>D>	ZANTAC IN PLASTIC CONTAINER					
>D>	+ COVIS PHARMA	EQ 1MG BASE/ML	N019593 002	Sep 27, 1991	Jun	DISC
>A>	@ COVIS PHARMA SARL	EQ 1MG BASE/ML	N019593 002	Sep 27, 1991	Jun	DISC

SYRUP; ORAL

RANITIDINE HYDROCHLORIDE

		@ APOTEX INC	EQ 15MG BASE/ML	A077602 001	Sep 17, 2007	Apr	DISC
	AA	BIO PHARM INC	EQ 15MG BASE/ML	A090102 001	May 26, 2009	Apr	CAHN
	AA	CARACO	EQ 15MG BASE/ML	A091091 001	Sep 20, 2011	Apr	CAHN
		ZANTAC					
>A>	AA	+ GLAXO GRP LTD	EQ 15MG BASE/ML	N019675 001	Dec 30, 1988	Jun	CAHN
>D>	AA	+ GLAXOSMITHKLINE	EQ 15MG BASE/ML	N019675 001	Dec 30, 1988	Jun	CAHN

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

		@ WATSON LABS	EQ 150MG BASE	A074864 001	Oct 20, 1997	Jan	DISC
		@	EQ 300MG BASE	A074864 002	Oct 20, 1997	Jan	DISC
		@ WATSON LABS INC	EQ 150MG BASE	A077426 001	Dec 19, 2005	Mar	DISC
		@	EQ 300MG BASE	A077426 002	Dec 19, 2005	Mar	DISC
		ZANTAC 150					
>A>	AB	GLAXO GRP LTD	EQ 150MG BASE	N018703 001	Jun 09, 1983	Jun	CAHN
>D>	AB	GLAXOSMITHKLINE	EQ 150MG BASE	N018703 001	Jun 09, 1983	Jun	CAHN
		ZANTAC 300					
>A>	AB	+ GLAXO GRP LTD	EQ 300MG BASE	N018703 002	Dec 09, 1985	Jun	CAHN
>D>	AB	+ GLAXOSMITHKLINE	EQ 300MG BASE	N018703 002	Dec 09, 1985	Jun	CAHN

TABLET, EFFERVESCENT; ORAL

ZANTAC 150

>A>	@ GLAXO GRP LTD	EQ 150MG BASE	N020251 001	Mar 31, 1994	Jun	CAHN
>D>	@ GLAXOSMITHKLINE	EQ 150MG BASE	N020251 001	Mar 31, 1994	Jun	CAHN

TABLET, EFFERVESCENT; ORAL

ZANTAC 25

>A>	+	GLAXO GRP LTD	EQ 25MG BASE	N020251 003	Apr 01, 2004	Jun	CAHN
>D>	+	GLAXOSMITHKLINE	EQ 25MG BASE	N020251 003	Apr 01, 2004	Jun	CAHN

RASAGILINE MESYLATE

TABLET; ORAL

AZILECT

>D>		TEVA	EQ 0.5MG BASE	N021641 001	May 16, 2006	Jun	CFTG
>A>	AB		EQ 0.5MG BASE	N021641 001	May 16, 2006	Jun	CFTG
>D>	+		EQ 1MG BASE	N021641 002	May 16, 2006	Jun	CFTG
>A>	AB	+	EQ 1MG BASE	N021641 002	May 16, 2006	Jun	CFTG
>A>		RASAGILINE MESYLATE					
>A>	AB	WATSON LABS INC	EQ 0.5MG BASE	A201823 001	Jul 01, 2013	Jun	NEWA
>A>	AB		EQ 1MG BASE	A201823 002	Jul 01, 2013	Jun	NEWA

RESERPINE

TABLET; ORAL

SERPALAN

@ LANNETT

@

0.1MG

0.25MG

N010124 001	May	DISC
N010124 002	May	DISC

RILUZOLE

TABLET; ORAL

RILUTEK

AB	+	COVIS PHARMA SARL	50MG	N020599 001	Dec 12, 1995	Apr	CAHN
----	---	-------------------	------	-------------	--------------	-----	------

RILUZOLE

>A>	AB	APOTEX CORP	50MG	A091300 001	Jun 18, 2013	Jun	NEWA
>A>	AB	GLENMARK GENERICS	50MG	A091394 001	Jun 18, 2013	Jun	NEWA
>A>	AB	MYLAN PHARMS INC	50MG	A203042 001	Jul 01, 2013	Jun	NEWA
>A>	AB	SUN PHARM INDS LTD	50MG	A091417 001	Jun 18, 2013	Jun	NEWA

RIMANTADINE HYDROCHLORIDE

TABLET; ORAL

RIMANTADINE HYDROCHLORIDE

@ COREPHARMA

100MG

A075916 001	Nov 02, 2001	Feb	DISC
-------------	--------------	-----	------

RISPERIDONE

SOLUTION; ORAL

RISPERIDONE

AA		BIO PHARM INC	1MG/ML	A078909 001	Jul 29, 2009	May	CAHN
----	--	---------------	--------	-------------	--------------	-----	------

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERIDONE

AB		MYLAN PHARMS INC	0.25MG	A091537 006	Feb 12, 2013	Feb	NEWA
AB		PAR PHARM	0.25MG	A077494 001	Apr 30, 2009	Feb	CTEC
AB		SUN PHARM INDS LTD	0.5MG	A078464 001	Apr 08, 2013	Mar	NEWA
AB			1MG	A078464 002	Apr 08, 2013	Mar	NEWA
AB			2MG	A078464 003	Apr 08, 2013	Mar	NEWA
AB			3MG	A078464 004	Apr 08, 2013	Mar	NEWA
AB			4MG	A078464 005	Apr 08, 2013	Mar	NEWA

RIVASTIGMINE TARTRATE

CAPSULE; ORAL

RIVASTIGMINE TARTRATE

AB		APOTEX INC	EQ 1.5MG BASE	A091072 001	May 16, 2013	Apr	NEWA
----	--	------------	---------------	-------------	--------------	-----	------

CAPSULE; ORAL

RIVASTIGMINE TARTRATE

AB	APOTEX INC	EQ 3MG BASE	A091072	002	May 16, 2013	Apr	NEWA
AB		EQ 4.5MG BASE	A091072	003	May 16, 2013	Apr	NEWA
AB		EQ 6MG BASE	A091072	004	May 16, 2013	Apr	NEWA

RIZATRIPTAN BENZOATE

TABLET; ORAL

RIZATRIPTAN BENZOATE

	AB	CIPLA LTD	EQ 5MG BASE	A077526	001	Mar 26, 2013	Mar	NEWA
	AB		EQ 10MG BASE	A077526	002	Mar 26, 2013	Mar	NEWA
>A>	AB	INVAGEN PHARMS	EQ 5MG BASE	A204339	001	Jul 01, 2013	Jun	NEWA
>A>	AB		EQ 10MG BASE	A204339	002	Jul 01, 2013	Jun	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

RIZATRIPTAN BENZOATE

>A>	AB	APOTEX INC	EQ 5MG BASE	A202477	001	Jul 01, 2013	Jun	NEWA
>A>	AB		EQ 10MG BASE	A202477	002	Jul 01, 2013	Jun	NEWA
>A>	AB	AUROBINDO PHARMA LTD	EQ 5MG BASE	A203062	001	Jul 01, 2013	Jun	NEWA
>A>	AB		EQ 10MG BASE	A203062	002	Jul 01, 2013	Jun	NEWA
>A>	AB	GLENMARK GENERICS	EQ 5MG BASE	A201914	001	Jul 01, 2013	Jun	NEWA
>A>	AB		EQ 10MG BASE	A201914	002	Jul 01, 2013	Jun	NEWA
>A>	AB	NATCO PHARMA LTD	EQ 5MG BASE	A203478	001	Jul 01, 2013	Jun	NEWA
>A>	AB		EQ 10MG BASE	A203478	002	Jul 01, 2013	Jun	NEWA
>A>	AB	SANDOZ	EQ 5MG BASE	A078739	001	Jul 01, 2013	Jun	NEWA
>A>	AB		EQ 10MG BASE	A078739	002	Jul 01, 2013	Jun	NEWA

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ZEMURON

	@	ORGANON USA INC	10MG/ML (10MG/ML)	N020214	002	Mar 17, 1994	Jan	CAHN
AP	+		50MG/5ML (10MG/ML)	N020214	001	Mar 17, 1994	Jan	CAHN
AP	+		100MG/10ML (10MG/ML)	N020214	003	Mar 17, 1994	Jan	CAHN

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

REQUIP

AB	+	GLAXOSMITHKLINE LLC	EQ 0.25MG BASE	N020658	001	Sep 19, 1997	Mar	CAHN
AB			EQ 0.5MG BASE	N020658	002	Sep 19, 1997	Mar	CAHN
AB			EQ 1MG BASE	N020658	003	Sep 19, 1997	Mar	CAHN
AB			EQ 2MG BASE	N020658	004	Sep 19, 1997	Mar	CAHN
AB			EQ 3MG BASE	N020658	006	Jan 27, 1999	Mar	CAHN
AB			EQ 4MG BASE	N020658	007	Jan 27, 1999	Mar	CAHN
AB			EQ 5MG BASE	N020658	005	Sep 19, 1997	Mar	CAHN

TABLET, EXTENDED RELEASE; ORAL

REQUIP XL

AB	+	GLAXOSMITHKLINE LLC	EQ 2MG BASE	N022008	001	Jun 13, 2008	Mar	CAHN
	@		EQ 3MG BASE	N022008	002	Jun 13, 2008	Mar	CAHN
AB			EQ 4MG BASE	N022008	003	Jun 13, 2008	Mar	CAHN
AB			EQ 6MG BASE	N022008	006	Apr 10, 2009	Mar	CAHN
AB			EQ 8MG BASE	N022008	004	Jun 13, 2008	Mar	CAHN
AB			EQ 12MG BASE	N022008	005	Oct 31, 2008	Mar	CAHN

ROPINIROLE HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	EQ 2MG BASE	A090869	001	May 17, 2012	Apr	CAHN
AB			EQ 4MG BASE	A090869	002	May 17, 2012	Apr	CAHN
AB			EQ 6MG BASE	A090869	003	May 17, 2012	Apr	CAHN
AB			EQ 8MG BASE	A090869	004	May 17, 2012	Apr	CAHN

TABLET, EXTENDED RELEASE; ORAL

ROPINIROLE HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	EQ 12MG BASE	A090869 005	May 17, 2012	Apr	CAHN
AB	ALEMBIC LTD	EQ 2MG BASE	A202786 001	Apr 22, 2013	Apr	NEWA
AB		EQ 4MG BASE	A202786 002	Apr 22, 2013	Apr	NEWA
AB		EQ 6MG BASE	A202786 003	Apr 22, 2013	Apr	NEWA
AB		EQ 8MG BASE	A202786 004	Apr 22, 2013	Apr	NEWA
AB		EQ 12MG BASE	A202786 005	Apr 22, 2013	Apr	NEWA

ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDIA

AB	SB PHARMCO	EQ 2MG BASE	N021071 002	May 25, 1999	Jan	CFTG
AB		EQ 4MG BASE	N021071 003	May 25, 1999	Jan	CFTG
AB	+	EQ 8MG BASE	N021071 004	May 25, 1999	Jan	CFTG

ROSIGLITAZONE MALEATE

AB	TEVA	EQ 2MG BASE	A076747 001	Jan 25, 2013	Jan	NEWA
AB		EQ 4MG BASE	A076747 002	Jan 25, 2013	Jan	NEWA
AB		EQ 8MG BASE	A076747 003	Jan 25, 2013	Jan	NEWA

ROTIGOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

NEUPRO

+	UCB INC	2MG/24HR	N021829 001	May 09, 2007	May	CRLD
		8MG/24HR	N021829 006	Apr 02, 2012	May	CRLD

SAQUINAVIR MESYLATE

TABLET; ORAL

INVIRASE

+	HOFFMAN LA ROCHE	EQ 500MG BASE	N021785 001	Dec 17, 2004	Feb	CAHN
---	------------------	---------------	-------------	--------------	-----	------

SELEGILINE HYDROCHLORIDE

TABLET; ORAL

SELEGILINE HYDROCHLORIDE

@	DAVA PHARMS INC	5MG	A074641 001	Aug 02, 1996	Jan	DISC
---	-----------------	-----	-------------	--------------	-----	------

SERTACONAZOLE NITRATE

CREAM; TOPICAL

ERTACZO

>D>	+	VALEANT INTL	2%	N021385 001	Dec 10, 2003	Jun	CAHN
>A>	+	VALEANT LUXEMBOURG	2%	N021385 001	Dec 10, 2003	Jun	CAHN

SERTRALINE HYDROCHLORIDE

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

@	DR REDDYS LABS LTD	EQ 25MG BASE	A076442 001	Apr 30, 2007	Apr	DISC
@		EQ 50MG BASE	A076442 002	Apr 30, 2007	Apr	DISC
@		EQ 100MG BASE	A076442 003	Apr 30, 2007	Apr	DISC

SILDENAFIL CITRATE

TABLET; ORAL

SILDENAFIL CITRATE

AB	ACTAVIS GRP PTC	EQ 20MG BASE	A200149 001	Feb 25, 2013	Apr	CAHN
AB	ACTAVIS PHARMA	EQ 20MG BASE	A200149 001	Feb 25, 2013	Feb	NEWA
AB	AMNEAL PHARMS	EQ 20MG BASE	A202025 001	Feb 28, 2013	Feb	NEWA

SODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.9%

MEDEFIL INC

18MG/2ML (9MG/ML)

N202832 002 Jan 06, 2012 Mar NEWA

22.5MG/2.5ML (9MG/ML)

N202832 003 Jan 06, 2012 Mar NEWA

27MG/3ML (9MG/ML)

N202832 004 Jan 06, 2012 Mar NEWA

45MG/5ML (9MG/ML)

N202832 005 Jan 06, 2012 Mar NEWA

90MG/10ML (9MG/ML)

N202832 006 Jan 06, 2012 Mar NEWA

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

MEDEFIL INC

9MG/ML (9MG/ML)

N202832 001 Jan 06, 2012 Mar CPOT

SOLUTION; IRRIGATION

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

@ BAXTER HLTHCARE

450MG/100ML

N017864 001 Jan DISC

SODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS

SODIUM FLUORIDE F-18

>A>

+ MCPRF

10-91.5MCI/ML

A203605 001 Jun 28, 2013 Jun NEWA

SODIUM PHENYLBUTYRATE

POWDER; ORAL

BUPHENYL

AB

+ MEDICIS

3GM/TEASPOONFUL

N020573 001 Apr 30, 1996 Mar CFTG

SODIUM PHENYLBUTYRATE

AB

SIGMAPHARM LABS LLC

3GM/TEASPOONFUL

A202819 001 Mar 22, 2013 Mar NEWA

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE; INJECTION

SODIUM PHOSPHATES IN PLASTIC CONTAINER

>D>

HOSPIRA

142MG/ML;276MG/ML

N018892 001 May 10, 1983 Jun CRLD

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION

SODIUM PHOSPHATES IN PLASTIC CONTAINER

>A>

+ HOSPIRA

142MG/ML;276MG/ML

N018892 001 May 10, 1983 Jun CRLD

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

KAYEXALATE

AA

+ COVIS PHARMA SARL

453.6GM/BOT

N011287 001 Apr CAHN

SUSPENSION; ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

@ ROXANE

15GM/60ML

A089049 001 Nov 17, 1986 Mar DISC

STAVUDINE

CAPSULE; ORAL

STAVUDINE

AB

HETERO LABS LTD III

15MG

A078957 001 Dec 29, 2008 Apr CAHN

AB

20MG

A078957 002 Dec 29, 2008 Apr CAHN

AB

30MG

A078957 003 Dec 29, 2008 Apr CAHN

AB

40MG

A078957 004 Dec 29, 2008 Apr CAHN

STREPTOZOCIN

INJECTABLE; INJECTION
ZANOSAR

+ TEVA PHARMS USA 1GM/VIAL N050577 001 May 07, 1982 Apr CAHN

SUCCIMER

CAPSULE; ORAL
CHEMET

+ RECORDATI RARE 100MG N019998 002 Jan 30, 1991 May CAHN

SULFACETAMIDE SODIUM

LOTION; TOPICAL
KLARON

AB + VALEANT BERMUDA 10% N019931 001 Dec 23, 1996 Feb CAHN

OINTMENT; OPHTHALMIC
SULFACETAMIDE SODIUM

>D> AT FERA PHARMS 10% A080029 001 Jun CAHN

>A> AT PERRIGO CO TENNESSEE 10% A080029 001 Jun CAHN

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION
SULFAMETHOXAZOLE AND TRIMETHOPRIM

+ TEVA PHARMS USA 80MG/ML;16MG/ML A073303 001 Oct 31, 1991 Mar CAHN

TABLET; ORAL

SULFAMETHOPRIM

@ NOVEL LABS INC 400MG;80MG A070022 001 Feb 15, 1985 Mar DISC

SULFAMETHOPRIM-DS

@ NOVEL LABS INC 800MG;160MG A070032 001 Feb 15, 1985 Mar DISC

SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH

>D> AB SANDOZ 800MG;160MG N018598 004 May 19, 1982 Jun DISC

>A> @ 800MG;160MG N018598 004 May 19, 1982 Jun DISC

SULINDAC

TABLET; ORAL
SULINDAC

AB HERITAGE PHARMS INC 150MG A073262 002 Sep 06, 1991 Apr CMFD

AB 200MG A073262 001 Sep 06, 1991 Apr CMFD

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS
SUMATRIPTAN SUCCINATE

AP AUROBINDO PHARMA LTD EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A202758 001 Apr 23, 2013 Apr NEWA

AP SAGENT AGILA EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A090641 001 Jul 28, 2010 Feb CAHN

AP TEVA PHARMS USA EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A077907 001 Feb 06, 2009 Mar CAHN

SYSTEM; IONTOPHORESIS
ZECUITY

+ NUPATHE EQ 6.5MG BASE/4HR N202278 001 Jan 17, 2013 Jan NEWA

TABLET; ORAL

SUMATRIPTAN SUCCINATE

AB HIKMA PHARMS EQ 25MG BASE A078298 001 May 21, 2013 May NEWA

AB EQ 50MG BASE A078298 002 May 21, 2013 May NEWA

AB EQ 100MG BASE A078298 003 May 21, 2013 May NEWA

TACROLIMUS

OINTMENT; TOPICAL

PROTOPIC

>D>	ASTELLAS	0.03%	N050777 001	Dec 08, 2000	Jun	CRLD
>A>	+	0.03%	N050777 001	Dec 08, 2000	Jun	CRLD

TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL

TAMSULOSIN HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	0.4MG	A202433 001	Apr 30, 2013	Apr	NEWA
----	----------------------	-------	-------------	--------------	-----	------

TECHNETIUM TC-99M TILMANOCEPT

INJECTABLE; INJECTION

LYMPHOSEEK KIT

+	NAVIDEA BIOPHARMS	N/A	N202207 001	Mar 13, 2013	Mar	NEWA
---	-------------------	-----	-------------	--------------	-----	------

TENIPOSIDE

INJECTABLE; INJECTION

VUMON

+	CORDEN PHARMA	10MG/ML	N020119 001	Jul 14, 1992	Apr	CAHN
---	---------------	---------	-------------	--------------	-----	------

TERBUTALINE SULFATE

INJECTABLE; INJECTION

TERBUTALINE SULFATE

@	TEVA PHARMS USA	1MG/ML	A076853 001	Jul 20, 2004	Mar	CAHN
---	-----------------	--------	-------------	--------------	-----	------

TESTOSTERONE

GEL; TRANSDERMAL

TESTOSTERONE

	PERRIGO ISRAEL	25MG/2.5GM PACKET	N203098 002	Jan 31, 2013	Jan	NEWA
		50MG/5GM PACKET	N203098 003	Jan 31, 2013	Jan	NEWA

GEL, METERED; TRANSDERMAL

TESTOSTERONE

	PERRIGO ISRAEL	12.5MG/1.25GM ACTUATION	N203098 001	Jan 31, 2013	Jan	NEWA
--	----------------	-------------------------	-------------	--------------	-----	------

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION

TESTOSTERONE CYPIONATE

AO	SUN PHARM INDS LTD	100MG/ML	A201720 001	Jun 03, 2013	May	NEWA
AO		200MG/ML	A201720 002	Jun 03, 2013	May	NEWA

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

DELATESTRYL

AO	+	ENDO PHARMS	200MG/ML	N009165 003		Jan	CAHN
	@		200MG/ML	N009165 001		Jan	CAHN

THEOPHYLLINE

TABLET, EXTENDED RELEASE; ORAL

THEOPHYLLINE

AB	+	TEVA PHARMS	450MG	A081236 001	Nov 09, 1992	Mar	CAHN
----	---	-------------	-------	-------------	--------------	-----	------

THIABENDAZOLE

SUSPENSION; ORAL

MINTEZOL

@ MERCK SHARP DOHME 500MG/5ML

N016097 001

May CAHN

TABLET, CHEWABLE; ORAL

MINTEZOL

@ MERCK SHARP DOHME 500MG

N016096 001

May CAHN

THIOGUANINE

TABLET; ORAL

THIOGUANINE

+ ASPEN GLOBAL INC 40MG

N012429 001

Mar CAHN

>D> TILUDRONATE DISODIUM

>D> TABLET; ORAL

>D> SKELID

>D> + SANOFI AVENTIS US EQ 200MG BASE

N020707 001 Mar 07, 1997 Jun DISC

>A> @ EQ 200MG BASE

N020707 001 Mar 07, 1997 Jun DISC

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

ISTALOL

BT + BAUSCH AND LOMB EQ 0.5% BASE

N021516 001 Jun 04, 2004 May CAHN

TIMOLOL MALEATE

>D> AT AKORN EQ 0.25% BASE

A074515 001 Mar 25, 1997 Jun DISC

>A> @ EQ 0.25% BASE

A074515 001 Mar 25, 1997 Jun DISC

@ APOTEX INC EQ 0.25% BASE

A075411 001 Sep 08, 2000 Apr DISC

@ EQ 0.5% BASE

A075412 001 Sep 08, 2000 Apr DISC

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC

TIMOPTIC-XE

AB + VALEANT PHARMS LLC EQ 0.25% BASE

N020330 001 Nov 04, 1993 Jan CAHN

AB + EQ 0.5% BASE

N020330 002 Nov 04, 1993 Jan CAHN

TIZANIDINE HYDROCHLORIDE

CAPSULE; ORAL

TIZANIDINE HYDROCHLORIDE

AB MYLAN PHARMS INC EQ 2MG BASE

A091502 001 Nov 09, 2012 May CAHN

AB EQ 4MG BASE

A091502 002 Nov 09, 2012 May CAHN

AB EQ 6MG BASE

A091502 003 Nov 09, 2012 May CAHN

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

@ MYLAN PHARMS INC EQ 2MG BASE

A076282 001 Dec 16, 2003 Feb DISC

@ EQ 4MG BASE

A076282 002 Dec 16, 2003 Feb DISC

TOBRAMYCIN

POWDER; INHALATION

TOBI PODHALER

+ NOVARTIS 28MG

N201688 001 Mar 22, 2013 Mar NEWA

SOLUTION/DROPS; OPHTHALMIC

TOBRAMYCIN

@ APOTEX INC 0.3%

A065087 001 Feb 25, 2002 Apr DISC

TOLAZAMIDE

TABLET; ORAL

TOLAZAMIDE

MYLAN PHARMS INC	250MG	A070259 001	Jan 02, 1986	Mar	CTEC
+	500MG	A070259 003	Mar 17, 1986	Mar	CTEC
@ WATSON LABS	250MG	A070514 001	Jan 09, 1986	Mar	DISC
@	500MG	A070515 001	Jan 09, 1986	Mar	DISC

TOPIRAMATE

TABLET; ORAL

TOPAMAX

AB	JANSSEN PHARMS	25MG	N020505 004	Dec 24, 1996	Apr	CRLD
AB	+	100MG	N020505 001	Dec 24, 1996	Apr	CRLD

TOPIRAMATE

AB	ACTIVIS TOTOWA LLC	25MG	A078637 001	Feb 27, 2013	Feb	NEWA
AB		50MG	A078637 002	Feb 27, 2013	Feb	NEWA
AB		100MG	A078637 003	Feb 27, 2013	Feb	NEWA
AB		200MG	A078637 004	Feb 27, 2013	Feb	NEWA
AB	UNICHEM LABS LTD	200MG	A090162 004	Feb 19, 2013	Feb	NEWA
>D>	AB	UPSHER SMITH	A078499 001	Jan 07, 2010	Jun	DISC
>A>	@	25MG	A078499 001	Jan 07, 2010	Jun	DISC
>D>	AB	50MG	A078499 002	Jan 07, 2010	Jun	DISC
>A>	@	50MG	A078499 002	Jan 07, 2010	Jun	DISC
>D>	AB	100MG	A078499 003	Jan 07, 2010	Jun	DISC
>A>	@	100MG	A078499 003	Jan 07, 2010	Jun	DISC
>D>	AB	200MG	A078499 004	Jan 07, 2010	Jun	DISC
>A>	@	200MG	A078499 004	Jan 07, 2010	Jun	DISC

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

TOPOTECAN HYDROCHLORIDE

>A>	AP	ACCORD HLTHCARE	EQ 4MG BASE/VIAL	A202351 001	Jun 26, 2013	Jun	NEWA
-----	----	-----------------	------------------	-------------	--------------	-----	------

TOREMIFENE CITRATE

TABLET; ORAL

FARESTON

+	PROSTRAKAN INC	EQ 60MG BASE	N020497 001	May 29, 1997	May	CAHN
---	----------------	--------------	-------------	--------------	-----	------

TORSEMIDE

TABLET; ORAL

TORSEMIDE

AB	HETERO LABS LTD III	5MG	A079234 001	Jan 27, 2009	Apr	CAHN
AB		10MG	A079234 002	Jan 27, 2009	Apr	CAHN
AB		20MG	A079234 003	Jan 27, 2009	Apr	CAHN
AB		100MG	A079234 004	Jan 27, 2009	Apr	CAHN

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

AB	ACCORD HLTHCARE INC	50MG	A202390 001	May 16, 2013	Apr	NEWA
AB	CSPC OUYI PHARM CO	50MG	A091498 001	Mar 29, 2013	Mar	NEWA

TABLET, EXTENDED RELEASE; ORAL

RYZOLT

@	PURDUE PHARMA	100MG	N021745 001	Dec 30, 2008	Jan	DISC
---	---------------	-------	-------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

RYZOLT

@ PURDUE PHARMA

200MG

N021745 002 Dec 30, 2008 Jan DISC

@

300MG

N021745 003 Dec 30, 2008 Jan DISC

TRAMADOL HYDROCHLORIDE

AB2 ACTAVIS ELIZABETH

100MG

A091609 001 Jun 27, 2012 Apr CAHN

AB2

200MG

A091609 002 Jun 27, 2012 Apr CAHN

AB2

300MG

A091609 003 Jun 27, 2012 Apr CAHN

AB1 PAR PHARM INC

100MG

A078783 001 Nov 13, 2009 Feb CRLD

AB2 + SUN PHARMA GLOBAL

100MG

A091607 001 Dec 30, 2011 Feb CRLD

TRAMETINIB DIMETHYL SULFOXIDE

TABLET; ORAL

MEKINIST

GLAXOSMITHKLINE LLC

EQ 0.5MG NON-SOLVATED PARENT

N204114 001 May 29, 2013 May NEWA

EQ 1MG NON-SOLVATED PARENT

N204114 002 May 29, 2013 May NEWA

+

EQ 2MG NON-SOLVATED PARENT

N204114 003 May 29, 2013 May NEWA

TRANDOLAPRIL

TABLET; ORAL

TRANDOLAPRIL

@ DR REDDYS LABS LTD

1MG

A078493 001 Aug 25, 2008 Apr DISC

@

2MG

A078493 002 Aug 25, 2008 Apr DISC

@

4MG

A078493 003 Aug 25, 2008 Apr DISC

TRANEXAMIC ACID

INJECTABLE; INJECTION

TRANEXAMIC ACID

>A> AP

CUSTOPHARM INC

100MG/ML

A201580 001 Jun 14, 2013 Jun NEWA

TRAVOPROST

SOLUTION/DROPS; OPHTHALMIC

TRAVOPROST

PAR PHARM

0.004%

A091340 001 Mar 01, 2013 Feb NEWA

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HYDROCHLORIDE

AB TEVA PHARMS USA

50MG

A071523 001 Dec 11, 1987 Mar CAHN

AB

100MG

A071524 001 Dec 11, 1987 Mar CAHN

TABLET, EXTENDED RELEASE; ORAL

OLEPTRO

>D>

@ ANGELINI LLC

150MG

N022411 001 Feb 02, 2010 Jun CMFD

@

150MG

N022411 001 Feb 02, 2010 May DISC

>D>

@

300MG

N022411 002 Feb 02, 2010 Jun CMFD

@

300MG

N022411 002 Feb 02, 2010 May DISC

>A>

+ ANGELINI PHARMA

150MG

N022411 001 Feb 02, 2010 Jun CMFD

>A>

300MG

N022411 002 Feb 02, 2010 Jun CMFD

TREPROSTINIL

INJECTABLE; IV (INFUSION)-SC

REMODULIN

UNITED THERAP

1MG/ML

N021272 001 May 21, 2002 May CAIN

2.5MG/ML

N021272 002 May 21, 2002 May CAIN

5MG/ML

N021272 003 May 21, 2002 May CAIN

INJECTABLE; IV (INFUSION)-SC									
REMODULIN									
>A>		+	UNITED THERAP	10MG/ML		N021272	004	May 21, 2002	Jun CAHN
SOLUTION; INHALATION									
TYVASO									
		+	UNITED THERAP	EQ 0.6MG BASE/ML		N022387	001	Jul 30, 2009	May CAHN
>D>	<u>TREPROSTINIL SODIUM</u>								
>D>	INJECTABLE; IV (INFUSION)-SC								
>D>	REMODULIN								
>D>		+	UNITED THERAP	10MG/ML		N021272	004	May 21, 2002	Jun CAHN
<u>TRETINOIN</u>									
CREAM; TOPICAL									
RETIN-A									
>A>	AB	+	VALEANT BERMUDA	0.025%		N019049	001	Sep 16, 1988	Jun CAHN
>A>	AB1	+		0.05%		N017522	001		Jun CAHN
>A>	AB	+		0.1%		N017340	001		Jun CAHN
>D>	AB	+	VALEANT INTL	0.025%		N019049	001	Sep 16, 1988	Jun CAHN
>D>	AB1	+		0.05%		N017522	001		Jun CAHN
>D>	AB	+		0.1%		N017340	001		Jun CAHN
GEL; TOPICAL									
ATRALIN									
		+	DOW PHARM	0.05%		N022070	001	Jul 26, 2007	Apr CAHN
<u>TRIAMCINOLONE ACETONIDE</u>									
CREAM; TOPICAL									
KENALOG									
			@ APOTHECON	0.025%		N011601	003		Apr DISC
			@	0.1%		N011601	006		Apr DISC
TRIACET									
			@ TEVA	0.025%		A084908	001		Apr DISC
			@	0.5%		A084908	003		Apr DISC
TRIAMCINOLONE ACETONIDE									
AT	+		FOUGERA PHARMS	0.025%		A085692	001		Apr CRLD
AT	+			0.1%		A085692	003		Apr CRLD
			@ G AND W LABS	0.025%		A089797	001	May 31, 1991	May DISC
			@ TARO	0.025%		A086277	001		Apr DISC
			@	0.1%		A086276	001		Apr DISC
			@	0.5%		A086275	001		Apr DISC
INJECTABLE; INTRA-ARTICULAR, INTRAMUSCULAR, INTRAVITREAL									
TRIVARIS									
			@ ALLERGAN	8MG/0.1ML (8MG/0.1ML)		N022220	001	Jun 16, 2008	May DISC
LOTION; TOPICAL									
TRIAMCINOLONE ACETONIDE									
AT			VERSAPHARM INC	0.025%		A202374	001	May 08, 2013	Apr NEWA
AT				0.1%		A202374	002	May 08, 2013	Apr NEWA
AT	+		WOCKHARDT EU OPERATN	0.025%		A088450	001	Apr 01, 1985	Apr CAHN
OINTMENT; TOPICAL									
KENALOG									
			@ APOTHECON	0.025%		N011600	003		Apr DISC
			@	0.1%		N011600	001		Apr DISC
TRIAMCINOLONE ACETONIDE									
			@ TARO	0.025%		A040040	001	Sep 30, 1994	May DISC
			@	0.025%		A040374	001	Jun 05, 2001	May DISC
			@	0.1%		A087902	001	Dec 27, 1982	May DISC

OINTMENT; TOPICAL

TRIAMCINOLONE ACETONIDE

@ TARO 0.5%

A040386 001 Jun 05, 2001 May DISC

TRIMETHOPRIM

TABLET; ORAL

TRIMETHOPRIM

>D> + TEVA 200MG

A071259 001 Jun 18, 1987 Jun DISC

>A> @ 200MG

A071259 001 Jun 18, 1987 Jun DISC

TROSPIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

TROSPIUM CHLORIDE

AB PADDOCK LLC 60MG

A201291 001 May 24, 2013 May NEWA

URSODIOL

TABLET; ORAL

URSODIOL

AB PAR PHARM 250MG

A202540 001 Feb 14, 2013 Feb NEWA

AB 500MG

A202540 002 Feb 14, 2013 Feb NEWA

@ TEVA PHARMS USA 250MG

A079184 001 May 13, 2009 Apr DISC

@ 500MG

A079184 002 May 13, 2009 Apr DISC

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

AB ACTAVIS GRP PTC EQ 500MG BASE

A090370 001 Mar 16, 2011 Mar CAHN

AB EQ 1GM BASE

A090370 002 Mar 16, 2011 Mar CAHN

VALPROIC ACID

CAPSULE; ORAL

VALPROIC ACID

AB SUN PHARM INDS LTD 250MG

A091037 001 Feb 22, 2013 Feb NEWA

>D> CAPSULE, DELAYED RELEASE; ORAL

>D> STAVZOR

>D> BANNER PHARMACAPS 125MG

N022152 001 Jul 29, 2008 Jun DISC

>A> @ 125MG

N022152 001 Jul 29, 2008 Jun DISC

>D> 250MG

N022152 002 Jul 29, 2008 Jun DISC

>A> @ 250MG

N022152 002 Jul 29, 2008 Jun DISC

>D> + 500MG

N022152 003 Jul 29, 2008 Jun DISC

>A> @ 500MG

N022152 003 Jul 29, 2008 Jun DISC

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

AP TEVA PHARMS USA 10MG/VIAL

A074688 001 Aug 25, 1999 Apr CAHN

AP 20MG/VIAL

A074688 002 Aug 25, 1999 Apr CAHN

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION

VERAPAMIL HYDROCHLORIDE

@ INTL MEDICATION 2.5MG/ML

A070451 001 Dec 16, 1985 Mar DISC

TABLET, EXTENDED RELEASE; ORAL

VERAPAMIL HYDROCHLORIDE

AB CARACO 120MG

A090529 001 Dec 30, 2011 May CAHN

TABLET, EXTENDED RELEASE; ORAL

VERAPAMIL HYDROCHLORIDE

AB	CARACO	180MG	A090529	002	Dec 30, 2011	May	CAHN
AB		240MG	A090529	003	Dec 30, 2011	May	CAHN

VERTEPORFIN

INJECTABLE; INJECTION

VISUDYNE

+	VALEANT PHARMS INC	15MG/VIAL	N021119	001	Apr 12, 2000	Jan	CAHN
---	--------------------	-----------	---------	-----	--------------	-----	------

VINCRIStINE SULFATE

INJECTABLE; INJECTION

VINCRIStINE SULFATE PFS

AP	TEVA PHARMS USA	1MG/ML	A075493	001	Sep 01, 1999	Apr	CAHN
----	-----------------	--------	---------	-----	--------------	-----	------

VINORELBINE TARTRATE

INJECTABLE; INJECTION

VINORELBINE TARTRATE

AP	TEVA PHARMS USA	EQ 10MG BASE/ML	A076028	001	Feb 03, 2003	Apr	CAHN
----	-----------------	-----------------	---------	-----	--------------	-----	------

VORICONAZOLE

FOR SUSPENSION; ORAL

VFEND

AB	+	PFIZER	200MG/5ML	N021630	001	Dec 19, 2003	May	CFTG
----	---	--------	-----------	---------	-----	--------------	-----	------

VORICONAZOLE

AB		MYLAN PHARMS INC	200MG/5ML	A202361	001	May 28, 2013	May	NEWA
----	--	------------------	-----------	---------	-----	--------------	-----	------

WARFARIN SODIUM

TABLET; ORAL

WARFARIN SODIUM

AB	AMNEAL PHARMS	1MG	A202202	001	Mar 04, 2013	Feb	NEWA	
AB		2MG	A202202	002	Mar 04, 2013	Feb	NEWA	
AB		2.5MG	A202202	003	Mar 04, 2013	Feb	NEWA	
AB		3MG	A202202	004	Mar 04, 2013	Feb	NEWA	
AB		4MG	A202202	005	Mar 04, 2013	Feb	NEWA	
AB		5MG	A202202	006	Mar 04, 2013	Feb	NEWA	
AB		6MG	A202202	007	Mar 04, 2013	Feb	NEWA	
AB		7.5MG	A202202	008	Mar 04, 2013	Feb	NEWA	
AB		10MG	A202202	009	Mar 04, 2013	Feb	NEWA	
>A>	AB	IPCA LABS LTD	1MG	A200104	001	Jun 27, 2013	Jun	NEWA
>A>	AB		2MG	A200104	002	Jun 27, 2013	Jun	NEWA
>A>	AB		2.5MG	A200104	003	Jun 27, 2013	Jun	NEWA
>A>	AB		3MG	A200104	004	Jun 27, 2013	Jun	NEWA
>A>	AB		4MG	A200104	005	Jun 27, 2013	Jun	NEWA
>A>	AB		5MG	A200104	006	Jun 27, 2013	Jun	NEWA
>A>	AB		6MG	A200104	007	Jun 27, 2013	Jun	NEWA
>A>	AB		7.5MG	A200104	008	Jun 27, 2013	Jun	NEWA
>A>	AB		10MG	A200104	009	Jun 27, 2013	Jun	NEWA

ZALEPLON

CAPSULE; ORAL

SONATA

AB	PFIZER	5MG	N020859	001	Aug 13, 1999	Apr	CAHN
AB	+	10MG	N020859	002	Aug 13, 1999	Apr	CAHN

ZIDOVUDINE

TABLET; ORAL

RETROVIR

@ VIIV HLTHCARE

300MG

N020518 002 Oct 04, 1996 Apr DISC

ZIDOVUDINE

AB HEC PHARM USA INC

300MG

A202058 001 Oct 07, 2011 Feb CMFD

@

300MG

A202058 001 Oct 07, 2011 Jan DISC

AB + HETERO LABS LTD III

300MG

A090092 001 Apr 25, 2008 Apr CRLD

ZOLEDRONIC ACID

INJECTABLE; INJECTION

ZOLEDRONIC ACID

AP DR REDDYS LABS LTD

EQ 5MG BASE/100ML

A091363 001 Mar 29, 2013 Mar NEWA

AP EMCURE PHARMS LTD

EQ 5MG BASE/100ML

A201801 001 Mar 29, 2013 Mar NEWA

INJECTABLE; IV (INFUSION)

RECLAST

AP + NOVARTIS

EQ 5MG BASE/100ML

N021817 001 Apr 16, 2007 Mar CTEC

ZOLEDRONIC ACID

AP ACTAVIS INC

EQ 4MG BASE/5ML

A202472 001 Mar 04, 2013 Feb NEWA

AP AGILA SPECLTS

EQ 4MG BASE/5ML

A202650 001 Mar 04, 2013 Feb NEWA

AP DR REDDYS LABS LTD

EQ 4MG BASE/5ML

A091186 001 Mar 04, 2013 Feb NEWA

AP EMCURE PHARMS LTD

EQ 4MG BASE/5ML

A201783 001 Mar 12, 2013 Mar NEWA

AP HIKMA FARMACEUTICA

EQ 4MG BASE/5ML

A202182 001 Jun 03, 2013 May NEWA

AP HOSPIRA INC

EQ 5MG BASE/100ML

A202837 001 Apr 05, 2013 Mar NEWA

AP PHARMACEUTICS

EQ 4MG BASE/5ML

A091170 001 Mar 04, 2013 Feb NEWA

AP PHARMS

EQ 4MG BASE/5ML

A202571 001 May 07, 2013 Apr NEWA

+ SUN PHARMA GLOBAL

EQ 4MG BASE/VIAL

A090018 001 Mar 04, 2013 Feb NEWA

AP

EQ 4MG BASE/5ML

A202746 001 Mar 04, 2013 Feb NEWA

ZOMETA

AP + NOVARTIS

EQ 4MG BASE/5ML

N021223 002 Mar 07, 2003 Feb CFTG

ZOLMITRIPTAN

TABLET; ORAL

ZOLMITRIPTAN

AB APOTEX INC

2.5MG

A202078 001 May 14, 2013 Apr NEWA

AB

5MG

A202078 002 May 14, 2013 Apr NEWA

AB GLENMARK GENERICS

2.5MG

A201779 001 May 14, 2013 Apr NEWA

AB

5MG

A201779 002 May 14, 2013 Apr NEWA

AB MYLAN PHARMS INC

2.5MG

A203186 001 May 14, 2013 Apr NEWA

AB

5MG

A203186 002 May 14, 2013 Apr NEWA

ZOMIG

AB IPR

2.5MG

N020768 001 Nov 25, 1997 Apr CFTG

AB +

5MG

N020768 002 Nov 25, 1997 Apr CFTG

TABLET, ORALLY DISINTEGRATING; ORAL

ZOLMITRIPTAN

AB APOTEX INC

2.5MG

A202476 001 May 14, 2013 Apr NEWA

AB

5MG

A202476 002 May 14, 2013 Apr NEWA

AB GLENMARK GENERICS

2.5MG

A202560 001 May 14, 2013 Apr NEWA

AB

5MG

A202560 002 May 14, 2013 Apr NEWA

AB ZYDUS PHARMS USA INC

2.5MG

A202890 001 May 15, 2013 Apr NEWA

AB

5MG

A202890 002 May 15, 2013 Apr NEWA

ZOMIG-ZMT

AB ASTRAZENECA

2.5MG

N021231 001 Feb 13, 2001 Apr CFTG

AB +

5MG

N021231 002 Sep 17, 2001 Apr CFTG

ZOLPIDEM TARTRATE

TABLET; ORAL

ZOLPIDEM TARTRATE

@ DR REDDYS LABS LTD 5MG

A077985 001 Apr 23, 2007 Apr DISC

@ 10MG

A077985 002 Apr 23, 2007 Apr DISC

TABLET, EXTENDED RELEASE; ORAL

ZOLPIDEM TARTRATE

AB ACTAVIS ELIZABETH 6.25MG

A078179 002 Oct 13, 2010 Apr CAHN

AB 12.5MG

A078179 001 Jun 06, 2011 Apr CAHN

AB WATSON LABS INC FL 6.25MG

A090153 001 Mar 25, 2013 Mar NEWA

AB 12.5MG

A090153 002 Mar 25, 2013 Mar NEWA

ZONISAMIDE

CAPSULE; ORAL

ZONISAMIDE

@ COREPHARMA 25MG

A077876 001 Feb 21, 2007 Feb DISC

@ 50MG

A077876 002 Feb 21, 2007 Feb DISC

@ 100MG

A077876 003 Feb 21, 2007 Feb DISC

@ DR REDDYS LABS LTD 25MG

A077645 002 Sep 29, 2006 Mar DISC

@ 50MG

A077645 003 Sep 29, 2006 Mar DISC

@ 100MG

A077645 001 Dec 22, 2005 Mar DISC

OTC DRUG PRODUCT LIST - 33RD EDITION

OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2013

2-1

ASPIRIN

CAPSULE; ORAL

ASPIRIN

+	PLX PHARMA	325MG	N203697	001	Jan 14, 2013	Jan	NEWA
---	------------	-------	---------	-----	--------------	-----	------

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

@	APOTEX INC	5MG/5ML	A090188	002	Apr 22, 2008	Apr	DISC
---	------------	---------	---------	-----	--------------	-----	------

	BIO PHARM INC	5MG/5ML	A090474	002	Mar 30, 2009	May	CAHN
--	---------------	---------	---------	-----	--------------	-----	------

	CARACO	5MG/5ML	A091327	001	Oct 17, 2011	May	CAHN
--	--------	---------	---------	-----	--------------	-----	------

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

@	APOTEX INC	5MG/5ML	A090188	001	Apr 22, 2008	Apr	DISC
---	------------	---------	---------	-----	--------------	-----	------

	BIO PHARM INC	5MG/5ML	A090474	001	Mar 30, 2009	May	CAHN
--	---------------	---------	---------	-----	--------------	-----	------

	CARACO	5MG/5ML	A091327	002	Oct 17, 2011	May	CAHN
--	--------	---------	---------	-----	--------------	-----	------

TABLET, CHEWABLE; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

+	SANDOZ	10MG	A078692	002	Feb 14, 2008	Apr	CRLD
---	--------	------	---------	-----	--------------	-----	------

CHILDREN'S ZYRTEC ALLERGY

@	MCNEIL CONS	5MG	N021621	003	Nov 16, 2007	Apr	DISC
---	-------------	-----	---------	-----	--------------	-----	------

+		5MG	N021621	003	Nov 16, 2007	Feb	CRLD
---	--	-----	---------	-----	--------------	-----	------

@		10MG	N021621	004	Nov 16, 2007	Feb	DISC
---	--	------	---------	-----	--------------	-----	------

CHILDREN'S ZYRTEC HIVES RELIEF

@	MCNEIL CONS	5MG	N021621	005	Nov 16, 2007	Apr	DISC
---	-------------	-----	---------	-----	--------------	-----	------

+		5MG	N021621	005	Nov 16, 2007	Feb	CRLD
---	--	-----	---------	-----	--------------	-----	------

@		10MG	N021621	006	Nov 16, 2007	Feb	DISC
---	--	------	---------	-----	--------------	-----	------

CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL

DYNA-HEX

	BAJAJ MEDICAL LLC	0.75%	N020111	001	Sep 11, 1997	Apr	CAHN
--	-------------------	-------	---------	-----	--------------	-----	------

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SWAB; TOPICAL

PREVANTICS MAXI SWABSTICK

+	PROF DSPLS	3.15%;70% (5.1ML)	N021524	003	Jun 03, 2005	Mar	CTNA
---	------------	-------------------	---------	-----	--------------	-----	------

PREVANTICS SWAB

+	PROF DSPLS	3.15%;70% (1ML)	N021524	001	Jun 03, 2005	Mar	CTNA
---	------------	-----------------	---------	-----	--------------	-----	------

PREVANTICS SWABSTICK

+	PROF DSPLS	3.15%;70% (1.6ML)	N021524	002	Jun 03, 2005	Mar	CTNA
---	------------	-------------------	---------	-----	--------------	-----	------

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE

	AVANTHI INC	6MG;120MG	A078648	001	Feb 27, 2013	Feb	NEWA
--	-------------	-----------	---------	-----	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE

TABLET, ORALLY DISINTEGRATING; ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

	DR REDDYS LABS LTD	30MG	A202978	001	Jan 18, 2013	Jan	NEWA
--	--------------------	------	---------	-----	--------------	-----	------

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

	DR REDDYS LABS LTD	30MG	A202978	002	Jan 18, 2013	Jan	NEWA
--	--------------------	------	---------	-----	--------------	-----	------

KETOTIFEN FUMARATE

SOLUTION/DROPS; OPHTHALMIC

KETOTIFEN FUMARATE

@ APOTEX INC

EQ 0.025% BASE

A077354 001 May 09, 2006 Apr DISC

LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL

LUPIN LTD

0.75MG

A091328 001 Jan 23, 2013 Jan NEWA

AB

NOVEL LABS INC

1.5MG

A202508 001 Feb 22, 2013 Feb NEWA

PLAN B ONE-STEP

+ TEVA BRANDED PHARM

1.5MG

N021998 001 Jul 10, 2009 Apr CAHN

LORATADINE

SYRUP; ORAL

LORATADINE

@ APOTEX INC

1MG/ML

A075565 001 Oct 05, 2004 Apr DISC

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

LORATADINE AND PSEUDOEPHEDRINE SULFATE

@ WATSON LABS INC FL 5MG;120MG

A076208 001 Jan 28, 2004 Feb DISC

MICONAZOLE NITRATE

CREAM; VAGINAL

MICONAZOLE NITRATE

APHENA PHARMA MD

2%

A074366 001 Feb 22, 1996 Jan CAHN

MINOXIDIL

SOLUTION; TOPICAL

MINOXIDIL (FOR MEN)

@ APOTEX INC

2%

A074924 001 Apr 29, 1998 Apr DISC

MINOXIDIL (FOR WOMEN)

@ APOTEX INC

2%

A074924 002 Apr 29, 1998 Apr DISC

MINOXIDIL EXTRA STRENGTH (FOR MEN)

@ APOTEX INC

5%

A075839 001 Oct 01, 2001 Apr DISC

NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

SOLUTION/DROPS; OPHTHALMIC

NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE

AKORN INC

0.025%;0.3%

A202795 001 Jan 24, 2013 Jan NEWA

OMEPRAZOLE; SODIUM BICARBONATE

>A>

FOR SUSPENSION; ORAL

>A>

ZEGERID OTC

>A>

+ MSD CONSUMER

20MG/PACKET;1.68GM/PACKET

N022283 001 Jun 17, 2013 Jun NEWA

OXYBUTYNIN

FILM, EXTENDED RELEASE; TRANSDERMAL

OXYTROL FOR WOMEN

+ MSD CONSUMER

3.9MG/24HR

N202211 001 Jan 25, 2013 Jan NEWA

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL

POLYETHYLENE GLYCOL 3350

PAR PHARM

17GM/SCOOPFUL

A079214 001 Jan 31, 2013 Jan NEWA

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

@ WATSON LABS

EQ 75MG BASE

A075212 001 Jan 14, 2000 Mar DISC

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 06 JUNE 2013

NO JUNE 2013 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO JUNE 2013 ADDITIONS

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST - 33RD EDITION

A - 1

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ACETYLCYSTEINE - ACETADOTE</u>						
N021539 001	8399445	Aug 24, 2025	U-1373			
<u>ACYCLOVIR - SITAVIG</u>						
N203791 001					NP	Apr 12, 2016
<u>ADAPALENE - DIFFERIN</u>						
N022502 001	8435502	Sep 15, 2026	DP U-1078			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N022320 001	>A> 8445543	Jul 12, 2027	U-1078		NPP	Feb 01, 2016
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N022271 001	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N022271 002	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N022271 003	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N203414 001	5965584	Jun 19, 2016	U-1339		NCE	Jan 25, 2018
	6150383	Jun 19, 2016	U-1330		NC	Jan 25, 2016
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N203414 002	5965584	Jun 19, 2016	U-1339		NCE	Jan 25, 2018
	6150383	Jun 19, 2016	U-1330		NC	Jan 25, 2016
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N022426 001	5965584	Jun 19, 2016	DP U-1339		NCE	Jan 25, 2018
	6150383	Jun 19, 2016	U-1330		NC	Jan 25, 2016
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N022426 002	5965584	Jun 19, 2016	DP U-1339		NCE	Jan 25, 2018
	6150383	Jun 19, 2016	U-1330		NC	Jan 25, 2016
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N022426 003	5965584	Jun 19, 2016	DP U-1339		NCE	Jan 25, 2018
	6150383	Jun 19, 2016	U-1330		NC	Jan 25, 2016
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N022426 004	5965584	Jun 19, 2016	DP U-1339		NCE	Jan 25, 2018
	6150383	Jun 19, 2016	U-1330		NC	Jan 25, 2016
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N022426 005	5965584	Jun 19, 2016	DP U-1339		NCE	Jan 25, 2018
	6150383	Jun 19, 2016	U-1330		NC	Jan 25, 2016
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N022426 006	5965584	Jun 19, 2016	DP U-1339		NCE	Jan 25, 2018
	6150383	Jun 19, 2016	U-1330		NC	Jan 25, 2016
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>AMBRISANTAN - LETAIRIS</u>						
N022081 001	8349843	Oct 07, 2015	DS DP			
<u>AMBRISANTAN - LETAIRIS</u>						
N022081 002	8349843	Oct 07, 2015	DS DP			
<u>AMOXICILLIN - MOXATAG</u>						
N050813 001	8357394	Dec 08, 2026	DP			
<u>APIXABAN - ELIQUIS</u>						
N202155 001	6413980	Dec 22, 2019	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1323			
	6967208	Feb 03, 2023	DS DP U-1200			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>APIXABAN - ELIQUIS</u>						
N202155 002	6413980	Dec 22, 2019	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1323			
	6967208	Feb 03, 2023	DS DP U-1200			
<u>ARFORMOTEROL TARTRATE - BROVANA</u>						
N021912 001	>A> 7348362	Jun 22, 2021	DP U-793			
	>A> 7462645	Jun 22, 2021	U-793			
	>A> 7465756	Jun 22, 2021	DP			
	>A> 7473710	Jun 22, 2021	U-793			
	>A> 7541385	Jun 22, 2021	U-793			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N202971 001	5006528	Apr 20, 2015	DS DP U-543		NDF	Feb 28, 2016
	7807680	Oct 19, 2024	DP			
	8030313	Oct 19, 2024	U-543			
	8338427	Mar 15, 2025	DP U-543			
	8338428	Aug 06, 2023	DP U-543			
	8399469	Dec 29, 2023	DS			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N202971 002	5006528	Apr 20, 2015	DS DP U-543		NDF	Feb 28, 2016
	7807680	Oct 19, 2024	DP			
	8030313	Oct 19, 2024	U-543			
	8338427	Mar 15, 2025	DP U-543			
	8338428	Aug 06, 2023	DP U-543			
	8399469	Dec 29, 2023	DS			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N022117 001	5763476	Jun 09, 2020	DP U-326			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N022117 002	5763476	Jun 09, 2020	DP U-326			
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N200153 001	5846966	Sep 21, 2013	DP U-1400		NC	May 03, 2016
	5846966*PED	Mar 21, 2014				
	RE42461	Oct 25, 2016	DS DP U-1400			
	RE42461*PED	Apr 25, 2017				
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N200153 002	5846966	Sep 21, 2013	DP U-1400		NC	May 03, 2016
	5846966*PED	Mar 21, 2014				
	RE42461	Oct 25, 2016	DS DP U-1400			
	RE42461*PED	Apr 25, 2017				
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N200153 003	5846966	Sep 21, 2013	DP U-1400		NC	May 03, 2016
	5846966*PED	Mar 21, 2014				
	RE42461	Oct 25, 2016	DS DP U-1400			
	RE42461*PED	Apr 25, 2017				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N200153 004	5846966	Sep 21, 2013	DP U-1400		NC	May 03, 2016
	5846966*PED	Mar 21, 2014				
	RE42461	Oct 25, 2016	DS DP U-1400			
	RE42461*PED	Apr 25, 2017				
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N202331 002					NCE NC	Feb 25, 2016 Dec 20, 2014
<u>AZTREONAM - CAYSTON</u>						
N050814 001	8399496	Dec 20, 2021	DP U-1377			
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N204384 001	7498343	Oct 02, 2024	DS DP U-1321		ODE	Dec 28, 2019
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N022249 001	8436190	Oct 26, 2030	DP			
	8436190*PED	Apr 26, 2031				
	8445524	Mar 26, 2029	DS DP U-1402			
	8445524*PED	Sep 26, 2029				
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N022249 002	8436190	Oct 26, 2030	DP			
	8436190*PED	Apr 26, 2031				
	8445524	Mar 26, 2029	DS DP U-1402			
	8445524*PED	Sep 26, 2029				
<u>BEPOTASTINE BESILATE - BEPREVE</u>						
N022288 001	>A> 6780877	Sep 19, 2019	DS DP			
<u>BESIFLOXACIN HYDROCHLORIDE - BESIVANCE</u>						
N022308 001	8415342	Nov 07, 2030	U-80			
<u>BOCEPREVIR - VICTRELIS</u>						
N202258 001					M-126 NPP	Feb 27, 2016 Feb 13, 2016
<u>BRIMONIDINE TARTRATE; BRINZOLAMIDE - SIMBRINZA</u>						
N204251 001					NC	Apr 19, 2016
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N021398 001	8354409	Apr 19, 2022	DP U-1371			
<u>BROMFENAC SODIUM - PROLENSA</u>						
N203168 001	8129431	Sep 11, 2025	DS DP		NP	Apr 05, 2016
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N020866 001	7888310	Jul 25, 2023	U-976			
	7888310	Jul 25, 2023	U-1379			
	8137992	Jul 25, 2023	U-1380			
	8137993	Jul 25, 2023	U-1379			
	8137994	Jul 25, 2023	U-1379			
	8431155	Apr 30, 2032	DP U-1379			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUDESONIDE - UCERIS</u>						
N203634 001	7410651	Jun 09, 2020	DP U-1325		NDF	Jan 14, 2016
	7431943	Jun 09, 2020	DP			
	8293273	Jun 09, 2020	DP			
	RE43799	Jun 09, 2020	DP U-1325			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N021929 001	8387615	Nov 10, 2024	DP			
	>A> 8461211	Sep 09, 2018	U-1118			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N021929 002	8387615	Nov 10, 2024	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N022410 001	>A> 8475832	Mar 02, 2030	DP U-1411			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N022410 002	>A> 8475832	Mar 02, 2030	DP U-1411			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N022410 003	>A> 8475832	Mar 02, 2030	DP U-1411			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N022410 004	>A> 8475832	Mar 02, 2030	DP U-1411			
<u>CABOZANTINIB S-MALATE - COMETRIQ</u>						
N203756 001					ODE	Nov 29, 2019
<u>CABOZANTINIB S-MALATE - COMETRIQ</u>						
N203756 002					ODE	Nov 29, 2019
<u>CALCITONIN SALMON RECOMBINANT - FORTICAL</u>						
N021406 001	RE43580	Feb 02, 2021	DP U-227			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N204042 001	7943582	Feb 26, 2029	DS DP U-493		NCE	Mar 29, 2018
	7943788	Jul 14, 2027	DS DP			
	8222219	Jul 30, 2024	U-493			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N204042 002	7943582	Feb 26, 2029	DS DP U-493		NCE	Mar 29, 2018
	7943788	Jul 14, 2027	DS DP			
	8222219	Jul 30, 2024	U-493			
<u>CANDESARTAN CILEXETIL - CANDESARTAN CILEXETIL</u>						
A078702 001					PC	Jul 09, 2013
<u>CANDESARTAN CILEXETIL - CANDESARTAN CILEXETIL</u>						
A078702 002					PC	Jul 09, 2013
<u>CANDESARTAN CILEXETIL - CANDESARTAN CILEXETIL</u>						
A078702 003					PC	Jul 09, 2013
<u>CANDESARTAN CILEXETIL - CANDESARTAN CILEXETIL</u>						
A078702 004					PC	Jul 09, 2013
<u>CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE - CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE</u>						
A090704 003					PC	Jun 02, 2013
<u>CARBINOXAMINE MALEATE - KARBINAL ER</u>						
N022556 001	8062667	Mar 29, 2029	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CELECOXIB - CELEBREX</u>						
N020998 001	RE44048	Jun 02, 2015	U-247			
	RE44048	Jun 02, 2015	U-1352			
	RE44048	Jun 02, 2015	U-1351			
	RE44048	Jun 02, 2015	U-1350			
	RE44048	Jun 02, 2015	U-1349			
	RE44048	Jun 02, 2015	U-1348			
	RE44048*PED	Dec 02, 2015				
<u>CELECOXIB - CELEBREX</u>						
N020998 002	RE44048	Jun 02, 2015	U-247			
	RE44048	Jun 02, 2015	U-1352			
	RE44048	Jun 02, 2015	U-1351			
	RE44048	Jun 02, 2015	U-1350			
	RE44048	Jun 02, 2015	U-1349			
	RE44048	Jun 02, 2015	U-1348			
	RE44048*PED	Dec 02, 2015				
<u>CELECOXIB - CELEBREX</u>						
N020998 003	RE44048	Jun 02, 2015	U-247			
	RE44048	Jun 02, 2015	U-1352			
	RE44048	Jun 02, 2015	U-1351			
	RE44048	Jun 02, 2015	U-1350			
	RE44048	Jun 02, 2015	U-1349			
	RE44048	Jun 02, 2015	U-1348			
	RE44048*PED	Dec 02, 2015				
<u>CELECOXIB - CELEBREX</u>						
N020998 004	RE44048	Jun 02, 2015	U-247			
	RE44048	Jun 02, 2015	U-1352			
	RE44048	Jun 02, 2015	U-1351			
	RE44048	Jun 02, 2015	U-1350			
	RE44048	Jun 02, 2015	U-1349			
	RE44048	Jun 02, 2015	U-1348			
	RE44048*PED	Dec 02, 2015				
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N020832 002	7422388	Apr 25, 2027	DP U-1397			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N020832 005	7422388	Apr 25, 2027	DP U-1397			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N020832 007	7422388	Apr 25, 2027	DP U-1397			
<u>CICLESONIDE - ALVESCO</u>						
N021658 002	8371292	Aug 25, 2027	U-1355		M-125	Dec 17, 2015
<u>CICLESONIDE - ALVESCO</u>						
N021658 003	8371292	Aug 25, 2027	U-1355		M-125	Dec 17, 2015
<u>CICLESONIDE - OMNARIS</u>						
N022004 001	8371292	Aug 25, 2027	U-1356			
	8383611	Oct 20, 2020	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CICLESONIDE - ZETONNA</u>						
N202129 001	8371292	Aug 25, 2027	U-1357			
<u>CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE - CIPRO XR</u>						
N021473 001	>A> 8187632	Jun 23, 2021	DP			
<u>CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE - CIPRO XR</u>						
N021473 002	>A> 8187632	Jun 23, 2021	DP			
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - PREPOPIK</u>						
N202535 001	8450338	Oct 10, 2028	DP			
	>A> 8481083	Oct 10, 2028	DP			
<u>CLOBAZAM - ONFI</u>						
N203993 001					ODE	Oct 21, 2018
<u>CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE</u>						
A201402 001					PC	Jul 31, 2013
<u>CLOBETASOL PROPIONATE - OLUX E</u>						
N022013 001	>A> 8460641	Nov 05, 2028	DP U-1410			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N203100 001	5814639*PED	Mar 29, 2016				
	5914331*PED	Jan 02, 2018				
	5922695*PED	Jan 25, 2018				
	5935946*PED	Jan 25, 2018				
	5977089*PED	Jan 25, 2018				
	6043230*PED	Jan 25, 2018				
	6642245*PED	May 04, 2021				
	6703396*PED	Sep 09, 2021				
	7635704	Oct 26, 2026	DS DP U-257			
<u>COLCHICINE - COLCRYS</u>						
N022352 001	8415395	Oct 06, 2028	U-1007			
	8415396	Oct 06, 2028	U-1007			
	8440721	Feb 17, 2029	U-1007			
	8440722	Feb 17, 2029	U-1020			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N203389 001	8026284	Sep 22, 2027	U-1399		NDF	Apr 30, 2016
	8129433	Jan 26, 2027	DP			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N203389 002	8026284	Sep 22, 2027	U-1399		NDF	Apr 30, 2016
	8129433	Jan 26, 2027	DP			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N202806 001	>A> 7994185	Jan 20, 2030	DS DP U-1406		NCE	May 29, 2018
	>A> 8415345	Jan 20, 2030	DS DP U-1406		>A> ODE	May 29, 2020
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N202806 002					NCE	May 29, 2018
					>A> ODE	May 29, 2020

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DALFAMPRIDINE - AMPYRA</u>						
N022250 001	>A> 5540938	Jul 30, 2018	U-1030			
	8354437	Dec 22, 2026	U-1030			
	>A> 8440703	Apr 08, 2025	U-1030			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 001					D-135 PED	Feb 01, 2016 Aug 01, 2016
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 002					D-135 PED	Feb 01, 2016 Aug 01, 2016
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 003					D-135 PED	Feb 01, 2016 Aug 01, 2016
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 004					D-135 PED	Feb 01, 2016 Aug 01, 2016
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 005					D-135 PED	Feb 01, 2016 Aug 01, 2016
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 006					D-135 PED	Feb 01, 2016 Aug 01, 2016
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N202895 001					D-135 PED	Feb 01, 2016 Aug 01, 2016
<u>DEFERASIROX - EXJADE</u>						
N021882 001					I-665	Jan 23, 2016
<u>DEFERASIROX - EXJADE</u>						
N021882 002					I-665	Jan 23, 2016
<u>DEFERASIROX - EXJADE</u>						
N021882 003					I-665	Jan 23, 2016
<u>DESONIDE - VERDESQ</u>						
N021978 001	>A> 8460641	Nov 05, 2028	DP U-1412			
<u>DESOXIMETASONE - TOPICORT</u>						
N204141 001	>A> 5990100	Mar 24, 2018	DP U-1408		NDF	Apr 11, 2016
	>A> 8277780	Apr 23, 2028	DP U-1408			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N021992 001	6673838	Feb 11, 2022	DS DP U-860			
	6673838	Feb 11, 2022	DS DP U-1364			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N021992 002	6673838	Feb 11, 2022	DS DP U-860			
	6673838	Feb 11, 2022	DS DP U-1364			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N022287 001	>A> 8461187	Jan 17, 2026	DP			
	>A> 8461187*PED	Jul 17, 2026				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N022287 002	>A> 8461187	Jan 17, 2026	DP			
	>A> 8461187*PED	Jul 17, 2026				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N021038 001	4910214	Jul 15, 2013	DS DP U-421			
	4910214*PED	Jan 15, 2014				
	6716867	Mar 31, 2019	U-572			
	6716867*PED	Oct 01, 2019				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N021038 002	4910214	Jul 15, 2013	DS DP U-421			
	4910214*PED	Jan 15, 2014				
	6716867	Mar 31, 2019	U-572			
	6716867*PED	Oct 01, 2019				
	8242158	Jan 04, 2032	DP			
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032	DP			
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032	U-421			
	8455527*PED	Jul 04, 2032				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N021038 003	4910214	Jul 15, 2013	DS DP U-421			
	4910214*PED	Jan 15, 2014				
	6716867	Mar 31, 2019	U-572			
	6716867*PED	Oct 01, 2019				
	8242158	Jan 04, 2032	DP			
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032	DP			
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032	U-421			
	8455527*PED	Jul 04, 2032				
<u>DIFLUPREDNATE - DUREZOL</u>						
N022212 001	6114319	May 18, 2019	DP		I-653	Jun 13, 2015
	6114319*PED	Nov 18, 2019			M-127	Mar 22, 2016
					ODE	Jun 13, 2019
					PED	Dec 13, 2019
					PED	Sep 22, 2016
					PED	Dec 13, 2015
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N204063 001	6509376	Oct 29, 2019	DP		NCE	Mar 27, 2018
	7320999	May 18, 2020	U-1384			
	7619001	Apr 01, 2018	U-1384			
	7803840	Apr 01, 2018	U-1385			
	8399514	Feb 07, 2028	U-1384			
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N204063 002	6509376	Oct 29, 2019	DP		NCE	Mar 27, 2018
	7320999	May 18, 2020	U-1384			
	7619001	Apr 01, 2018	U-1384			
	7803840	Apr 01, 2018	U-1385			
	8399514	Feb 07, 2028	U-1384			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT</u>						
N022568 001	>A> 8481565	Oct 04, 2026	DP			
<u>DOXYCYCLINE - ORACEA</u>						
N050805 001	>A> 8394405	Apr 07, 2024	DP U-925			
	>A> 8394406	Apr 07, 2024	DP U-925			
	>A> 8470364	Apr 07, 2024	DP U-925			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N050795 004	6958161	Dec 15, 2022	DP U-918			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N050795 005	6958161	Dec 15, 2022	DP U-918		D-136 NS	Apr 11, 2016 Apr 11, 2016
<u>DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE - DICLEGIS</u>						
N021876 001	6340695	Jun 21, 2021	DP U-1382		NP	Apr 08, 2016
	7560122	Jan 25, 2019	DP			
<u>DRONEDARONE HYDROCHLORIDE - MULTAQ</u>						
N022425 001	5223510	Jul 26, 2016	DS DP U-992			
	5223510	Jul 26, 2016	DS DP U-1261			
	8410167	Apr 16, 2029	U-1388			
	8410167	Apr 16, 2029	U-1387			
<u>DROSPIRENONE; ETHINYL ESTRADIOL - YAZ</u>						
N021676 001	RE43916	Jun 30, 2014	U-1326			
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - BEYAZ</u>						
N022532 001	RE43916	Jun 30, 2014	U-1326			
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N021427 001					M-61 PED	Oct 18, 2015 Apr 18, 2016
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N021427 002					M-61 PED	Oct 18, 2015 Apr 18, 2016
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N021427 004					M-61 PED	Oct 18, 2015 Apr 18, 2016
<u>EFAVIRENZ - SUSTIVA</u>						
N020972 001	5519021	May 21, 2013	DS DP		NPP	May 02, 2016
	5519021*PED	Nov 21, 2013			PED	Nov 02, 2016
	5663169	Sep 02, 2014	U-257			
	5663169*PED	Mar 02, 2015				
	6238695	Apr 06, 2019	DP			
	6238695*PED	Oct 06, 2019				
	6555133	Apr 06, 2019	U-248			
	6555133*PED	Oct 06, 2019				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE	
EFAVIRENZ - SUSTIVA								
N020972 002	5519021	May	21, 2013	DS DP				
	5519021*PED	Nov	21, 2013					
	5663169	Sep	02, 2014	U-257				
	5663169*PED	Mar	02, 2015					
	6238695	Apr	06, 2019	DP				
	6238695*PED	Oct	06, 2019					
	6555133	Apr	06, 2019	U-248				
	6555133*PED	Oct	06, 2019					
	6639071	Feb	14, 2018	DS				
	6639071*PED	Aug	14, 2018					
	6939964	Jan	20, 2018	DS				
	6939964*PED	Jul	20, 2018					
EFAVIRENZ - SUSTIVA								
N020972 003	5519021	May	21, 2013	DS DP		NPP	May	02, 2016
	5519021*PED	Nov	21, 2013			PED	Nov	02, 2016
	5663169	Sep	02, 2014	U-257				
	5663169*PED	Mar	02, 2015					
	6238695	Apr	06, 2019	DP				
	6238695*PED	Oct	06, 2019					
	6555133	Apr	06, 2019	U-248				
	6555133*PED	Oct	06, 2019					
	6639071	Feb	14, 2018	DS				
	6639071*PED	Aug	14, 2018					
	6939964	Jan	20, 2018	DS				
	6939964*PED	Jul	20, 2018					
EFAVIRENZ - SUSTIVA								
N021360 001	5519021	May	21, 2013					
	5519021*PED	Nov	21, 2013					
	5663169	Sep	02, 2014					
	5663169*PED	Mar	02, 2015					
	6639071	Feb	14, 2018	DS				
	6639071*PED	Aug	14, 2018					
	6939964	Jan	20, 2018	DS				
	6939964*PED	Jul	20, 2018					
EFAVIRENZ - SUSTIVA								
N021360 002	5519021	May	21, 2013	DS DP		NPP	May	02, 2016
	5519021*PED	Nov	21, 2013			PED	Nov	02, 2016
	5663169	Sep	02, 2014	U-248				
	5663169*PED	Mar	02, 2015					
	6639071	Feb	14, 2018	DS				
	6639071*PED	Aug	14, 2018					
	6939964	Jan	20, 2018	DS				
	6939964*PED	Jul	20, 2018					

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N021937 001	5519021	May 21, 2013	DS DP			
	5519021*PED	Nov 21, 2013				
	5663169	Sep 02, 2014			U-750	
	5663169	Sep 02, 2014			U-1170	
	5663169*PED	Mar 02, 2015				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>EPINEPHRINE - AUVI-Q</u>						
N201739 001	7731686	Jun 01, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8206360	Feb 27, 2027	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N201739 002	7731686	Jun 01, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8206360	Feb 27, 2027	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
<u>EPOPROSTENOL SODIUM - VELETRI</u>						
N022260 001	8318802	Mar 15, 2027	DP			
<u>EPOPROSTENOL SODIUM - VELETRI</u>						
N022260 002	8318802	Mar 15, 2027	DP			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N021743 001	6900221	Nov 09, 2020	DS DP U-875		I-671	May 14, 2016
	6900221	Nov 09, 2020	DS DP U-659			
	6900221	Nov 09, 2020	DS DP U-1403			
	6900221	Nov 09, 2020	DS DP U-1046			
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1403			
	7087613	Nov 09, 2020	U-1045			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N021743 002	6900221	Nov 09, 2020	DS DP U-875		I-671	May 14, 2016
	6900221	Nov 09, 2020	DS DP U-659			
	6900221	Nov 09, 2020	DS DP U-1403			
	6900221	Nov 09, 2020	DS DP U-1046			
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1403			
	7087613	Nov 09, 2020	U-1045			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N021743 003	6900221	Nov 09, 2020	DS DP U-875		I-671	May 14, 2016
	6900221	Nov 09, 2020	DS DP U-659			
	6900221	Nov 09, 2020	DS DP U-1403			
	6900221	Nov 09, 2020	DS DP U-1046			
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1403			
	7087613	Nov 09, 2020	U-1045			
<u>ESTRADIOL - MINIVELLE</u>						
N203752 001	5646286	Aug 12, 2014	DS DP			
	6024976	Jan 07, 2014	DS DP			
	8231906	May 24, 2030	DS DP			
<u>ESTRADIOL - MINIVELLE</u>						
N203752 002	5646286	Aug 12, 2014	DS DP			
	6024976	Jan 07, 2014	DS DP			
	8231906	May 24, 2030	DS DP			
<u>ESTRADIOL - MINIVELLE</u>						
N203752 003	5646286	Aug 12, 2014	DS DP			
	6024976	Jan 07, 2014	DS DP			
	8231906	May 24, 2030	DS DP			
<u>ESTRADIOL - MINIVELLE</u>						
N203752 004	5646286	Aug 12, 2014	DS DP			
	6024976	Jan 07, 2014	DS DP			
	8231906	May 24, 2030	DS DP			
<u>ESZOPICLONE - LUNESTA</u>						
N021476 001					M-61 PED	Oct 10, 2015 Apr 10, 2016
<u>ESZOPICLONE - LUNESTA</u>						
N021476 002					M-61 PED	Oct 10, 2015 Apr 10, 2016
<u>ESZOPICLONE - LUNESTA</u>						
N021476 003					M-61 PED	Oct 10, 2015 Apr 10, 2016
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - QUARTETTE</u>						
N204061 001	8415332	Mar 11, 2029	DP		NP	Mar 28, 2016
	8450299	Oct 07, 2025	U-1			
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE</u>						
N203667 001	5552394	Jul 22, 2014	U-1		NDF	May 08, 2016

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE						
N204426 001	5552394	Jul 22, 2014	U-1			
	6652880	Mar 29, 2020	DP			
EVEROLIMUS - AFINITOR						
N022334 001	8410131	May 22, 2025	DS DP U-1368			
	8410131*PED	Nov 22, 2025				
	8436010	Feb 22, 2022	DS DP U-1396			
	8436010*PED	Aug 22, 2022				
EVEROLIMUS - AFINITOR						
N022334 002	8410131	May 22, 2025	DS DP U-1368			
	8410131*PED	Nov 22, 2025				
	8436010	Feb 22, 2022	DS DP U-1396			
	8436010*PED	Aug 22, 2022				
EVEROLIMUS - AFINITOR						
N022334 003	8410131	May 22, 2025	DS DP U-1368			
	8410131*PED	Nov 22, 2025				
	8436010	Feb 22, 2022	DS DP U-1396			
	8436010*PED	Aug 22, 2022				
EVEROLIMUS - AFINITOR						
N022334 004	8410131	May 22, 2025	DS DP U-1368			
	8410131*PED	Nov 22, 2025				
	8436010	Feb 22, 2022	DS DP U-1396			
	8436010*PED	Aug 22, 2022				
EVEROLIMUS - ZORTRESS						
N021560 001	5665772	Sep 09, 2019	DS DP U-1365		I-668	Feb 15, 2016
	5665772	Sep 09, 2019	DS DP U-1049			
	5665772*PED	Mar 09, 2020				
	6004973	Jul 12, 2016	DP U-1365			
	6004973	Jul 12, 2016	DP U-1049			
	6004973*PED	Jan 12, 2017				
	6440990	Sep 24, 2013	DP U-1365			
	6440990	Sep 24, 2013	DP U-1049			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1365			
	6455518	Jul 29, 2017	U-1049			
	6455518*PED	Jan 29, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 002	5665772	Sep 09, 2019	DS DP U-1365		I-668	Feb 15, 2016
	5665772	Sep 09, 2019	DS DP U-1049			
	5665772*PED	Mar 09, 2020				
	6004973	Jul 12, 2016	DP U-1365			
	6004973	Jul 12, 2016	DP U-1049			
	6004973*PED	Jan 12, 2017				
	6440990	Sep 24, 2013	DP U-1365			
	6440990	Sep 24, 2013	DP U-1049			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1365			
	6455518	Jul 29, 2017	U-1049			
	6455518*PED	Jan 29, 2018				
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 003	5665772	Sep 09, 2019	DS DP U-1365		I-668	Feb 15, 2016
	5665772	Sep 09, 2019	DS DP U-1049			
	5665772*PED	Mar 09, 2020				
	6004973	Jul 12, 2016	DP U-1365			
	6004973	Jul 12, 2016	DP U-1049			
	6004973*PED	Jan 12, 2017				
	6440990	Sep 24, 2013	DP U-1365			
	6440990	Sep 24, 2013	DP U-1049			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1365			
	6455518	Jul 29, 2017	U-1049			
	6455518*PED	Jan 29, 2018				
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N022200 001	8431685	Apr 13, 2025	DP U-412			
	>A> 8461105	Apr 13, 2025	DP U-412			
<u>FAMOTIDINE; IBUPROFEN - DUEXIS</u>						
N022519 001	8449910	Jul 18, 2026	DP			
<u>FEBUXOSTAT - ULORIC</u>						
N021856 001	5614520	Mar 25, 2019	DS DP U-954			
	8372872	Sep 08, 2031	U-1346			
<u>FEBUXOSTAT - ULORIC</u>						
N021856 002	5614520	Mar 25, 2019	DS DP U-954			
	8372872	Sep 08, 2031	U-1346			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N022030 001	8338478	May 11, 2019	DS DP U-913			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N022030 002	8338478	May 11, 2019	DS DP U-913			
<u>FLUTICASONE FUROATE - VERAMYST</u>						
N022051 001	8347879	Apr 01, 2027	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N204275 001	5873360	Feb 23, 2016	DP			
	6537983	Aug 03, 2021	DP U-1401			
	6759398	Aug 03, 2021	DP U-1401			
	6878698	Aug 03, 2021	U-1401			
	7101866	Aug 03, 2021	DS DP U-1401			
	7361787	Mar 23, 2023	DS DP U-1401			
	7439393	Sep 11, 2022	DS DP U-1401			
	7629335	Aug 03, 2021	DP			
	7776895	Sep 11, 2022	DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N021211 001	5929028	Jan 14, 2018	DP U-567			
	5929028	Jan 14, 2018	DP U-1366			
	7563763	Aug 23, 2019	U-993			
	7563763	Aug 23, 2019	U-1367			
	7563763	Aug 23, 2019	U-1183			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N021211 002	5929028	Jan 14, 2018	DP U-567			
	5929028	Jan 14, 2018	DP U-1366			
	7563763	Aug 23, 2019	U-993			
	7563763	Aug 23, 2019	U-1367			
	7563763	Aug 23, 2019	U-1183			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N021211 003	5929028	Jan 14, 2018	DP U-567			
	5929028	Jan 14, 2018	DP U-1366			
	7563763	Aug 23, 2019	U-993			
	7563763	Aug 23, 2019	U-1367			
	7563763	Aug 23, 2019	U-1183			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N021211 004	5929028	Jan 14, 2018	DP U-567			
	5929028	Jan 14, 2018	DP U-1366			
	7563763	Aug 23, 2019	U-993			
	7563763	Aug 23, 2019	U-1367			
	7563763	Aug 23, 2019	U-1183			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N021273 001	5767251	Jun 16, 2015	DS			
	5929028	Jan 14, 2018	DP U-1366			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N021273 002	5767251	Jun 16, 2015	DS			
	5929028	Jan 14, 2018	DP U-1366			
<u>GABAPENTIN - GRALISE</u>						
N022544 001	8333992	Oct 25, 2022	DP U-1114			
<u>GABAPENTIN - GRALISE</u>						
N022544 002	8333992	Oct 25, 2022	DP U-1114			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N021711 001	8394356	Feb 01, 2015	U-1112			
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N021711 002	8394356	Feb 01, 2015	U-1112			
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N204781 001					NCE	Mar 20, 2018
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N204781 002					NCE	Mar 20, 2018
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N204781 003					NCE	Mar 20, 2018
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N204781 004					NCE	Mar 20, 2018
<u>GADOXETATE DISODIUM - EOVI</u>						
N022090 002					NCE	Jul 03, 2013
<u>GANIRELIX ACETATE - GANIRELIX ACETATE INJECTION</u>						
N021057 001	6653286	Jun 16, 2018	U-1354			
<u>GLATIRAMER ACETATE - COPAXONE</u>						
N020622 002	8367605	May 24, 2014	DS			
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N203284 001	5968979	Feb 07, 2015	DS DP U-1378		NE	Feb 01, 2016
	8404215	Mar 09, 2032	U-1383		ODE	Feb 01, 2020
<u>GLYCOPYRROLATE - ROBINUL</u>						
N012827 001	7091236	Apr 24, 2024	U-877	Y		
<u>GLYCOPYRROLATE - ROBINUL FORTE</u>						
N012827 002	7091236	Apr 24, 2024	U-877	Y		
<u>IBUPROFEN LYSINE - NEOPROFEN</u>						
N021903 001	8415337	Mar 02, 2032	DS DP			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N202057 001	8357677	Feb 09, 2030	U-1287			
	8367652	Feb 09, 2030	U-1287			
	8377920	Feb 09, 2030	U-1287			
	8399446	Feb 09, 2030	U-1287			
	8415335	Feb 09, 2030	U-1287			
	8426399	Feb 09, 2030	U-1287			
	8431560	Feb 09, 2030	U-1287			
	8440650	Feb 09, 2030	U-1287			
	8445003	Apr 29, 2030	U-1287			
	8445013	Apr 29, 2030	U-1287			
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N021588 001	7544799	Jan 16, 2019	DS DP	Y	I-666	Jan 25, 2016
	RE43932	Jan 16, 2019	DS DP		ODE	Jan 25, 2020
	RE43932*PED	Jul 16, 2019				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N021588 002	7544799	Jan 16, 2019	DS DP	Y	I-666	Jan 25, 2016
	RE43932	Jan 16, 2019	DS DP		ODE	Jan 25, 2020
	RE43932*PED	Jul 16, 2019				
<u>INDACATEROL MALEATE - ARCAPTA NEOHALER</u>						
N022383 001	8067437	Jun 02, 2020	U-1168			
<u>INGENOL MEBUTATE - PICATO</u>						
N202833 001	>A> 6844013	Dec 13, 2018	DS DP U-1221			
	8372827	Dec 18, 2026	DS DP			
	8372828	Dec 18, 2026	DS DP			
	8377919	Dec 18, 2026	DS DP			
<u>INGENOL MEBUTATE - PICATO</u>						
N202833 002	>A> 6844013	Dec 13, 2018	DS DP U-1221			
	8372827	Dec 18, 2026	DS DP			
	8372828	Dec 18, 2026	DS DP			
	8377919	Dec 18, 2026	DS DP			
<u>IOBENGUANE SULFATE I-123 - ADREVIEW</u>						
N022290 001					I-669	Mar 20, 2016
<u>IRON SUCROSE - VENOFER</u>						
N021135 005					NPP	Sep 21, 2015
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 001	8367102	Sep 21, 2021	U-1347			
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 002	8367102	Sep 21, 2021	U-1347			
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 003	8367102	Sep 21, 2021	U-1347			
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 004	8367102	Sep 21, 2021	U-1347			
<u>IVACAFTOR - KALYDECO</u>						
N203188 001	8410274	Dec 28, 2026	DP			
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N021528 001	8377982	May 28, 2024	U-1363			
	8377982*PED	Nov 28, 2024				
<u>LENALIDOMIDE - REVLMID</u>						
N021880 001	>A> 7468363	Oct 07, 2023	U-1414		>A> I-672	Jun 05, 2016
	8404717	Apr 11, 2023	U-1215		>A> ODE	Jun 05, 2020
<u>LENALIDOMIDE - REVLMID</u>						
N021880 002	>A> 7468363	Oct 07, 2023	U-1414		>A> I-672	Jun 05, 2016
	8404717	Apr 11, 2023	U-1215		>A> ODE	Jun 05, 2020
<u>LENALIDOMIDE - REVLMID</u>						
N021880 003	>A> 7468363	Oct 07, 2023	U-1414		>A> I-672	Jun 05, 2016
	8404717	Apr 11, 2023	U-1215		>A> ODE	Jun 05, 2020

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 004	>A> 7468363	Oct 07, 2023	U-1414		>A> I-672	Jun 05, 2016
	8404717	Apr 11, 2023	U-1215		>A> ODE	Jun 05, 2020
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 005	>A> 7468363	Oct 07, 2023	U-1414		>A> I-672	Jun 05, 2016
	8404717	Apr 11, 2023	U-1215		>A> ODE	Jun 05, 2020
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 006	>A> 7468363	Oct 07, 2023	U-1414		>A> I-672	Jun 05, 2016
					>A> NS	Jun 05, 2016
					>A> ODE	Jun 05, 2020
<u>LEVALBUTEROL HYDROCHLORIDE - LEVALBUTEROL HYDROCHLORIDE</u>						
A077756 001					PC	Feb 16, 2013
<u>LEVALBUTEROL HYDROCHLORIDE - LEVALBUTEROL HYDROCHLORIDE</u>						
A077756 002					PC	Feb 16, 2013
<u>LEVALBUTEROL HYDROCHLORIDE - LEVALBUTEROL HYDROCHLORIDE</u>						
A077756 003					PC	Feb 16, 2013
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N020140 001	6500829	Mar 07, 2022	DS DP			
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N020140 002	6500829	Mar 07, 2022	DS DP			
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N020140 003	6500829	Mar 07, 2022	DS DP			
<u>LEVONORGESTREL - SKYLA</u>						
N203159 001	5785053	Dec 05, 2015	DP		NP	Jan 09, 2016
	7252839	Nov 13, 2023	DP			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N021301 001	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N021301 002	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N021301 003	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N021301 004	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N021301 005	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N021301 006	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N021301 007	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N021301 008	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N021301 009	7101569	Oct 02, 2023	U-759			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N021301 010	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N021301 011	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N021301 012	7101569	Oct 02, 2023	U-759			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N203858 001	5712279	Feb 21, 2015	DS U-1317		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N203858 002	5712279	Feb 21, 2015	DS U-1317		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N203858 003	5712279	Feb 21, 2015	DS U-1317		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N021906 001	8025899	Dec 14, 2027	DP			
	8025899*PED	Jun 14, 2028				
	8377952	Oct 22, 2027	U-1372			
	8377952*PED	Apr 22, 2028				
	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N021906 002	8025899	Dec 14, 2027	DP			
	8025899*PED	Jun 14, 2028				
	8377952	Oct 22, 2027	U-1372			
	8377952*PED	Apr 22, 2028				
	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
<u>LOTEPREDNOL ETABONATE - LOTEMAX</u>						
N202872 001	5800807	Jan 29, 2017	DP			
<u>LOXAPINE - ADASUVE</u>						
N022549 001	6716416	May 20, 2022	DP			
	7052679	Mar 20, 2022	DP			
	7078020	Oct 26, 2021	DP U-1375			
	7090830	Oct 26, 2021	DP			
	7458374	Aug 18, 2024	DP			
	7537009	Oct 26, 2021	DP			
	7585493	Oct 26, 2021	DP			
	7601337	Oct 26, 2021	DP			
	8074644	Oct 26, 2021	DP			
	8173107	Oct 26, 2021	DP			
	8235037	Oct 26, 2021	DP			
	8387612	Oct 23, 2026	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LUBIPROSTONE - AMITIZA</u>						
N021908 001	6414016	Sep 05, 2020	U-717		I-670	Apr 19, 2016
	6414016	Sep 05, 2020	U-1392			
	6982283	Dec 04, 2022	U-1391			
	7064148	Aug 30, 2022	U-739			
	7064148	Aug 30, 2022	U-1404			
	8026393	Oct 25, 2027	DP			
	8071613	Sep 05, 2020	U-1393			
	8071613	Sep 05, 2020	U-1203			
	8097653	Nov 14, 2022	U-1394			
	8097653	Nov 14, 2022	U-1214			
	8389542	Nov 14, 2022	DP U-1395			
	8389542	Nov 14, 2022	DP U-1345			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603 001	5532372	Jul 02, 2018	DS			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603 002	5532372	Jul 02, 2018	DS			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603 003	5532372	Jul 02, 2018	DS			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603 004	5532372	Jul 02, 2018	DS			
<u>MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; POTASSIUM SULFATE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE - SUCLEAR</u>						
N203595 001					NC	Jan 18, 2016
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N022525 001	8168209	Nov 22, 2025	DP			
	8173708	Nov 22, 2025	U-539			
	8283379	Nov 22, 2025	U-539			
	8329752	Nov 22, 2025	DP			
	8362085	Nov 22, 2025	U-539			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N022525 002	8168209	Nov 22, 2025	DP			
	8173708	Nov 22, 2025	U-539			
	8283379	Nov 22, 2025	U-539			
	8329752	Nov 22, 2025	DP			
	8362085	Nov 22, 2025	U-539			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N022525 003	8168209	Nov 22, 2025	DP			
	8173708	Nov 22, 2025	U-539			
	8283379	Nov 22, 2025	U-539			
	8329752	Nov 22, 2025	DP			
	8362085	Nov 22, 2025	U-539			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N022525 004	8168209	Nov 22, 2025	DP			
	8173708	Nov 22, 2025	U-539			
	8283379	Nov 22, 2025	U-539			
	8329752	Nov 22, 2025	DP			
	8362085	Nov 22, 2025	U-539			
<u>MESALAMINE - CANASA</u>						
N021252 002	8217083	Jun 06, 2028	DP			
	8436051	Jun 06, 2028	DP			
<u>MESALAMINE - DELZICOL</u>						
N204412 001	5541170	Jul 30, 2013	DP U-141			
	5541171	Jul 30, 2013	DP U-141			
	>A> 6649180	Apr 13, 2020	DP			
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
N021574 001	>A> 8475841	Mar 20, 2018	U-604			
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
N021574 002	>A> 8475841	Mar 20, 2018	U-604			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N022024 001	>A> 8470368	Sep 19, 2023	DP			
	>A> 8475841	Mar 20, 2018	U-973			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N022024 002	>A> 8470368	Sep 19, 2023	DP			
	>A> 8475841	Mar 20, 2018	U-973			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N200678 001	RE44186	Jul 31, 2023	DS DP U-1097			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N200678 002	RE44186	Jul 31, 2023	DS DP U-1097			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N200678 003	RE44186	Jul 31, 2023	DS DP U-1097			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N022044 001	7459428	Feb 02, 2019	U-1036			
	8414921	Jul 21, 2028	DP U-1036			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N022044 002	7459428	Feb 02, 2019	U-1036			
	8414921	Jul 21, 2028	DP U-1036			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N021964 001	8420663	Sep 30, 2029	U-1185			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N021964 002	8420663	Sep 30, 2029	U-1185			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N021964 003	8420663	Sep 30, 2029	U-1185			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLIVANT XR</u>						
N202100 001	8062667	Mar 29, 2029	DP			
	8287903	Feb 15, 2031	DP			
	>A> 8465765	Feb 15, 2031	DP U-1415			
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N201922 001	5908838	Feb 19, 2018	U-1376			
	7541347	Apr 02, 2027	U-917			
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025	U-124			
	7919483	Mar 07, 2027	U-124			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-124			
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N201922 003	5908838	Feb 19, 2018	U-1376			
	7541347	Apr 02, 2027	U-917			
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025	U-124			
	7919483	Mar 07, 2027	U-124			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-124			
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N201922 005	5908838	Feb 19, 2018	U-1376			
	7541347	Apr 02, 2027	U-917			
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025	U-124			
	7919483	Mar 07, 2027	U-124			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-124			
<u>MIPOMERSEN SODIUM - KYNAMRO</u>						
N203568 001	5914396	Jun 22, 2016	DS		NCE	Jan 29, 2018
	6166197	Dec 26, 2017	DS		ODE	Jan 29, 2020
	6222025	Mar 06, 2015	DS			
	6451991	Feb 11, 2017	DS			
	7015315	Mar 21, 2023	DS			
	7101993	Sep 05, 2023	DS			
	7407943	Aug 01, 2021	U-1353			
	7511131	Dec 13, 2025	DS			
<u>MOMETASONE FUROATE - ELOCON</u>						
N019625 002					NP	Apr 19, 2016
<u>MOXIFLOXACIN HYDROCHLORIDE - MOXEZA</u>						
N022428 001	8450311	May 29, 2029	DP			
<u>MUPIROCIN CALCIUM - BACTROBAN</u>						
N050703 001	5569672	Oct 29, 2013	U-1358			
<u>MUPIROCIN CALCIUM - BACTROBAN</u>						
N050746 001	5569672	Oct 29, 2013	U-1358			
<u>MYCOPHENOLIC ACID - MYFORTIC</u>						
N050791 001	6306900	Feb 27, 2018	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MYCOPHENOLIC ACID - MYFORTIC</u>						
N050791 002	6306900	Feb 27, 2018	DP			
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N204286 001					>A> NP	Jun 27, 2016
<u>NEPAFENAC - NEPAFENAC</u>						
N203491 001	5475034	Jun 06, 2014	U-100			
	6403609	Jul 17, 2018	DP			
	7947295	Jun 08, 2024	DP			
<u>NEVIRAPINE - VIRAMUNE XR</u>						
N201152 001	>A> 8460704	Mar 12, 2029	U-1409			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N019734 004	>A> 8455524	Sep 22, 2022	U-1029			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N019734 003	>A> 8455524	Sep 22, 2022	U-1029			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER</u>						
N019734 002	>A> 8455524	Sep 22, 2022	U-1029			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER</u>						
N019734 005	>A> 8455524	Sep 22, 2022	U-1029			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N022068 001	8389537	Jul 18, 2026	DS DP U-1374			
	>A> 8415363	Jul 18, 2026	DS DP U-1407			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N022068 002	8389537	Jul 18, 2026	DS DP U-1374			
	>A> 8415363	Jul 18, 2026	DS DP U-1407			
<u>NIMODIPINE - NYMALIZE</u>						
N203340 001					ODE	May 10, 2020
<u>NITRIC OXIDE - INOMAX</u>						
N020845 002	8431163	Jun 30, 2029	U-1286			
	8431163*PED	Dec 30, 2029				
<u>NITRIC OXIDE - INOMAX</u>						
N020845 003	8431163	Jun 30, 2029	U-1286			
	8431163*PED	Dec 30, 2029				
<u>OLOPATADINE HYDROCHLORIDE - PATANASE</u>						
N021861 001	8399508	Sep 17, 2022	U-726			
	8399508*PED	Mar 17, 2023				
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID</u>						
N021636 001	>A> 6489346	Jul 16, 2016	DS DP U-588	Y		
	>A> 6645988	Jul 16, 2016	DS DP	Y		
	>A> 6699885	Jul 16, 2016	U-588	Y		

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID</u>						
N021636 002	>A> 6489346	Jul 16, 2016	DS DP U-624	Y		
	>A> 6489346	Jul 16, 2016	DS DP U-623	Y		
	>A> 6645988	Jul 16, 2016	DS DP	Y		
	>A> 6699885	Jul 16, 2016	U-624	Y		
	>A> 6699885	Jul 16, 2016	U-623	Y		
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID OTC</u>						
N022281 001	6489346	Jul 15, 2016	DP U-1025	Y		
	6645988	Jul 15, 2016	DP	Y		
	6699885	Jul 15, 2016	DP	Y		
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021087 001					NPP	Dec 21, 2015
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021087 002					NPP	Dec 21, 2015
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021087 003					NPP	Dec 21, 2015
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021246 001					NPP	Dec 21, 2015
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021246 002					NPP	Dec 21, 2015
<u>OSPEMIFENE - OSPHENA</u>						
N203505 001	6245819	Jul 21, 2020	U-1369		NCE	Feb 26, 2018
	8236861	Aug 11, 2026	U-1370			
	8236861	Aug 11, 2026	U-1369			
<u>OXYBUTYNIN - OXYTROL FOR WOMEN</u>						
N202211 001	5601839	Apr 26, 2015	DP U-1329		NP	Jan 25, 2016
	5834010	Apr 26, 2015	DP U-1329			
	6743441	Apr 26, 2020	DP U-1329			
	7081249	Apr 26, 2020	DP U-1329			
	7081250	Apr 26, 2020	DP U-1329			
	7081251	Apr 26, 2020	DP U-1329			
	7081252	Apr 26, 2020	DP U-1329			
	7179483	Apr 26, 2020	U-1329			
<u>OXYCODONE HYDROCHLORIDE - OXECTA</u>						
N202080 001	8409616	Nov 26, 2023	DP			
<u>OXYCODONE HYDROCHLORIDE - OXECTA</u>						
N202080 002	8409616	Nov 26, 2023	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OXYMORPHONE HYDROCHLORIDE</u>						
A079087 006					PC	Jul 07, 2013
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N020725 005					M-93 NCE	Jul 29, 2019 Apr 30, 2014
<u>PAROXETINE MESYLATE - BRISDELLE</u>						
N204516 001	>A> 5874447	Jun 10, 2017	DS			
	>A> 7598271	Feb 12, 2023	DS			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N202088 001	8440170	Mar 14, 2029	DP			
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N202088 002	8440170	Mar 14, 2029	DP			
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N202088 003	8440170	Mar 14, 2029	DP			
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N022363 001	5856336	Jan 01, 2021	DS U-998			
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N022363 002	5856336	Jan 01, 2021	DS U-998			
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N022363 003	5856336	Jan 01, 2021	DS U-998			
<u>PLERIXAFOR - MOZOBIL</u>						
N022311 001	RE42152	Dec 10, 2018	DP			
<u>POMALIDOMIDE - POMALYST</u>						
N204026 001	5635517	Jul 24, 2016	U-1359		NCE	Feb 08, 2018
	6045501	Aug 28, 2018	U-1361		ODE	Feb 08, 2020
	6315720	Oct 23, 2020	U-1361			
	6316471	Aug 10, 2016	DP U-1360			
	6476052	Jul 24, 2016	DP U-1360			
	6561976	Aug 28, 2018	U-1361			
	6561977	Oct 23, 2020	U-1361			
	6755784	Oct 23, 2020	U-1361			
	6908432	Aug 28, 2018	U-1361			
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024	U-1360			
	8204763	Aug 28, 2018	U-1361			
	8315886	Oct 23, 2020	U-1361			
<u>POMALIDOMIDE - POMALYST</u>						
N204026 002	5635517	Jul 24, 2016	U-1359		NCE	Feb 08, 2018
	6045501	Aug 28, 2018	U-1361		ODE	Feb 08, 2020
	6315720	Oct 23, 2020	U-1361			
	6316471	Aug 10, 2016	DP U-1360			
	6476052	Jul 24, 2016	DP U-1360			
	6561976	Aug 28, 2018	U-1361			
	6561977	Oct 23, 2020	U-1361			
	6755784	Oct 23, 2020	U-1361			
	6908432	Aug 28, 2018	U-1361			
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024	U-1360			
	8204763	Aug 28, 2018	U-1361			
	8315886	Oct 23, 2020	U-1361			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>POMALIDOMIDE - POMALYST</u>						
N204026 003	5635517	Jul 24, 2016	U-1359		NCE	Feb 08, 2018
	6045501	Aug 28, 2018	U-1361		ODE	Feb 08, 2020
	6315720	Oct 23, 2020	U-1361			
	6316471	Aug 10, 2016	DP U-1360			
	6476052	Jul 24, 2016	DP U-1360			
	6561976	Aug 28, 2018	U-1361			
	6561977	Oct 23, 2020	U-1361			
	6755784	Oct 23, 2020	U-1361			
	6908432	Aug 28, 2018	U-1361			
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024	U-1360			
	8204763	Aug 28, 2018	U-1361			
	8315886	Oct 23, 2020	U-1361			
<u>POMALIDOMIDE - POMALYST</u>						
N204026 004	5635517	Jul 24, 2016	U-1359		NCE	Feb 08, 2018
	6045501	Aug 28, 2018	U-1361		ODE	Feb 08, 2020
	6315720	Oct 23, 2020	U-1361			
	6316471	Aug 10, 2016	DP U-1360			
	6476052	Jul 24, 2016	DP U-1360			
	6561976	Aug 28, 2018	U-1361			
	6561977	Oct 23, 2020	U-1361			
	6755784	Oct 23, 2020	U-1361			
	6908432	Aug 28, 2018	U-1361			
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024	U-1360			
	8204763	Aug 28, 2018	U-1361			
	8315886	Oct 23, 2020	U-1361			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N203469 001					ODE	Dec 14, 2019
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N203469 002					ODE	Dec 14, 2019
<u>PRALATREXATE - FOLOTYN</u>						
N022468 001	6028071	Jul 16, 2022	DS DP U-1004			
<u>PRALATREXATE - FOLOTYN</u>						
N022468 002	6028071	Jul 16, 2022	DS DP U-1004			
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N022307 001	8404703	Mar 02, 2022	U-1381			
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N022307 002	8404703	Mar 02, 2022	U-1381			
<u>PREDNISONE - RAYOS</u>						
N202020 001	8394407	Apr 23, 2024	DP U-1362		M-128	Jul 26, 2015
<u>PREDNISONE - RAYOS</u>						
N202020 002	8394407	Apr 23, 2024	DP U-1362		M-128	Jul 26, 2015
<u>PREDNISONE - RAYOS</u>						
N202020 003	8394407	Apr 23, 2024	DP U-1362		M-128	Jul 26, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PREGABALIN - LYRICA</u>						
N022488 001					I-651	Jun 20, 2015
<u>PROPOFOL - DIPRIVAN</u>						
N019627 002	>A> 8476010	Dec 01, 2024	DS DP			
	>A> 8476010*PED	Jun 01, 2025				
<u>RABEPRAZOLE SODIUM - ACIPHEX SPRINKLE</u>						
N204736 001	5045552	May 08, 2013	DS DP U-385		NDF	Mar 26, 2016
	5045552*PED	Nov 08, 2013			PED	Sep 26, 2016
<u>RABEPRAZOLE SODIUM - ACIPHEX SPRINKLE</u>						
N204736 002	5045552	May 08, 2013	DS DP U-385		NDF	Mar 26, 2016
	5045552*PED	Nov 08, 2013			PED	Sep 26, 2016
<u>RADIUM RA-223 DICHLORIDE - XOFIGO</u>						
N203971 001	6635234	Jan 03, 2020	U-1405		NCE	May 15, 2018
<u>REGORAFENIB - STIVARGA</u>						
N203085 001					I-667 ODE	Feb 25, 2016 Feb 25, 2020
<u>RITONAVIR - NORVIR</u>						
N022417 001	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
<u>RIZATRIPTAN BENZOATE - RIZATRIPTAN BENZOATE</u>						
A078173 001					PC	Jun 29, 2013
<u>RIZATRIPTAN BENZOATE - RIZATRIPTAN BENZOATE</u>						
A078173 002					PC	Jun 29, 2013
<u>ROFLUMILAST - DALIRESP</u>						
N022522 001	8431154	Feb 19, 2023	DP			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N020533 001	5670524	Sep 23, 2014	DS DP U-833			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N020533 003	5670524	Sep 23, 2014	DS DP U-833			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N020533 004	5670524	Sep 23, 2014	DS DP U-833			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N020533 005	5670524	Sep 23, 2014	DS DP U-833			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N202192 001	8415362	Dec 24, 2027	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N202192 002	8415362	Dec 24, 2027	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N202192 003	8415362	Dec 24, 2027	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N202192 004	8415362	Dec 24, 2027	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N202192 005	8415362	Dec 24, 2027	DS DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N022181 001	8318745	Nov 17, 2024	DP			
<u>SAQUINAVIR MESYLATE - INVIRASE</u>						
N020628 001					M-61 PED	Nov 30, 2015 May 30, 2016
<u>SAQUINAVIR MESYLATE - INVIRASE</u>						
N021785 001					M-61 PED	Nov 30, 2015 May 30, 2016
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N022350 001	RE44186	Jul 31, 2023	DS DP U-995			
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N022350 002	RE44186	Jul 31, 2023	DS DP U-995			
<u>SERTRALINE HYDROCHLORIDE - ZOLOFT</u>						
N020990 001	7067555	Oct 11, 2019	DP			
	7067555*PED	Apr 11, 2020				
<u>SODIUM OXYBATE - XYREM</u>						
N021196 001	>A> 8457988	Dec 17, 2022	U-1110			
<u>SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO</u>						
N022239 001	8343130	Oct 18, 2022	DP			
<u>SUMATRIPTAN SUCCINATE - ZECUITY</u>						
N202278 001	6745071	Feb 21, 2023	DP		NDF	Jan 17, 2016
	7973058	Apr 12, 2027	U-1328			
	8155737	Apr 12, 2027	U-1328			
	8366600	Apr 21, 2029	U-1327			
	>A> 8470853	Apr 12, 2027	U-1328			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 001	8114383	Oct 10, 2024	DP	Y		
	8420056	Nov 20, 2023	DP			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 002	8114383	Oct 10, 2024	DP	Y		
	8420056	Nov 20, 2023	DP			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 003	8114383	Oct 10, 2024	DP	Y		
	8420056	Nov 20, 2023	DP			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 004	8114383	Oct 10, 2024	DP	Y		
	8420056	Nov 20, 2023	DP			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 005	8114383	Oct 10, 2024	DP	Y		
	8420056	Nov 20, 2023	DP			
<u>TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT</u>						
N202207 001					NCE	Mar 13, 2018

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TEDUGLUTIDE - GATTEX KIT</u>						
N203441 001	5789379	Apr 14, 2015	DS DP U-1320		ODE	Dec 21, 2019
	7056886	Sep 18, 2022	DP U-1320			
	7847061	Nov 01, 2025	U-1320			
<u>TELAPREVIR - INCIVEK</u>						
N201917 001	8431615	May 30, 2028	U-1398			
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N022110 001	6635618	Sep 11, 2023	DS DP U-728			
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N022110 002	6635618	Sep 11, 2023	DS DP U-728			
<u>TELIVUDINE - TYZEKA</u>						
N022011 001					M-124	Jan 28, 2016
<u>TELIVUDINE - TYZEKA</u>						
N022154 001					M-124	Jan 28, 2016
<u>TEMSIROLIMUS - TORISEL</u>						
N022088 001	>A> 8455539	Jul 25, 2023	DP			
<u>TESTOSTERONE - ANDROGEL</u>						
N022309 001	>A> 8446138	Oct 12, 2026	U-1103			
	>A> 8466136	Oct 12, 2026	DP			
	>A> 8466137	Oct 12, 2026	U-1103			
<u>TESTOSTERONE - ANDROGEL</u>						
N022309 002	>A> 8446138	Oct 12, 2026	U-1103			
	>A> 8466136	Oct 12, 2026	DP			
	>A> 8466137	Oct 12, 2026	U-1103			
<u>TESTOSTERONE - ANDROGEL</u>						
N022309 003	>A> 8446138	Oct 12, 2026	U-1103			
	>A> 8466136	Oct 12, 2026	DP			
	>A> 8466137	Oct 12, 2026	U-1103			
<u>TESTOSTERONE - AXIRON</u>						
N022504 001	8419307	Feb 26, 2027	U-1386			
	8435944	Jul 05, 2027	U-1390			
<u>TESTOSTERONE - TESTOSTERONE</u>						
N203098 001					NP	Jan 31, 2016
<u>TESTOSTERONE - TESTOSTERONE</u>						
N203098 002					NP	Jan 31, 2016
<u>TESTOSTERONE - TESTOSTERONE</u>						
N203098 003					NP	Jan 31, 2016
<u>TICAGRELOR - BRILINTA</u>						
N022433 001	8425934	Dec 18, 2029	DP			
<u>TIGECYCLINE - TYGACIL</u>						
N021821 001	8372995	Oct 08, 2030	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TOBRAMYCIN - BETHKIS</u>						
N201820 001	6987094	Sep 22, 2022	DP			
	7696178	Mar 17, 2023	DP			
	7939502	Jun 14, 2022	U-1324			
<u>TOBRAMYCIN - TOBI PODHALER</u>						
N201688 001	7097827	Jun 27, 2021	DP		NP	Mar 22, 2016
	7368102	Dec 19, 2022	DP U-909			
	7442388	May 10, 2020	DP			
	7516741	Jan 11, 2024	DP			
	7559325	Oct 27, 2025	DP			
	8069851	Sep 24, 2024	DP			
	8349294	May 10, 2020	DP			
<u>TOLTERODINE TARTRATE - DETROL LA</u>						
N021228 001	6911217	Nov 11, 2019	DP U-544			
	6911217*PED	May 11, 2020	DP U-544			
<u>TOLTERODINE TARTRATE - DETROL LA</u>						
N021228 002	6911217	Nov 11, 2019	DP U-544			
	6911217*PED	May 11, 2020	DP U-544			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N204114 001	7378423	Sep 13, 2025	DS DP		NCE >A> ODE	May 29, 2018 May 29, 2020
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N204114 002	7378423	Sep 13, 2025	DS DP		NCE >A> ODE	May 29, 2018 May 29, 2020
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N204114 003	7378423	Sep 13, 2025	DS DP		NCE >A> ODE	May 29, 2018 May 29, 2020
<u>TRANEXAMIC ACID - TRANEXAMIC ACID</u>						
A202093 001					PC	Jul 02, 2013
<u>TRAVOPROST - TRAVATAN Z</u>						
N021994 001	8388941	Sep 20, 2027	DP			
<u>TREPROSTINIL - REMODULIN</u>						
N021272 001	>A> 7999007	Mar 29, 2029	DP U-1413			
<u>TREPROSTINIL - REMODULIN</u>						
N021272 002	>A> 7999007	Mar 29, 2029	DP U-1413			
<u>TREPROSTINIL - REMODULIN</u>						
N021272 003	>A> 7999007	Mar 29, 2029	DP U-1413			
<u>TREPROSTINIL - REMODULIN</u>						
N021272 004	>A> 7999007	Mar 29, 2029	DP U-1413			
<u>TROSPIUM CHLORIDE - TROSPIUM CHLORIDE</u>						
A091289 001					PC	Apr 10, 2013
<u>ULIPRISTAL ACETATE - ELLA</u>						
N022474 001	8426392	Jun 12, 2030	U-1389			
<u>UNOPROSTONE ISOPROPYL - RESCULA</u>						
N021214 001	6770675	Nov 24, 2018	DP U-1322			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ZOLEDRONIC ACID - RECLAST</u>						
N021817 001	8052987	Oct 27, 2023	U-1199			

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 33rd Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>